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I' .. :. , 
CLINICAL AND BIOCHEMICAL STUDIES ON THE HUMAN GLUTATHIONE 
S-TRANSFERA SES 
The glutathione S-transferases . (ligandins) are a ubiquitous sys-
tem .:.t xenobiotic metabolising enzymes. In the rat liver they comprise 
up to 10% of soluble hepatic protein. Studies in the rat suggested 
that ligandin was an accurate and sensitive marker of hepatocellular 
necrosis. and of renal tubular necrosis. The first part of this thesis 
exam:nes the releas~· of ligandin from liver and kidney in human liver 
and renal disease in an attempt to determine whether the measurement of 
ligandin is clinically useful. 
Ligandin was purified from human liver cytosol using a combination 
of anion ·exchange chromatography and gel filtration. The purified pro-
tein had similar physicochemical characteristics to ligandin purified 
by others. The protein was used to raise a monospecific antibody. 
Ligandin was iodinated by the Chloramine-T method. which yielded a 
labelled protein of high specific activity. A sensitive and specific 
radioimmunoassay for human ligandin was developed which had a low 
intra- and interassay variation. 
The assay was applied to the study of human liver disease. In 
acute hepatitis ligandin is released from the liver into serum early in 
the illness. High serum ligandin levels are seen in the first week of 
acute hepatitis. The rapid return to normal suggests that ligandin may 
provide an early indication of recovery. 
In chronic hepatitis ligandin levels correlated significantly with 
histological severity of disease. whereas SGOT showed no such co1·-
i. 
relation. Ligandin may be a better index of severity of disease and 
for treatment than SGOT. 
Ligandin was released from the kidney in severe renal ischaemia 
and in acute tubular necrosis, but was not a reliable predictor or in-
dicator of acute tubular necrosis. 
Part two examines the distribution of of GSH-T activity in organs 
and in hepatocellular carcinoma. Ligandin was shown to be immunologic-
ally similar in all tissues studied. lsoelectric focusing of cytosol 
separated the three groups of GSH-T activity. Considerable variety in 
the t:listribution anC:. activity of GSH-T's was shown in different organs 
from a single donor, and in the same organs from different donors. An-
ionic transfera_se activity was shown to contribute a significant pro-
portion cf activity in organs other than the liver. and to be the major 
source of activity in ovary and lung. In hepatocellular carcinoma cat-
ionic GSH-T activity was present in amounts varying from near normal to 
absent. The anionic and neutral GSH-T's were present in amounts 
similar to that seen in normal liver. lmmunohistochemical studies us-
ing a peroxidase-antiperoxidase method showed a rough correlation bet-
ween tumour differentiation and the amount of ligandin in the tumour. 
ii. 
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2. 
PREFACE 
The world in which we live is a hostile, inimical place, in which 
we are daily assaulted and abused by hundreds of noxious stimuli. Many 
are or' natural origin; sun, wind, extremes of temperature, but many are 
man-made. We are faced with the problem of explaining how it is that 
man, and ,other animals, have developed over millenia, through ages when 
chemical industries were non-existent, protective systems of enzymes, 
which seem to have man made chemicals as their major substrates. Such 
is the diversity of drug metabolising systems, that of tne vast array 
of sub~trates tested, only a relatively small proportion can be said to 
occur naturally. Should one consider cooked food with its polycyclic 
aromatic hydrocarbon carcinogens as a "natural product". If cooked 
food is 'natural' are petrol and diesel fuel less natural, since the 
fractional distillation of crude oil to yield various grades of fuel is 
merely a sophisticated type of cooking. Rather than try to separate 
'natural' from m~.n-made toxins, all exogenous substances which the org-
anism can metabolise can be considered to be 'natural' substrates. 
After . all evolution could not predict the advent of the plastics 
industry. 
Even before man appeared on the scene to enormously increase the 
· likelihood of being exposed to toxins, many environmental pollutants 
must have been present. Fire and smoke produce their fair share of 
carcinogens. Fungi produce aflotoxins. Various foods contain toxic 
alkaloids, and man, in his perversity, will insist in using the leaves 
of various plants, which are nutritionally useless, to produce potions 
3. 
and essences containing toxic substances. e.g. tea, coffee, tobacco and 
marijuana. Even oxygen, the most basic requirement for life, may be 
toxic. 
It is not therefore surprising that a highly efficient enzyme sys-
tem of very broad specificity exists to deal with these toxins. Selec-
tive pressures would have put organisms with these enzymes at an advan-
tage. 
Furthermore, an organism's metabolism produces its own poisons -
the unknown toxins of uraemia and liver failure for in5tan~e. The kid-
ney and the liver hav~ systems for handling endogenously produced tox-
ins and it should not come as too much of a surprise if metabolising 
systems for endogenous and exogenous toxins overlap. 
This thesis deals with one such group of drug metabolising en-. 
zymes. the glutathione S-tranc:ferases. 
The work developed out of time spent in the Liver Research Group 
at the University of Cape Town. This group is concerned with clinical 
research in liver diseases and basic scientific research in liver meta-
bolism and pathophysiology. In parallel with the interest of the group, 
this thesis covers both clinical and biochemical work. 
The clinical side of this thesis arose out of a realisation that 
an adequate test to estimate the extent of hepatic necrosis does not 
exist. Initial work carried out in the Group suggested that assay of 
these proteins (also known as ligandin) in serum may be just such a 
test. This work also suggested that the study of human urinary ligand-
in might be of use in the diagnosis of renal disease. 
Because the subject of this thesis is so broad, encompassing as it 
does both clinical and biochemical work, it has been necessary to split 
4. 
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the thesis into two parts. Part one descnbes the purification of lig-
andin, the development of a radioimmunoassay for ligandin, and the app-
lication of the RIA to the study of human disease. The experimental 
section is preceded by a review o.f the literature on ligandin, together 
with a consideration of the role of ligandin as a diagnostic tool. 
Part 2, whfoh deals with the biochemical investigations into the 
distribution and structure of the human glutathione S-transferases 
(GSH-T), is preceded by a review of the chemistry of the GSH-T's. In 
addition since the physiological functions of the glutathione S-trans-
ferases are in some measure dependant on their anatomical localisation, 
this review will include a consideration of the evidence for and 
against the various physiological functions that have been ascribed to 
the GSH-T's. 
The subject of glutathione conjugation has been reviewed many 
















In 1967 Dr. Ketterer at , the Courtauld Institute of Biochemistry 
working with carc>inogen-binding proteins showed that the aminoazodye 
carcinogen 4-dimethylaminoazobenzene (fig. 1.1) when injected into rats · 
was bound to three hepatic cytosolic proteins (4). They were able to 
purify the most basic of these proteins, which they found to have a pl 
of 8.4 (measured by electrophoresis), a sedimentation coefficient of 
3.5S, and a molecular size (measured by Sephadex chromatography) of 
45. 000 daltons ( 4). 
In 1969 at the Fels Institute in Philadelphia Dr Litwak and co-
workers, who were studying cortisol binding in the liver cell, found 
labelled cortisol was taken up by rat liver bound to four cytosol pro-
teins (5), which they called cortisol metabolite ~inders I, II, III and 
IV. Binder I was purified to homogeneity. and was found to have a p I of 
8.9 (by isoelectric focusing). a sedimentation coefficient of 3.47S, 
and a molecular weight of 37,000 daltons using amino acid analysis, and 
50-60, 000 daltons by Sephadex chromatography (5). Binder I was shown 
. to be identical to the aminoazodye bi.,ding protein described by 
Ketterer et al (6), and to the protein binding the polycyclic hydro-
carbon 3-methylcholanthrene (3-MC)(fig. 1.2) in rat liver cytosol (7). 
Also in 1969 at the Liver Research Centre of the Albert Einstein 
College of Medicine, Dr. Arias and his colleagues. studying the uptake 
of bilirubin and organic anions by the liver produced the now classical 















DIMETHYLAMINOAZOBENZENE / I 
Fig. 1.1. Structural formula of 4-Dimethylaminoazobenzen&. 
1 2 
3 -METHYL CHOLANTHRENE 
- > , 
Fig. 1.2. Structural formula of 3-Methylchalanthrene. 
sulphophthalein (BSP)(fig. 1.3) or labelled bilirubin (fig. 1.4) is 
added to the cytosol fraction of rat liver and chromatographed on Seph-
adex G-75, the ligand elutes in three peaks (8). The X peak elutes at 
the void volume, the Y peak at a molecular size of .:!:_47. 000 daltons and 
Z at a . molecular size of .:!:_14, 000 daltons. 
Y protein \~'as p'.lrified to homogeneity and found to have a pl of 
8.9, and · a molecular weight of 46,000 daltons by Sephadex chromato-
graphy (84,214). The physicochemical similarities between Y protein, 
cortisol metabolite binder I and the aminoazodye binding protein were 
soon recognised and t.hese three proteins were shown to be immunologic-
ally id,mtical. The term ligandin was proposed, on the basis of the 
wide spectrum of ligands known to bind to this protein, to replace the 
older terms, which were too restrictive (9). 
Identity between G SH-T B and ligandin was suspected when it was 
found that there was a significant formation of BSP-GSH conjugate when 
BSP was added as a marker during Y protein purification (10). When G SH 
was added to cytosol it eluted from G-75 Sephadex at the same elution 
volume as BSP bound to Y protein. In addition G SH-T activity with 
3,4-dichloronitrobenzene (DCNB) and BSP eluted at the same elution vol-
ume with superimposable curves (10,11). Thus it was proposed that Y 
protein and GSH-aryl transferase were identical. Some doubt was cast 
on this finding when it was shown that rat liver cytosol subjected to 
isoelectric focusing resulted in clear separation of GSH-T activity to-
wards DCNB and ligandin immunoreactivity (12). In retrospect this 
finding was due to the fact that DCNB is a poor enzyme substrate for 
ligandin and thus failed to detect activity due to this protein. The 















Fig. 1.4. Structu~al formula of Bilirubin. 
CH 
II 
arated from ligandin by the isoeletrofocusing procedure. On gel filtr-
ation all the GSH-T's eluted at the same volume because they all have 
approximately the same molecular size (approximately 46,000 daltons). 
This confusion was resolved when it was shown unequivocally that puri-
fied ligandin and GSH-T B were identical with respect to substrate spe-
cificity. kinetics, em;yme inhibition kinetics, binding activity, phys-
ical properties, and antigenicity (13). 
Jakoby (14) suggested the use of ligandin as a generic term, used 
interchangably with G SH-T. Arias (15) defined ligandin ai; a basic dim-
eric cytoplasmic prot~in, which binds various electrophiles non-coval-
ently and some carcinogens covalently. In addition it has glutathione 
S-transferase (GSH-T) activity with several substrates. By this defin-
ition all cationic GSH-T's from any organ, from any species, are ligan-
dins. However generally the use of the term is more restricted, and in 
the rat is used interchangeably with G SH-T B, to denote either of the 
two dimeric forms in which the molecule may exist in the liver (see 
table 1.1). Th.is is the sense in which the term will be used in this 
thesis. This terminology conforms to common usage in the literature. 
However since there is plethora of other terms which have also been 
used these are summarised in table 1.1. 
In contrast to the rat, in man the cationic GSH-T's are immuno-
logically identical (16, 17) and have similar enzyme and binding ac-
tivity. These proteins have also been called ligandin, and it is in 
this sense that the term will be used in reference to man. Other human 
GSH-T's will not be refered to as ligandin. 
8. 
Ligandin:- In the rat this term refers to either of two immunologic-
ally similar dimers YaYa or YaYc. These dimers are also known as GSH-T 
B. In man this · term refers to all GSH-T's with isoelectric points 
above 7.5, and which are immunologically similar. . . 
Y-protein :- 40-50 ,000 molecular weig_ht peak on gel filtration following 
incubation of cytosol and BSP or bilirubin, which on PAGE-SDS has three 




22,000 molecular weight monomer. 
23,500 molecular weight monomer. 
25,000 molecular .weight monomer. 
Glutathione S-transferase B:- used synonymously with ligandin. 
Glutathione S-transferase A:- GSH-T from rat liver consisting of YbYb 
subunits. Enzymatically and immunologically s:f.milar to GSH-T C. 
Glutathione S-transferase C:-
subunits. See also GSH-T A. 
GSH-T from rat liver consisting of YbYb 
Glutathione S-transferase AA:- GSH-T from rat liver consisting of YcYc 
subunits. 
Cationic human GSH-T' s :- GSH-T a, B, y , 6, £ • Also known as human 
ligandi.n 
Neutral human GSH-T's:- GSH-T with isoelectric 6-6.5. 
GSH-T u. 
Also known as 
Anionic human GSH-T' s :- GSH-T with isoelectric point 4 .5-5 .4. In the 
erythrocyte known as GSH-T p, and in liver as GSH-T Ill • 
Table 1.1. Definition of terms used in this thesis. This usage con-
forms to that commonly seen in the literature. Terms refer to species 
and subunits of rat and human glutathione S-transferases. 
Rat liver ligandin: -
CHAPTER II 
PHYSIOCHEMICAL CHARACTERISTICS 
Discontinuou:; SDS-PAGE analysis of the pooled rat liver Y protein 
peak shows approximately equal concentrations of three bands in the 
22-24,000 dalton range. These have been named Ya, Yb, and Ye in in-
creasing order of molecular size by Bass et al (18). Purified rat liver 
GSH-T B and ligandin have two bands, corresponding to Y<1 and Ye and 
called YA and YB by Bhargava et al (19,20a). I have adopted the Bass 
nomenclature, as have most other workers in the field since it permits 
consideration of Yb which has recently become of relevance. 
From studies with circular dichroism it is known that ligandin has 
a structure, consisting of 40% a-helix, 15% 13- pleated structure, and 
45% random coil (20). Ligandin purified as originally described con-
sisted of two non-identical monomers, molecular weight 22,000 -and 
24,000 daltons (18, 20a). If however the anion exchange steps of the 
ligandin purification are performed at a higher pH i.e. 9.1, then only 
one band, Ya, is seen on SDS-PAGE (18). The resulting dimer has char-
acteristics very similar to YaYc ligandin (table 2.1). 
Bass et al (18) showed that phenobarbitone induction increased the 
concentration of Ya and Yb but not Ye, and suggested that the native 
ligandin .consisted of two dimers YaYa, and YcYc. Bhargava et al (20a) 
using dimethyl suberimidate as a cross linking reagent, could 
only show one band in the 47,000 dalton range on SDS-PAGE and suggested 
that the native protein was a YaYc dimer. Carne et al were able to 
9. 
Table 2.1. 
COMPARISON OF YaYc LIGANDIN WITH YaYa LIGANDIN 
YaYc YaYa 
pl 8.7-9.1 8.7-9.1 
Mol. size :!:_46,000 :!:_46,000 
Subunit size 22,000 + 2x22,000 
25,000 
Specific activity ( )41101/min/mg) 
CDNB 11 25 DCNB 0.003 0.021 
Ka with bilirubin (M-1) 1x106 1.1x106 BSP (M-1) 6xl06 4.5x106 
separate a YaYa dimer from a YaYc dimer on CM-cellulose (21). Sub-
sequently Bhargava et al (19) showed that fresh preparations of ~igan-
din contained equal amounts of Ya and Ye. but on storage the Ya subunit 
increased without loss of catalytic activity. lsoelectric focusing of 
stored ligandin gave two bands. A more basic band contained Ya only 
but the other hR~ equal amounts of Ya and Ye. When a stored sample of 
ligandin was applied to thiol Sepharose no YaYc appeared in the wash. 
Only Ya subuni.ts were seen on PAGE-SDS of the wash (Ye has most of the 
cysteine residues in ligandin). When a fresh preparation of ligandin 
was applied to the same column no ligandin (YaYa or YaYc) appeared in 
the wash. This evidence suggested that native ligandin existed as a 
YaYc heterodimer. 
Hayes et al (22) using anion exchange chromatography of phenobarb-
itone induced rat iiver cytosol found two adjacent protein peaks with 
GSH-T activity with aryl substrates. SDS-PAGE analysis of these peaks 
showed the first to consist mainly of Ya (indicating a YaYa dimer). 
The early fractions of the second peak consisted of YaYc with a trace 
of Yb, but the later fractions consisted predominantly of Yb. These 
workers also showed that GSH-T B purified according to the method of 
Jakoby ~luted from CM-Sephadex at the same ionic strength as their Ye.Ye 
dimer. and purified ligandin prepared according to Bass et al eluted at 
the same ionic strength as their YaYa dimer. These two dimers had sim-
ilar enzyme activity (22). The evidence therefore suggests that in the 
native state both species, YaYa and YaYc exist, but whether they have a 
precursor-product relationship, or are the products of different genes 
is not clear. 
10. 
Of the GSH-T's, the structure/function relationships of ligandin 
have been best studied. The two subunits are not disulphide linked 
(20a). The two C-terminal amino acids are argenine and phenylalanine. 
N-terminal analysis could not be done. Amino acid analysis of the two 
subunits was similar, except that Ye has most of the cysteine molecules 
of native ligandin (19). YaYc ligandin binds bilirubin at a stoichio-
metric ratio of·. 1: 1 at a high affinity site (Ka- 5xl07 M-1)(20), 
but there is also a low affinity site. YaYa ligandin binds bilirubin 
with a ratio of 2:1 (bilirubin:ligandin)(19). 
Covalent bind.ing occu_rs largely through the cysteine residues 
(23) which are mainly on Ye (19). Labelled aminoazodye and 3-methyl 
cholanthrene have been shown to be covalently bound. This binding is 
to Ye and occurs in vivo and in cell culture but not with homogenate 
(26) suggesting that microsomal activation is required prior to bind-
ing. 
Ligandin can be chemically modified so that bilirubin binding at 
the high affinity site is lost, but GSH-T activity is retained (20a). 
Concentrations of bilirubin · sufficient to saturate the high affinity 
site do not inhibit enzyme activity, but at higher concentrations there 
is binding to 'a second low affinity site and GSH-T activity is inhibit-
ed. This suggests that the GSH-T substrate binding site is the same 
site as _the low affinity binding site. This site is present on both Ya 
and Ye, accounting for the presence of similar GSH-T activity in the 
YaYa and YaYc dimers (19). 
11. 
Human Glutathione S-Transferases :-
Originally five immunologically identical cationic GSH-T's (ligan-
dins) with pl's ranging from 7 .8 to 8.5 were described in human liver 
tissue. All five have similar amino acid composition and are thought 
to represent post-translational modification, eg. deamidation, of a 
singie gene product (15). r.fore recently several new GSH-T's have been 
described. A GSH-T with a pl of 6 - 6.5 is present in some specimens 
or human liver. Its presence corresponded with the ability to catalyse 
conjugation of 4-phenyl-3-buten-2-one. This was the only peak of act-
ivity with this substrate (~7, 28). This GSH-T has a higher specific 
activity with benzo(a)pyrene-4, 5-oxide than the basic GSH-T's, but does 
not react with cumene hydroperoxide or 6.5-androstenedione (see chap-
ter XV) (27). In addition in some specimens there is at least one 
major GSH-T with a pl of 4.6 (GSH-T w) and two minor GSH-T's with pl's 
about 5.4 (29,30). GSH-T w is slightly smaller than the cationic 
GSH-T's with a molecular weight of 46,000 daltons. It too consists of 
two E:ubunits, molecular weight 22,500 daltons (30). Antibodies to the 
cationic GSH-T's have been shown to cross react with the anionic GSH-T. 
However the published amino acid analysis of GSH-T w is sufficiently 
different to that of the cationic GSH-T's to cast doubt on claims that 
they are related. In fact th.e amino acid analysis of GSH-Tw closely 
resembles that of GSH-T p in the red cell, which is immunologically 
different from the cationic liver GSH-T's (table 2.2). Like GSH-T p , 
GSH-T III is only active with CDNB as substrate. 
GSH-T p, the major GSH-T present in red blood cells, has a pl of 
4.51 (31). The enzyme has also been demonstrated in lymphocytes, but 

































































































































































































































































































































have failed to show any difference from the liver enzymes (32). The 
red cell enzyme is possibly not as homogenous as first thought. An 
electrophoretic system has shown two charge species. which varied in 
concentration from sample to sample (33). These differences could be 
artefacts rather than due to true differences in structure. 
There is a single CSH-'.': in human placenta which resembles the red 
cell enzyme in substrate specifity (only active with CDNB). pl (4.65). / 




Pure hepatic ligandin (YaYc) has a single high affinity binding 
site and a second, low affil'.ity, binding site (36.37). Several authors 
have noted that ligandin appears to lose binding sites with purific-
ation (28,29,40). The binding affinity may also be decreased. These 
findings are partly explained by the presence of other contar.rinating 
GSH-T's in cytosol, but ad~ition of GSH increases the binding ability 
of ligandin (~6,38). Others have failed to show that bilirubin binding 
is increased by the addition of GSH (39). On adding albumin to cyto-
sol, bilirubin remains bound to ligandin (39), despite the fact that 
the Ka of albumin exceeds that of li[!andin. However addition of albu-
min to purified ligandin resulted in the fo~·mation of bilirubin-albumin 
complexes at the expense of bilirubin-ligandin complexes. Low concen-
trations of serum could remove bilirubin from pure ligandin. These 
data suggest that the affinity of ligandin for bilirubin is higher 
intracellularly than when ligandin is removed from its intracellular 
environment (39). 
The ligandin YaYa dimer has two high affinity binding sites for 
bilirubin (19). The high affinity binding site therefore is thought to 
reside on the Ya peptide. BSP is normally non-covalently bound, but by 
photoactivation can be made to bind covalently. Labelled BSP under 
these conditions binds virtually exclusively to the Ya subunit of a 
YaYc dimer, confirming that Ya carries the high affinity binding site 
(19). Chemical modification of ligandin shows that enzyme activity re-
14. 
quires the presence of the low affinity binding site, which is probably 
also the enzyme substrate binding site (20a,40). Non-substrate ligands 
can competitively inhibit GSH-T activity once the primary site is fully 
saturated (36). Not all binding is that simple however, as instances 
of noncompetitive and uncompetitive ·inhibition of binding have been de-
scrfoed (41.42). 
Non-covalent binding of ligands by the other GSH-T's and covalent 





LIOANDINAEMIA IN LIVER DISEASE 
Clinical enzymology had its origins in 1908 when serum and urine 
from patients with pancreatitis were shown to have a-amylase activity 
(43). Clinical use of enzyme tests was slow to develop and only became 
wide spread when Ladue . et al (44) and DeRitis et al (45) simultaneously 
deecribed the clinical use of transaminase reactions in liver disease. 
Since then a host of different enzyme activities have been shown 
in serum in disease states. However only a mere handful have survived 
into modern clinical pract_ice. 
In hepatology commonly used measurements include glutamic oxalo-
acetic transaminase (SOOT). also known as aspartate amino transferase 
(AST), glutamate pyruvate transaminase (SGPT). also known as alanine 
amino transferase (ALT). alkaline phosphatase (AP). lactic dehydrogen-
ase (LDH). and 1 glutamyl trans peptidase (OGT). Since this study ex-
amines the measurement of ligandin in serum as an index of hepato-
cellular necrosis only those enzyme activities which reflect necrosis 
i.e. SOOT and SOPT. will be discussed. 
The Transaminases: -
The transaminases catalyse the intermolecular transfer of an amino 
group from an a-amino acid to an a-keto acid. This is an oxidative de-
aminntion, and does not involve decarboxylation. Ammonia is not form-
16. 
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ed. Enzyme catalysed transamination was first described in pigeon 
breast muscle (47) in 1937. 
Although the term transaminase is in common usage it is perhaps 
more correct to use the term aminotransferase and specify the partic-
ular enzyme by product e.g. alanine aminotransferase. 
There are a · V&riety of transamination reactions recorded in 
plants. animals ·and man. but only two. SGOT and SGPT are clinically 
useful (48). 
SGOT catalyses the reaction (3.1); 
COOH COOH COOH I I I CH 2 CH 2 CH 2 
bH + 
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Both enzymes require pyridoxal phosphate as a cofactor. SGOT has been 
separated from SGPT and has been purified (49.50). 
The transinainase activities of different tissues vary, with dis-
tinct species differences. In any one tissue however the SGOT activity 
exceeds the SGPT activity. SGOT activity is highest in skeletal 
muscle, diaphragm. heart muscle and liver. but is also present in 
brain, red cells. and kidney. SGPT is more restricted in its distrib-
ution. being found mainly in the liver. and to a lesser extent in skel-
etal muscle ( 48. 51). Different isoenzymes of SGOT are present in cyto-
• plasm and mitochondria, but SGPT is purely a cytoplasmic enzyme. SGOT 
has a .molecular weight of 100,000 daltons. and SGPT 110,000 daltons 
(52). 
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Measurement of the transaminases: -
Many techniques have been described to measure activity of these 
two enzymes, most of which are modifications of three basic techniques, 
spectrophotometric, flourimetric, and colorimetric. 
With the spectrophotometric method NADH, and an excess of malic 
dehydrogenase (SGOT) \lr lactic dehydrogernase (SGPT), are added to the 
reaction mixture. Oxaloacetate is converted to malic acid, and pyru-
vate is converted to lactate. NADH is oxidised in both these react-
ions, and this can be followed by the change in absorbance at 340 nm. 
Thl.; technique is suitable for micromethodology, and .is commonly used 
in clinical laboratories. 
The fluorometric method (53, 54) utilises the oxidation of NADH as 
before, but measures the fluorescence of the condensation product of 
the NAD which is generated, with methyl-ethyl ketone. The colorimetric 
method measures the amount of pyruvate formed. For SGOT oxaloacetate 
\ is converted to pyruvate first, which then reacts with dinitrophenyl-
hydrazine, which can be detected on addition of alcoholic potassium 
hydroxide. For SGPT pyruvate is formed directly (55). The rate of 
transamination is very sensitive to temperature (56, 57), which has led 
to difficulties· with standardization. These have largely been overcome 
with automation. Haemolysis is probably the major physiological factor 
which affects the reaction rate, causing an increased reaction rate, 
possibly due to release of enzyme from red cells (56,58). 
Distribution of transaminases in extracellular fluid:-
There is a considerable gradient in transaminase concentration 
between the cell and the extracellular fluid. The maintainance of this 
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gradient depends up on the integrity of the cell membrane. Although it 
has long been known that leakage of potassium and other small molecules 
into serum was an early indication of cell damage it became more re-
cently apparent that larger molecules. such as enzymes are also re-
leased in the early stages of cell injury (59.GO). 
'rhe coacentratior: of a tissue derived enzyme in serum depends on 
many factors. e.g. rate of release from cells. volume and rate of dis-
tribution. and clearance from the extracellular space. These factors 
will be discussed in turn. 
The rate of r·elease from cells depends on the intracellular con-
centration of enzyme. the size of the organ involved, and the extent of 
the injury to the cells (61). It is important to realise that releas~ 
docs not only occur from necrotic cells. but that even minimally dam-
aged cells may release enzymes. Evi.dence for this has come from work 
with cell suspensions, isolated muscle. am~ experir.ients with isolated 
perfused livers (59,60,62,63). 
In the isolated perfused ;•at liver it has been shown that a rel-
ative or absolute oxygen lack causes release of enzymes into the per-
fusate (64). The perfused livers of fasted rats release more enzyme 
than the livers of fed rats. Following perfusion these livers were 
histologically normal. This and other evidence suggests that enzymes 
can leak out of intact cells (64). 
Work in isolated perfused livers has also shown that the rate of 
release of enzymes depends on their intracellular location. Mito-
chondrial enzymes are released in smaller quantities and more slowly 
than cytoplasmic enzymes (63.65,66). The release of mitochondrial enz-
ymes has been correlated with cell death (67), whereas the release of 
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cytoplasmic enzymes precedes necrosis. Similarly, the release of 
smaller enzymes is more rapid than larger molecules (67). 
The blood disappearance curves for most enzymes are biphasic, with 
an initial rapid clearance, followed by a slower clearance phase. Once 
in serum the enzymes are rapidly redistributed throughout the extra-
cellulr.r spa-::e (68, 69). This redistribution is responsible for the the 
initial rapid clearance. The second slower disapearancc curve may be 
due to catabolism and uptake by tissues. It has been shown that loss 
of activity does not contribute much to plasma disappearance (7~). 
It is not known how SGOT and SGPT or most other enzymes are clear-
ed from the extravascular compartment. Clearance is not affected by 
hepatectomy, nephrectomy, or intestinal evisceration ( 69, 71, 72). Most 
tissues will take up circulating enzymes, us•rnlly by the parenchymal 
cells, and not the reticulo-endothelial cells. Very little intact enz-
yme is excreted in urine or bile ( 70). 
Other enzymes have been used for the study of liver damage, e.g. 
ornithine carbamyl trnnsferase and isocitric dchydrogenasc are liver 
specific, but do not give any more information than transaminases 
(73, 74). Sorbitol dehydrogenase is also liver specific out is relativ-
ely unstable. · Activity of this enzyme tends to follow SGPT activity 
(75). 
Alcohol preferentially damages the centrilobular zone and is also 
a mitochondrial toxin. Therefore glutamate dehydrogenase which is pre-
sent in a centrilobular distribution and is a mitochondrial enzyme is 
possibly a more sensitive index of hepatocellular damage in alcoholic 
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Fig. 4.1. Response of plasma ligandin and SCOT 24 hrs after CCl4. After Bass et al (84). 
Non-enzymatic markers such as serum ferritin (78). serum iron 
(79), and bile salts (80) have also been investigated as markers of 
hepatoccllular damage but have not received universal acceptance. 
Ligandin and GSH-T activity in experimental liver disease:-
The u se of the G:::;H-T's in the diagnosis of liver disease has been 
little studied. GSH-T activity with BSP (81,82) and CDNB (83) has been 
studied in rats given carbon tetrPchloride. BSP proved a r ather insen-
sitive substrate, but activity with CDNB was found to be d .evated 
ear;y, peaking 12 hours before SGOT activity. GSH-T activity was also 
cleared befor·.: SGOT and SGPT activity. Ligandin has also been measured 
immunologically by radioimmunoassay (RIA) in CCI4 treated rats (84). 
At three hours ligandin was more than ten times the upper limit of nor-
mal, but SGOT was not significantl!' raised. · Peak ligandin concentr-
ation was nearly 400x normal levels , whereas peak SGOT was 150x normal 
levels. The mag nitude of release of ligandin was dose dependent up to 
a dose of 0.25 ml/11)0 gm body weight, . after which the dose response 
curve flattened out (fig. 4.1), The SGOT response curve correlated 
less well with dose than did the ligandin response. 
The finding that ligandin was released early, and that the magni-
tude of ligandin release was so great, led Bass et al (84) to conclude 
that in the rat the measurement of serum ligandin was a more sensitive 
index of hepatocellular necrosis than SGOT. 
Bass (85) also studied the disappearance of ligandin and showed 
that its half life was less that one hour. 
The question then arises as to which of the two, RIA or enzyme 
assay, is preferable. Since the first introduction of the radioimmuno-
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assay (RIA) (86), its use in clinical medicine has increased dramatic-
ally. RIA has the advantage of being able to detect lower concentr-
ations of protein (or other antigens) than enzyme activity or function-
al assays of the same protein. Functional activity is dependent on 
upon assay conditions and is subject to many exogenous inhibitors of 
activity. RIA in contrast, · measures the mass of an antigen, irrespect-
ive of its functional state. A good example of the difference between 
these two techniques is the assay of prostatic acid phosphatase in pro-
static carcinoma. Use of RIA to detect prostatic carcinoma has in-
creased detection rate considerably compared to the older enzyme assay 
(87). GSH-T enzyme assay in particular may be prone to exogenous in-
hibition, since many therapeutic agents which may be present in blood 
of patients may either be enzyme substrates, e.g. paracetamol, or may 
be competitive inhibitors of enzyme activity, e.g. penicillin. 
Enzime diagnosis in human liver disease:-
It . is unfortunate that among enzymes used in clinical practice 
there are very few organ specific, and certainly no disease specific 
enzymes. Diagnostic enzymology flourishes best in hepatology, where 
the size of the organ, the lack of a basement membrane around sinu-
soids, and 1:he diverse enzyme equipment of hepatocytcs combine to be 
uniquely useful (61). 
It is common cause that SGOT and SGPT rise dramatically in acute 
viral hepatitis. Clermont and Chalmers (57) analysed data from a num-
ber of groups and concluded that by the time that patients became jaun-
diced all had elevated transaminases, but that the onset of transamin-
ase elevation occurred as many as 16 days prior to the onset of jaun-
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dice. The peak transaminase elevation most frequently occurred about 
1-2 days before the onset of jaundice (88) and reached more than 20x 
normal levels (57). At least 50% of patients will have levels exceed-
ing 600 Karmen units, and only rarely will the admission SGOT be nor-
mal. SGOT returns to normal before SGPT. Up to 95% of patients may 
hav~ -.:esidur.l elevatior. of S'JPT when SGOT has fallen to within normal 
limits. 
Data from the Willowbrook State School studies suggest that in 
hepatitis A transaminases rapidly return to normal, whereas ir hepa-
titi.: B this may be delayed . by months (89). It is common experience 
that SGOT aHd SGPT may remain elevated long after clinical remission 
has occurred. Up to 26% of patients may have persistently elevated 
transaminases at 6 months (90). 
Ligandin was first studied in human disease in 1978 (91), but 
since our first communication only a handful of further publications 
have appeared. 
Normal serum 1.evels in man h ave varied from less than 4 ng/ml 
(92,93) to less than 8.5 ng/ml (91). 
Bass et al reported that ligandin is elevated in acute vir al hepa-
titis and chronic active hepatitis more frequently than the serum glut-
amic oxaloacetic transaminase (SGOT)(AST). wherea s in non-hepatic dis-
eases the SGOT is elevated more frequently than ligandin is (91). 
Ohmi et al (92) studied ligandin measured by RIA in acute hepat-
itis and found that in fatal cases of fulminant viral hepatitis ligan-
din levels are markedly elevated in those patients in whom it was meas-
ured within two days of the onset of coma (range 58 to 780 ng/m1, mean 
316 ng/ml). In patients who survived, the mean elevation of ligandin 
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measured at the same stage of illness was 47 ng/ml (range 8 to 82 
ng/ml). In patients with acute drug induced hepatitis due to paracet-
amol or halothane the mean elevation was 2297 ng/ml (range 68·0 - 5350 
ng/ml). Based on the assumption that the serum ligandin reflects necr-
osis, the authors interpreted these results as indicating different 
meci1anisms .:,f necrosi~ in the two conditions. In drug-induced hepat-
itis they felt n·ecrosis occurs in a single massive burst following ex-
posure to the drug, but in viral hepatitis necrosis occurs over a long-
er period of time and is intermittent or progressive, and less :nassive 
(9:i). A time cour.,e study. of the release of ligandin in hepatitis was 
not performed. 
Tsuru et al (93), also using a RIA for ligand in, showed correlat-
ion with serum glutamic pyruvic transaminase (SGPT)(ALT) in acute and 
chronic -hepatitis, but not in cirrh0sis . Levels of ligandin in acute 
hepatitis were reported to be 16. 8 + 11.1 ng/ml. The highes t reported 
levels were 67 and 37 ng/ml. In chronic hepatitis the levels were 36.0 
~ 19 ng/ml. In this study the authors concluded that measure ment of 
ligandin was not clinically useful. 
Serum GSH-T activity with CDNB as substrate has also been studied 
in human liver disease and shown to correlate with the SGOT in acute 
hepatitis, especially if the SGOT was markedly elevated (94). There 
was also a correlation between serum GSH-T and SCOT in fulrnina nt hepat-
itis. Correlation with SGPT was generally better than with SGOT, exc-
ept in those patients with acute hepatitis who had low levels of SGPT, 
and in patients with fulminant hepatitis. Over the course of the dis-
ease serum GSH-T activity more or less paralleled the transaminase 
levels but returned to normal well before the transaminases did (94). 
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Chronic active hepatitis ( CAH): -
In chronic active hepatitis the diagnosis rests on clinical sus-
picion and liver biopsy. Currently used laboratory methods to assess 
disease activity include the transaminase activity. scrum globulin con-
cent;:ation, ~nd histolo6y. Given the possibility of sampling error, 
biopsy appearane:e is the standard against which all other tests must be 
compared. Since biopsy cannot be repeated at weekly or monthly inter-
vals the transaminases are commonly used for day to day monito .. ing. 
It is well kno\\'n that CAH can be asymptomatic (95), and that hist-
ologically active disease can be present in the absence of elevated 
transaminnse s (80). Summerskill et al (96) showed that clinical and 
biochemie:al remission occurred simultaneously, but that histological 
remission lagged, so that nt 24 months less than 60% of thos e in clin-
ical and biochemical · remission were in hh,tological remission. Czaja 
et al (97) investigated the relationship between serum transa minase and 
hist.Jlogical severity . and showed that about 50% of patients ·with CAH 
will have transaminase levels less than 2x normal, and about 19% will 
have normal transaminases. Most of these patients will have histolog-
ical changes that are not associated with an aggressive course. On the 
other hand when the transaminases were more than twice normal this was 
associated with more severe histological changes. Transaminases how-
ever, do not differentiate between CAH and chronic persistent hepatitis 
(98). Liver biopsy is required for this purpose. 
Serum bile acids have been measured in CAH. and shown to reflect 
the histological status of the liver better than the transaminases 
(80). Although these have been used in specialist units, serial meas-
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urements of bile acids have not . achieved the popularity of the transam-
inases. 
Ligandin has also been studied in CAH (91, 93). but only superfic-
ially. Ligandin immunoreactivity was elevated in CAH (36 .:!:. 19 ng/ml) 
(91, 93), but was not found to be clinically useful. The authors were 
able to show that, as in a,:ute hepatitis, ligandin concentration corr-
elated with SGPT activity. However when GSH-T activity with CDNB as 
substrate was examineq (94) no correlation with SGOT or SGPT could be 
demonstrated. 
Other liver diseases:-
Ligandinaemia has also. been studied in cirrhosis and hepatocell-
ular carcinoma. In cirrhosis no correlation could be found between 
transaminase activity and ligandin immunoreactivity ( 93), or serum GSH-
T activity (94). 
Ligandin is absent or reduced in hepatic tumours in rat and man 
(99,100,101). In the rat well differentiated hepatoccllular carcinomas 
retain ligandin better than poorly differentiated carcinomas do (99). 
Ligandin was present in 9 of 12 Morris hepatoma cell lines. These 
cells retained• ligandin when transplanted into rats, but ligandin was 
absent from most metastases. Serum ligandin was elevated in all but 
one recipient of the tumour (100). The serum ligandin could have come 
either from the tumour or from the surrounding liver. This question 
was examined by transplanting hepatoma cells into a thymic nude mice at 
a site distant from the liver. These animals do not accept normal hep-
atic tissue, but will accept hepatocellular carcinoma cells. As the 
tumour grew in size the serum ligandin rose, suggesting that the tumour 
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itself was secreting ligandin, since the mouse liver ligandin was shown 
not to cross react with the antibody used. 
Ligandin was present in 7 of 11 specimens of human hepatoccllular 
carcinoma (5.2 _:: 2.1 tg/ml range O - 17.4 ug/ml). Elevated levels were 
found in the serum of some these patients (251 _:: 93 ng/ml). Serum lig-
and!.1 was elevated in nnly ?. of 9 patients with hepatic metastases from 
primary neoplasm., elsewhere (100). Tsuru et al (93) were able to show 
a correl_ation between serum GSH-T activity with CDNB and SGOT in pat-
ients with hepatocellular carcinoma. 
The usefu}lneGs of ligandin as an index of hepatic disease is 
still not clear. Questions remain about the release of ligandin in 
hepatic disease, particularly in acute viral hepatitis. There is thus 
a need for a prospective study over a period of weeks, months or years, 
depending on the disease, which will determine whether serum ligandin 
levels represent a better index of necrosfr or prognosis than curr-
ently available. tests. 
28. 
CHAPTER V 
LIGANDINUIUA IN RENAL DISEASE 
The use of urinary enzymology in the diagnosis of renal disease 
has .10t met •1ith wide e,:;ceptunce. Several tubular brush border enzymes 
e.g alkaline phm,phatase (102), maltase (102) and a-fucosidase (103), 
as well as lysosomal enzymes such as B-galactosidase, B-glucosidase and 
N-acetyl-e-D-glucosaminidase (N AG), have been investigated (104-106). 
NAC! and e-glucosil•ase hav~ been shown to be elevated in rejection of 
the transplan~ed kidney. Enzymuria may be the first rr.anifestation of 
rejection, appearing before any clinical or other biochemical manifest-
ations (107,108). 
Experimental tubular necrosis, induced with mercuric chloride or 
potassium dichromate causes enzymuria, but not in advance of. other ind-
icators of renal dysfunction (102). In gentamicin treated rats urinary 
NAG and a -fucosida c;e are increased before other early manifestations, 
such as proteinuria and changes in osmolality (103). This difference 
may be due to the degree of necrosis, i.e. the sudden massive necrosis 
caused by HgCl2 and K2Cr207, which may result in release of tu-
bular enzymes, con·comitant with a deteriora~ion in renal function, 
whereas gentamycin toxicity results in a gradual loss of cells, and 
thus enzymuria can occur for some time prior to the onset of renal dys-
function, which occurs only after considerable loss of tubular cells. 
NAG excretion has been studied in various types of human renal 
disease (105,108). In tubular necrosis following hypotension urinary 
NAG levels are elevated up to 1200x normal levels. In acute and 
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chronic glomerulonephritis NAG levels of up to 10:ic normal nre seen, 
while in the nephrotic syndrome levels of up to 40x normal commonly 
occur. However in some patients in whom nn episode of hypotension is 
e.ssociated with a period of oliguria, but who do not develop acute tu-
bular necrosis, urinary NAG levels in the acute tubular necrosis range 
werl:! found (105). 
It is beca·use of this extreme sensitivity and lack of specifity 
that the use of urinary enzymes for diagnosis has not become wide-
spread. Thus urinary enzyme excretion increases in renal disee.se, but 
doe::; not distinguish one form from another. with the possible exception 
that acute tubular necrosis is associated with massive enzyme excret-
ion. This can be considered to be the renal equivalent of massive SGOT 
release in acute viral hepatitis. However •Jnlike liver disease, the 
massive release of enzymes is also seen in patients who do not have 
clinically significant renal disease. In uddition, unlike liver dis-
ease there are other easily performed tests to detect the presence of 
renul disease, e.g. secum creatinine . 
The localisation of ligandin to the proximal renal tubules has 
prompted the study of the release of ligand in in to the urine. The ex-
perimental model of proximal tubular necrosis is mercuric chloride 
(HgClz) or potassium dichromate (K2Cr207) intoxication (109, 
110) • Hg Cl~ produces necrosis limited to the pars recta of the prox-
imal tubules. K2cr207 causes necrosis localised to the pars con-
voluta. Rats treated with llgClz excrete ligandin in the urine and 
release ligandin into the blood within 12 hours (111). This is assoc-
iated with a rise in the serum urea at 12 hours. Urine ligandin excr-
etion ceases by 24 hours but ligandin is still detectable in the serum 
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at this time. The kidneys of animals sacrificed at 24 hours show a re-
duction of ligandin concentration to approximately 30% of control 
levels (111). 
It had been reported that K2Cr207 intoxication does not 
cause ligandinuria or measurable GSH-T in the urine (112,113). With 
the 11dvent of the more sensitive RIA this was studied in more detail 
and it has now ,been shown that ligandin is indeed released into the ur-
ine in K2Cr207 tr~ated rats (111). However in contrast to 
HgCl2 intoxication, ligandinuria is only detectable after 24 hours 
and persists to at least 72 hours. This release of ligand in h.:..s been 
shown to correlate with histological extension of K2Cr207 induced 
necrosis into the pars recta (111). Most of the immunoreactive ligan-
din in the urine of nephrotoxin treated rats elutes from Sephadex G-100 
at the same elution volume as purifo,d ligandin (85). and has the same 
affinity for the antibody as purified ligandin, indicating that the 
immunoreactivity detected in the urine is due to native ligandin. This 
contrasts with the finding that serum ligandin is excreted as a larger 
molecule with reduced immunoreactivity. and suggests a possible means . 
of determining the origin of urinary ligandin (85). 
Rats giv~n a toxic dose of gentamicin excrete ligandin (measured 
by immunodiffusion) and GSH-T activity in the nrine, whereas these are 
undetectable in normal urine (114). 
Ligandinuria in man:-
In man the measurement of ligandinuria may have an application in 
the diagnosis of acute tubular necrosis, a leading cause of acute renal 
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failure. At present the diagnosis rests on clinical grounds, and is 
supported by side room investigations and a few biochemical tests. 
Clinically in the setting in which acute tubular necrosis occurs, 
(excluding those cases caused by drugs), i.e. hypotension and septic-
aemia, the initial differential diagnosis lies between prerenal renal 
failure and acute tubltlar necrosis. The two conditions may be differ-
entiated by several factors, detailed in table 5 .1., but in many cases 
uncertainty exists, and any test which could differentiate between the 
two would obviously be clinically useful. It is possibl'-! that ligan-
dinuria may Le able t9 differentiate between these conditions. 
Re n&l transplantation has become a common form of therapy. One of 
the major remaining problems is the elucidation renal dysfunction in 
the immediate post transplant period. A renal allograft may never 
fu"nction, may function initially but fail suddenly within a week, or 
after some months, or function may gradually deteriorate (119). 
In the immediate post-transplant period the differential diagnosis 
of a non-functioning graft includes dehydra tion, ureteric or catheter 
obstruction, urinary leak, acute tubular necrosis or hyperacute reject-
ion. In the later post-transplant period acute and chronic rejection, 
ureteric- stenosis and septicaemia may cause · decreasing renal function 
(119). 
Despite inevitable ischeamia, kidneys from living related donors 
function well following transplantation (119). However cadaver kid-
neys, or kidneys which have been perfused fare less well. Twenty to 
50% of these kidneys may develop acute tubular necrosis, which may 




DIFFERENTIATION BETWEEN ACUTE TUBULAR NECROSIS & PRF.RENAL RENAL FAILURE 
Test Prerenal failure Acute tubular necrosis refs 
Urine moderate hyaline Brown granular casts 115 sedi.::.:nt & granul1r casts epithelial cells++ 
Urine sodium less than 10 mEq/1 more than 25 mEq/1 115 
Urine/plasma 116 osmolality increased isosthenuria 
Urifle./plasma 
117 urea more than 20:1 less than 3:1 116 
Urine/plasma 
117 creatinine more than 40:1 less than 15:1 
U/P I,a 
U/P creatinine less than 1 more th,n 1 118 
Acute or cellular rejection can occur at any time after the first 
week post transplantation. This condition is characterised by n cell-
ular infiltrate in the interstitium, but may be accompanied by varying 
degrees of humoral rejection - vasculitis and fibrin deposition (119). 
Acute cellular rejection may be diagnosed clinically by the pres-
ence of fever, E1Ilogri>.ft tenderness. leucocytosis, and decreased renal 
function (119). These criteria however apply equally well to perineph-
ric abcsess, haematoma, or urinary leak with infection. 1311-
hippurate renogram scans are helpful in the diagnosis of rejection, but 
these really only measure renal perfusion, which may be altered for 
reason~ other than rejection (120). 
Acute tubular necrosis is a diagnosis by exclusion in this situat-
ion. Urinalysis in the post transplant period is unreliable (121), es-
pecially in the presence of preexisting decreased renal func t ion. The 
diagnosis can only be made with certainty in r e trospect, when renal 
function r eturns without r ecourse to trea t ment for rejection, or on 
biopsy. 
The differentiation between acute tubula r necrosis and acute re-
jection is important since the former requires only mnintainance dia-
lysis until renal function returns, but ncute rejection requires early 
diagnosis and prompt treatment if irrerv~rsible renal damage is to be 
prevented. Despite the importance of this differentiation renal biopsy 
is not often performed in the first two weeks after transplantation, 
because of the fear of endangering the graft. On the other hand one 
cannot treat all patients as if the diagnosis is acute rejection as 
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Therefore there is a definite need for a simple, safe and accurate 
test to diagnose either acute tubular necrosis or acute rejection, with 
certainty • 
Studies of renal ligandin excretion in man are very limited. In a 
study of enzymuria following renal angiography some patients excreted 
G SH-T activity iu the urine. Ligandin immunoreactivity was also detec-
table in t'he urine (122). This was not associated with any evidence of 
tubular necrosis or deteriorating renal function, and presumably repre-
sented sub-clinical tubular cell damage. 
Ligandin immunoreactivity (by immunodiffusion, which has a limit 
of dete,!tion of 1 - 10 ug/ml) and GSH-T activity were measured in the 
perfusates of donor kidneys. All those kidneys which produced ligandin 
in the perfusate developed post-transplant oliguria, while those kid-
neys which did not produce lii;nndin and G SH-T activity fundioned nor-
mally (123). in a further study (124,125) G SH-T enzyme activity was 
studied in the perfusates and ultrafiltrate from donor kidneys. The 
G SH-T activity in the perfusates from kidneys which developed post 
transplant oliguria was si~ nificantly higher than from those kidneys 
which functioned normally. The difference was such thut 100% predict-
ability could be achieved. Ligandin in ultrafiltrates did not have the 
same predictabilty, although there was a difference in the mean G SH-T 
activity between those kidneys that did, and those that did not develop 
oliguria (125). 
Urine from normal subjects, patients with acute and chronic renal 
failure, and acute renal failure not associated with tubular necrosis 
were negative for ligandin, measured by immunodiffusion. In two pat-












hours of the onset of illness ligandin was detected in the urine. In a 
further 10 patients with acute tubular necrosis in whom urine was only 
available 96 hours after the precipitating insult, no ligandin was det-
ectable in the urine (12G). 
It is clear from these studies that ligandinuria reflects tubular 
necrosis. However the specificity of the test has not been completely 
defined. Nor has it been shown that the assay of ligandinuria is clin-
ically useful. Sequential temporal patterns of ligandinuria in pat-
ients with renal disease have also not been defined.' 
For these reasons further studies of ligandinuria were thought to 





PURIFICATION OF HUMAN LIGANDIN 
Several methods for purification of the human transferases have 
been reported, most in'.rolve either affinity chromatography or anion· ex-
change chromatography, and are somewhat lengthy. Purification of rat 
liver ligandin requires a simple three step procedure without the use 
of gradient elution. Thus human G SH-T was purified utilising a scheme 
base:! on that used to purify ligandin from rat liver. The following 
description is representative of several purifications performed during 
the course of this study. 
MATERIALS AND METHODS 
Human liver was obtained within 12 hou::-s of death from victims of 
trauma. The liver was macroscopically normal. Tissue was used immed-
iately or frozen at -70°C until r equired. 
Enzyme Activity:-
This was -measured spectrophotometrically monitoring the formation 
of adducts of glutathione and 1-chloro-2,4-dinitrobenzene at 25°C 
(127). The light path was l cm and the cuvette volume was 3 ml. Final 
·concentration of CDNB and GSH was lmM. tie was 9600 M-1 cm-1. 
>. max was 340nm. The buffer was O.lM potassium phosphate pH 7.5. Cor-
rection was made for non-enzymatic activity. Results were expressed as 
mmoles product formed per minute per ml. Specific activity is express-
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cd as mmoles product/minute/mg protein. Protein was measured by the 
Lowry method (128). 
Purification:-
All procedures were performed at 4°C. Approximately 100 gm of 
liver was cut fine by i-c-issors and homogenised in 3 volumes of O.OlM 
Tris:HCl, 0.25M sucrose, pH 8.67, using a vortex homogeniser (Ultra 
Turrex). The suspension was homogenised further with a motor driven 
teflon-glass mortar and pestle. 'Inc resulting homogenate was -centrif-
ugecl at 27,000 xg fc.r 30 minutes and the pellets discarded. The super-
natant was thr.n centrifuged at 100,000 xg for 2 hours, £.nd the pellet 
discarded. The supernatant was concentrated to 50 ml using positive 
pressure ultrafiltration in an Amicon stirred cell with a PM 10 mem-
brane, and applied to a 32 x 3. 5 cm column of triethylaminoethyl-
cellulose (TEAE) equilibrated with 0,01M Tri!-:HCl, pH 8.67 (buffer A), 
The column was developed by gravity with the same buffer at a flow rate 
of 6(1 ml per hour. Fractions of 8. 4 ml were collected and the eluate 
monitored spectrophotometrically at 280 nm. Fractions were tested for 
GSH-T activity with CDNB. 
The activ.e fractions were pooled, diafiltrated to 15 ml in O. lM 
sodium phosphate buffer, 0, 15M sodium chloride, pH 7. 4 in an Amicon 
stirred cell using a PM 10 membrane, and applied to a 90 x 2.5 cm col-
umn of Sephadex G-100 previously equilibrated with the same buffer. 
The column was developed with the same buffer by pump driven upward 
flow at a rate of 30 ml per hour. Fractions of 4 ml were collected. 
The eluate was monitored at 280 nm and fractions were assayed for act-
ivity with CDNB. The active fractions were pooled, concentrated to 10 
37 .. 
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ml, re-applied to the same column, and eluted under the same cond-
itions. 
The active fractions from the second Sephadcx G-100 column were 
pooled, dialyzed into buffer A and concentrated to 7 ml. The concentr-
ate was applied to a 45 x 2. 5 cm column of QAE-Sephadex equilibrated 
with the samo buffer. The protein was eluted by gravity with the same 
buffer at a flow· rate of 45 ml per hour. Fractions of 4 ml were col-
lected. The eluate was monitored as before for enzyme activity and at 
280 nm. The active fractions were pooled. 
This procedure resulteq in a protein which was only slightly cont-
aminated. Fhal purification was achieved by either of the following 
methods.:-
1. Rechromatography on QAE-Sephadex :- This was performed under iden t-
ical conditions to the previous step. 
2. Isoelecfric focusing ( IEF): - This was pErformed in a sucrose den-
sity gradient in the pH range 3 - 10, using an LKB 4101 column. The 
sample was applied after 50% of the column volume had been filled. The 
column was developed at 600V for 16 hours and then drained by pump at a 
rate of 1-2 ml/ min. Fractions of 2 ml were collected. 
Polyacrylamide gel electrophoresis (PAGE):-
The discontinuous system of Maizel was used (129). The resolving 
gel was cast between 25 x 10 cm glass plates separated by a 2 mm pers-
pex spacer. The resolving gel consisted of 11% polyacrylamide in 
0.375M Tris:HCI, 0.1% SDS, pH 8.9. The stacking gel was 3% polyacryl-
amide in 0.0625M Tris:phosphate, 0.1% SDS, pH 6.7. Gels were polymer-
ized by light in the presence of riboflavin. Electrophoresis was per-
38. 
formed for 16 hours at 100V. The electrode buffer was 0.005M Tris: 
glycine, 0.1% sns. pH 8.6. 
Samples were prepared for electrophoresis by heating at 100°C for 
2 minutes with 1% SDS, 1% 2-mercaptoethanol, 10\. glycerol and 0.002% 
bromophenol blue in 0.0625M Tris:phosphate pH 6.7. Five to 20 vl of 
each :;ample, containing 1 - 100 vg of protein were applied. After el-
ectrophoresis the gels were fixed and stained in O .1 % Coomassie Blue. 
8% TCA in 33% methanol/67% water for 2 - 3 hours and destained in 5% 
methanol/ 7% acetic acid. The gels were either photographed wet or 
drieri down by vacm··.m and heat between Whatman No. 3 chromatoE;1·aphic 
paper and cellophane, prior to photography. 
Isoelectric focusing in polyacrylamide tube gels:-
This was performed in 5% acryiamide tube gels according to the 
method of Wrigley (130-) in a water cooled MRA apparatus. The gels were 
cast in 10.5 x 0.3 cm rods and polymerized with 0.045% ammonium persul-
phatc. The gels contained 5% ampholyte pH 3-10. After polymerization 
the gels were left to stand overnight at 4°C. After pre-running for 20 
mins at 300 V to remove the ammonium persulphatc. the sample was app-
lied. The sample application solution consisted of 20 o l of protein 
solution containing .:!:_20 0 g protein, 50 ol glycerol and 100 v -1 of 0.1% 
ampholyte. About 80-100 o l were applied to each gel. Anolyte was 
O.OlM 4-(2-hydroxyethyl)-1-piperazine ethane sulphonic acid (HEPES) and 
catholyte was O.OlM ethanolamine. The sample was overlaid with 10 v l 
of ampholyte. Focusing was initiated at 200 mV. Voltage was increased 
at 1/2-hourly intervals to 500 mV and then held constant for a further 
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Coomassie Blue in acetic acid:ethanol:water (2:9:9 v/v) and destained 
with acetic acid :ethanol :water ( 2: 5: 13 v /v). Alternatively the gels 
were cut into 2 mm sections which were shaken for two hours in O. 3 ml 
normal saline. 
samples. 
Enzyme activity and pH were determined on these 
Molecular Weight' Estimation:-
The molecular size of purified ligandin was estimated by gel filt-
ration on a 90 X 2.5 cm column of Sephadex G-100 in O.OlM. sodium phos-
phatti, O.lM sodium chloride, pH 7 .4, run under identical conditions to 
that describe<1 above. Molecular weight markers were blue Dextran 
(100,000). bovine serum albumin (67,000), ovalbumin (43,000), and cyto-
chrome C (13,000). The molecular size of liga,din subunits was deter- _ 
mined by PAGE in SDS using phosphorylase b (94,000), BSA (67,000), 
ovalbumin (43,000). carbonic anhydrase (30, IJOO), soy bean trypsin in-
hibitor (20,100) and a -lactalbumin (14,400) (Pharmacia). Rf ve.lucs 




This purification procedure resulted in a 60 fold purification 
with a yield of 7% (table 6.1). The elution profiles from TEAE-cell-
ulose, Sephadex G-100 and QAE-Sephadex chromatography steps are shown 
in fig. 6.1 A-E. Fifty nine percent of GSH-T activity applied to the 
TEAE-cellulose is not bound and elutes at the protein front as a single 
peak with a prominant trail. Only the peak was pooled. Chromato-
40. 







PURIFICATION OF HUMAN LIGANDIN 
Volume Protein Total Specific Purific- % Yield of 
concen- activity activity ation activity 
ml mg/ml umol/min/ml umol/mg x-fold 
Cyto.,-,1 235 28.40 4605 0.69 100 
TEAE 101 6.5~ 2735 4.10 5.9 59 
G-100' 75 4.37 2000 6.10 8.8 43 
G-100'' 72 2.79 1962 9.76 14 .1 43 
QAE' 13 0.93 432 35.75 51.8 9 
QAE'' 17 0.47 327 41.10 59.6 7 
Tabl~ 6.1. Summary of purification of human ligandin using l-chloro-
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Fig. 6.1. Purification of human ligandin. (A), Elution of protein 
and GSH-T enzyme activity from TEAE-cellulose in O.OIM Tris HCl pP. . 
8.67; (B), Elution of protein and enzyme activity from Scphadcx G-100' 
in O.OIM phosphate buffer, 0,1511 NaCl, pH 7.4; (C), Elution of protein 
and enzyme -activity from G-100'' in phosphate buffer; (D), Elution of 
protein and enzyme activity from QAE-Sephadex A-50 in O.OlM Tris HCl pH 
8.67; (E) Elution of protein and enzyme acitivity from the second QAE-
Sepha<lex A-50 column in Tris buffer. (See Methods and Results for 
details). 
graphy on Sephadex G-100 yielded a single symmetrical peak of GSH-T ac-
tivity eluting at 1.5x the void volume. The first QAE-Sephadex step 
resulted in two peaks. GSH-T activity was confined to the second peak. 
Further purification was achieved by one of the following pro-
cedures :-
1. Isoelectric focusing, which yielded a single peak of enzyme ac-
tivity. Since th,_is method required a further step to remove ampholytes 
and sucrose this method was not routinely used. 
2. Repeat QAE-Sephadex chromatography, which yielded two protein 
peaks, both of which had enzyme activity. The second peak contained 
most of the G SH-T activity, and contained a protein homogenous by SDS-
PAGE. This method was simpler than 1, but was associated with con-
siderable loss of activity. 
The .second peak from the QAE-Sephadex column was pooled and had 
the following characteristics:-
1. On discontinuous SDS-PAGE the protein migrated as a single band in 
the 26600 dalton molecular weight region (fig. 6.2). 
2. The prot~in eluted as a single homogenous peak with symmetrical 
enzyme activity when chromatographed on Sephadex G-100. The molecular 
size of the peak was estimated by comparison with chromatographic stan-
dards to be 4 7, 500 daltons, with the entire peak eluting between 43 0 000 
and 54,000 daltons (fig. 6.3). 
3. lsoelectric focusing in gels yielded two adjacent catalytically 








7 6 5 4 3 2 1 
Fig . 6 . 2. Discontinuous slab PAGE in SDS (11% polyacrylamide) of; 
(1) 100,000 xg supernatant of human liver; (2) pooled protein peak f~om 
TEAE-cellulose; (3) pooled peak of enzyme activity from G-100'; (4) 
pooled peak of enzyme activity from G-100''; (5) pooled peak o~ enzyme 
activity from QAE'; (6) pooled peak of enzyme activity from QAE''; 
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Fig. 6.3. De~ennination of comparative m~lecular weights of purified 
human hepatic lieandin on Sephac!ex G-100 chromatography. Details of 
the procedures used and of the molecular weights of the standard pro-
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FRACTION NO. 
E!_,s:;. 6.4. Tube gel iscelectric focusing of purified huIBc:n lig.mdin 
in the pH range 3 - 10. The gel was sliced into 2 mm sections. Enzyme 
.icti vi ty was recoverable in two adj a cent slice-:; correspor,diug to pH 
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showed two closely foeused strongly staining bands corresponding to the 
two active fractions. In adciition there were several very faint bands 
visible which focused at lower pH (fig. 6. 5). 
4. Specific activity with CDNB as substrate was 27. 56 umol/min/mg 
prote,.n. Km and Vm11x estimated by the Lineweaver-Durke double 
reciprocal plot .were 0.35 and 579 umol/min/mol enzyme respectively 
(fig. 6. 6). 
DISCJSSION 
Purification: -
The purification procedure described here results in the purific-
ation of two catalytically active charge isomers of GSH-T. 
The- protein isolated here is pare by several accepted criteria. 
The protein eluted from Sephadex G-100 as a single symmetrical peak, 
consisted of a single band on PAGE in SDS, and could be used to raise 
an antiserum in rabbits which resulted in a single line on immuno-
diffusion and immunoelectrophoresis against soluble liver proteins 
(chapter V). 
The 2 bands seen on IEF may represent two immunologically iden-
tical G SH-T's of identical size or may be an example of 'microhetero-
geneity'. Comparison of pl estimated by gel electrofocusing with those 
of previously · published results suggests that these may correspond to 
GSH-Ta and a. GSH-Ta has a pl of 7.8. and GSH-·.ra 8.25 (16). The 
faintly seen bands of lower pl may indicate inhomogeneity of the prep-
aration, but since these extra bands are not seen on PAGE, they may re-




Fig. 6.5. Tube gel isoelectric focusing of purified human ligandin 
in the pll range 3 - 10 of purified human hepatic ligandin. The ge l was 



















































































































































































































too low to detect cactalytic activity. The specific activity recorded 
here however is closer to thi.t of G SH-To •. which is given as 34 u mol/ 
min/mg protein (16). The molecular size of the dimer and the monomer 
are in agreement with previously published values for the cationic 
human G SH-T's. Unlike the rat. the human hepatic cationic G SH-T's have 
two iJcntical subunits. Density gradient polyacrylamide gel electro·-
phoresis did not. succeed in separating the monomers. 
The Km and Vmax found in this study are somewhat lower than thosa 
quoted by Kamisaka et al (16). T:tis may be due to the presence of p:.'e-
ser1.,E1tives. glycerol, GSH and EDTA, which were used in that stm.:y, but 




This chapter describes the production of an antiserum and testing 
thereof for specifity. 
METHODS 
Inoculation:-
Three month old male albino rabbits were immunized with . purified 
liga!l1in according tci the following schedule:-
!. 15 ug of protein in 1 ml of O.OlM sodium phosphate l::uffer pH 7.4, 
0.15M NaCl was emulsified with 1.5 ml of complete Freund's ad-
juvant by expulsion via a 21 gauge syringe needle. 
2. The emulsion was injected into multiple subcutaneous sites on the 
back of each rabbit at 3-weck intervals. 
3. Animals were bled at 10-day intervals following each booster inn-
oculation. 
Processing of antiscra :-
Bl.ood obtained from immunized rabbits was allowed to clot at room 
temperature for 1 hour then stored at 4°C for 24 hours. Serum was sep-
arated by centrifugation at 4,000 xg for 30 minutes at 4°C (131). Ali-
quots of separated sera were stored at -20°C with 0.1% sodium azide 























Testing of s.ntiscra: -
The antib0dy was tested by immunodiffusion and immunoelectro-
phoresis in agar against purified ligandin and human liver cytosol. 
Immune precipitates were stained with amido black (132). Non-immune 
rabbit sera (NIRS) were used as antiserum controls. Normal saline, 
humr..,1 serum and other humRn proteins were antigen controls. 
Immunodiffusion (133) :-
This was performed in 1.2% agar in 0.05M sodium phosphate buffer 
pH 7 .4, 0.15M NaCl with lOQ mg of sodium azide added. Wells o1 4 mm 
diameter ( 10 ul capacity) were routinely employed. Antigen samples 
were placed in peripheral wells and antiserum in the central well. The 
plate was allowed to develop at room temperature for 24 hours and at 
4°C for Ii further 24 to 48 hours. 
Immunoelectrophoresis ( 134) :-
This was perforrned in 1% Agar in 0.14M Veronal buffer pH 8.7/0.2% 
sodium azide. Electrophoresis was performed at 12mA/plate for 1.5-2 
hours. Antiserum was then added to the troughs and the plates were 
allowed to develop as for immunodiffusion. 
Cross Absorption: -
50 vl of human liver cytosol and 400 vl of rabbit antihuman ligan-
din antiserum were incubated for 48 hours at 4°C. Liver cytosol was 
also incubated with non-immune rabbit serum and 0.9M saline. After 4:8 
hours the mixture- was centrifuged at 18,000 xg for 30 minutes and the 
supernatants tested by immunodiffusion. 
45. 











Fig. 7 .1. Immunodiff:usion in agar gel. The centre well contains 
rabbit :-nti-hl'man ligandin an~iserum . Peripheral wells contain; (1) 
human l1epatic cyt:>sol; (2) purified human ligandin; ( 3) human 
albumin; (4) horse heart myoglobin . 
cyt osol 
Ii ga ndi n 
albumin 
myoglobin 
Fig. 7 .2. Immunoelectrophoresis in agar gel. 1'he troughs contain 
rabbit anti-human ligandin antiserum. 
RESULTS 
Rabbit antiserum to human ligandin produced a single precipitin 
line on immunodiffusion and immunoelectrophoresis against purified lig-
andin and hepatic cytosol (figs. 7.1, 7.2). No precipitin lines were 
seer. with nonimmune ra :)bit serum in the central well or with proteins 
other than ligandin in the peripheral wells. Purified ligandin gave a 
single precipitin line against a polyvalent rabbit antiserum prepared 
against human hepatic cytosol proteins. Following absorption with 
hep<1tic cytosol the antiserum no longer produced precipitin lin,:;.,; with 
ligandin but formed precipitin lines with control cytos:il which had 
been preincubated with non-immune rabbit serum or saline. 
DISCUSSION 
The rabbit anti~human ligaridin antiserum raised in the present 
study was shown to be monospecific in that it gave single precipitin 
lines on immunodiffusion and immunoelectrophoresis with purified human 
hepatic ligandin and with human hepatic cytosol. Multivalant rabbit 
anti-human hepatic cytosol also gave a single precipitin line with pur-
ified ligandin. , Other human proteins tested against rabbit anti-human 






Several methods exist for the production of labelled proteins. 
All have disadvantages. Iodination is usually chosen for in vitro lab-
elling because of ease of counting, and the ease of the labelling proc-
edure. 125Iodine is usually prefered to 13liodine tccause 
of the longer half life of the former. Direct iodination has the ad-
vantage of a high specific activity, however the labelling procedure 
may alter the immunogenicity of the antigen. Since labelling involves 
the introduction of an atom not usually present in the molecule, this 
too may alter the immunogenicity of the protein. or may alter physico-
chemical characteristics such as the pl. Finally labelled proteins are 
subject to degradation or aggregation on storage. or to loss of iodine 
from the molecule. All these factors have to be taken into account 
when selecting and testing a method of iodination. A further step is 
required to separate intact labelled protein from damaged products of 
iodination and · from free iodine, both present in the reaction mixture. 
Since rat ligandin had been successfully iodinated by the chlor-
amine-T method and separation of intact labelled ligandin from damaged 
protein and free iodine easily achieved. a similar system was used for 
the iodination of human ligandin. 
47. 
METHODS 
All counting was performed in standard tubes in a Packard Auto-
gamma Scintillation Spectrometer connected to a Teletype printer. 
Background radioactivity was automatically subtracted from all samples• 
For the RIA counts were recorded on paper tape for use on a computer. 
Iodination:-
A modification of the method of Greenwood et al (135) was used to \ 
iodinate ligandin. Reagents were mixed at room temperature in a small 
glass test tube using constriction pipettes. Reagents were added in 
the following order. 
Carrier free 
125
1, 1 mCi 
0.5M sodium phosphate buffer pH 7 .4 (PBS) 
The following reagents were then added with mixing:-
Ligandin, 15 ug 
Chloramine-T, 10 ug in 10 ml PBS 
10 u 1 
25 u 1 
25 u 1 
25 v 1 
The reaction was allowed to proceed for 30 seconds and was terminated 
by the addition of:-
Sodium metabisulphite, 50 ug in 10 ml PBS 
Potassium iodide, 2 mg in 10 ml PBS 
100 vl 
200 vi 
Purification of the reaction mixture was achieved using a combin-
ation of gel filtration and ion exchange chromatography. The entire 
reaction mixture mixed with 0.5 ml 0.1% BSA in 0.03M Tris/HCl buffer, 
pH 8.8 was applied to a 30 x O. 7 cm glass Biorad disposable column 
packed to a height of 4 ems with TEAE-cellulose and to an additional 25 






















reaction mixture was eluted by gravity with the same buffer at a flow 
rate of 18-20 ml/hour • . Fractions of 0.4-0.6 ml were collected. 
Assessment of iodination: -
The incorporation of 1251 into ligandin, the nature and ex-
tent vf iodi-1:i.tion damei;e, the efficiency of the procedures used to 
purify the labE:l, and the stability of 1251-labelled ligandin 
were assessed by the following methods: 
1. 'j,'richloroacetic ::tcid (TCA) precipitation was performed using 5 ti! 
of reaction mi :.dure or 20 u 1 of the purification column fractions to 
which were added 1 ml 0.05M sodium phosphate buffer pH 7.4, 0.1% bovine 
serum albumin. The mixture was incubated at 4°C for 30 minutes and 
then centrifuged for 30 minutes at 2,000 xg. Radioac tivity in the pre-
cipitate and in O. 5 ml ·of the supernatant was counted separately. Res-
ults were expressed as the percentage precipitable counts vs total 
radioactivity in the o':'ibinal sample . 
2. Chromatelectrophoresis (136) w&.s performed on 50 X 3.5 cm strips 
of Toyo 514 paper using 5 ul of human albumin as a carrier, and bromo-
phenol blue as a marker for . damaged protein i,roducts of iodination. 
The system was validated by digesting a 0.5 ml aliquot of 1251-
ligandin with O. 5 ml of trypsin ( 1. 8 mg/ ml) and applying the digest to 
the same chromatoelectrophoresis system. The chromatelectrophoresis 
was run in 0.05M veronal buffer, pH 8.6, for 1 hour at 400V. The strips 
were then dried and cut into l cm portions for determination of radio-
activity. Once the characteristic migration of the "intact", 11 damaged" 
49. 
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FRACTION NO. 
~8 .1. Purifiotion of 125!-ligandin by Sephadex G-25/TEAE-
cellulose chromatograJh7. The iodination reaction mixture was adced to 
0.5 ml 0.1% BSA in 0.03M Tris HCl and applied to the colui;in, which was 
~un in the same buffer. 
and "free" fractions were established the strips were cut into 3 por-
tions for determination of . radioactivity. Results were expressed as 
percentage of total radioactivity per strip. 
3. Gel filtration was performed using Sephadex G-100 in O.U.1 sodium 
phos;:hate buffer, 0.15M NaCl on a 1.5 x 60 cm column. 10 v 1 of the 
peak fraction frorr. peak 1 of the purification column was added to 5 ml 
of unlabelled ligandin (0. 2 mg/ ml), and applied to the column. The 
column was developed with the same buffer at a flow rate of 4ml/min. 
The <:luate was monitored at 280 nm and radioactivity determined. 
4. Isoelectric focusing (IEF) :- 10 "1 of labelled protein was added 
to 20 ml of unlabelled protein ( O. 2 mg/ ml). IEF of the labelled pro-
tein was 'performed in tube gels under identical running conditions as 
before, except that an'lpholytes in the pH ranf.e 6.5 - 9 were used. An-
olyte and catholyte were O.OlM HEPES and O.OlM ethanolamine respectiv-
ely. 
RESULTS 
Elution of the iodination reaction mixture from the combination 
gel filtration/anion exchange column resulted in three peaks (fig 8.1). 
The iodination reaction mixture and an aliquot from each peak tube was 
assessed by TCA precipitation and chromatelectrophoresis. 
Validation of the chromatelectrophoresis :-
An aliquot from peak 1 subjected to chromatelectrophoresis re-




















Fig • . 8 .2. Validation of chromatelectrophoresis. An aliquot fro:n the 
peak tube fro:n the iodination purification column remained at the 
origin. Another aliquot frou1 the same tube was subjected to tryvtic 
digestion and rai g rated with the blue front (shown by the hatched bar). 
- Free 1251 migrated ahead of the blue front (not shown). 
PURIFICATION OF LABELLED LIGANDIN 
TCA % Chromatelectorphoresis % 
origin blue front fast running 
reaction 52.5 + 6.56 40.4 + 9.37 26.4 + 7.9 33.2 .:!:. 8.0 
mixture 
Peak I 93.1 + 1.98 94.7 + 2.90 4.2 + 3.2 1.1 .:!:. 1.1 
Peak II 93.2 + 5.94 15.2 + 12.95 73.9 + 10.2 10.8 .± 9.8 
Peak 111 6.3 + 1.83 1.8 + 1.62 4.2 + 3.9 94.3 + 5.0 
Table 8.1. Assessment of purification of labelled ligandin by 
chromatelectrophoresis and TCA precipitation. An aliquot from the 
peak tube was assessed. Radioactivity remaining at the origin re-
presents intact labelled protein. radioactivity migrating with the 
bl~e front indicates damaged labelled protein, and fast migrating 
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Fig. 8 .3. Chroraatelectrophoresis of (A), iodination reaction miY.-
ture; (B), fraction 9 from the purification colmnn; (C), fraction 15 
(D) fraction 26. The blue front is represented by the hatched bar. 
with the bromophenol blue front (fig. 8. 2). Free iodine migrated ahead 
of the blue front (data not shown). 
Separation of intact labelled protein from free iodine and damaged 
products of iodination:-
An aliquot from peak 1 was more than 90 % TCA precipitable (table 
8.1) and on chromatelectrophoresis remained largely at the origin (fig. 
8. 3). These criteria, plus the result of the tryptic digest suggest 
that this peak contains mainly intact ligandin. Peak 2 was 80 - 90% 
TCA precipitable and migrated with the blue front (fig. 8.3.)(table 
8.1), suggesting that this peak contained mainly damaged products of 
iodination. Peak three was barely precipitable with TCA and migrated 
ahead of the blue front (fig. 8.3) )(table 8.1), and consisted of free 
iodine. 
Characterisation of 125 I-ligandin :-
On gel filtration an aliquot from peak 1 eluted with unlabelled 
·ligandin. On IEF the labelled protein focused at the same pl as G SH-T 
enzyme . activity and purified ligandin, i.e. between pH 7 .8 and 8.1 
(fig. 8.4). 
Optimization of iodination conditions:-
Optimum iodination conditions were determined using chromat-
electrophoresis. Conditions were chosen so that between 30 and 50% of 
1251 was incorporated into ligandin. The technique was highly 












Fig . 8.4 . Isoelectric focusing of 125I-l igandin . 10 ul 
.of 
fraction --9 ar.d 100 ul of pur~.fied ligandin were mixed and subjected 
t o 
isoelect rric fo:.using . Enzyme act i vity and radioactivity both focu
sed 
at between pH 7. 8 and 8 .1. 
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phoresis for 10 consecutive iodination/purification procedures per-
formed over several months are given in table 6.1. 
The average incorporation of 1251 into ligandin (derived 
from both TCA and chromatoelectrophoretic data) was 35%. The approx-
imate specific activity of the labelled protein was calculated from the 
form\.i8 -
Specific Activity ·. (SA) = incorporation of 1251 1, OOOJ Ci 
mass of iodinated protein 
and was 44.87 uCi/og ligandin. The number of iodine atoms incorporated 
per n>olecule was derived from the formula -
mmole 1251/mmole ligandin = 
ligandin SA x ligandin mol wt 
1251 SA x 1251 atomic wt 
Using the quoted specific activity of 1251 of 13 - 17 mCi/ 
0 g I, and assuming a molecular weight of 47,500 for ligandin, the 
incorporation was 0 •. 99 - 1. 33 mmole 1231/mmole ligandin. This 
calculation assumes that the specific activity of labelled ligandin was 
not altered by the purification procedure, in other words, the proced-
ure did not differentiate between unlabelled, monoiodinated intact, or 
' polyiodinated intact ligandin. 
Storage of labelled ligandin :-
This was assessed by chromatelectrophoresis (fig. 8.5). On storage 
labelled ligandin deteriorated with loss of iodine from the molecule. 
This is in contrast to iodinated rat ligandin, where an increase in the 
damaged fraction occurs with storage. The rate of loss of ligandin was 





























INTACT 125 1- LIGANDIN • • 
DAMAGED 1251-LIGANDIN A • 
FREE 125 1 • • 
14 21 28 
Fig, 8 ,5. Ston;ge of 1251-ligandin. The change in the 
percentagE: of label migrat:ing in the chromatelectrophoresis systeu as 
intact, damaged or free freactions is plotted against time, 
DISCUSSION 
Using the method used by of Bass et al (18) to iodinate rat ligan-
din a successful iodination of human ligandin was achieved. The iod-
ination yielded more than 90% pure labelled ligandin and was sufficient 
to allow dilution of up to 200 times prior to use in the RIA. 
!mmunoreactivity of labelled ligandin was not directly tested, but 
iodination did not appear to change the physicochemical characteristics 
greatly. Elution of labelled protein from gel filtration and from IEF 
tube gels was identical to elution of unlabelled ligandin. Overiodin-
ation. which is aswciated with a loss of immunoreactivity did not 
occur since ttie average incorporation of iodine was 1: 1 iodine :ligan-
din. 
The iodination was associated with a considerable amount of damag-
ed products. much of which was TCA precipita:t>le. This is born out by 
the fact that the second peak of the purification column migrated with 
the products of tryptic digestion of the labelled protein. Unlike the 
damaged products of iodination of rat ligandin. which were mainly frag-
ments and small peptides. the damag ed iodinated human ligandin seems to 
consist of mainly larger fragments which are TCA precipitable. 
Labelled .rat ligandin decays with an increase in the damaged frac-
tion. whereas labelled human ligandin decays tlirough loss of iodide. 
Loss of iodide per se does not result in a reduction of immunoreact-
ivity. but causes a decrease in specific activity. There is however a 
general loss of immunoreactivity of most labelled stored proteins, pro-
bably reflecting simple degradation of the proteir1. To avoid this, 





lh.ving obtained purifiEd ligandin, purified labelled ligandin and 
a monospecific antiserum to ligandin, all the necessary ingredients for 
the radioimmunoassay were now a,:ailable. This sect.ion discusses the 
development. of the RIA, the met.hod of separating bound fro~,! free 
labelled antigen, assessment of assay performance, and of ant.ibody-
antigen affinity . 
METHODS 
Determination of radioactivity: -
The double antibody method of Hunter (137) was used to separate 
antibody-bound from free labelled ant.igen. 
All counting waE". performed as previously described. A minimum of 
10,000 counts per tube were accumulated. Data was captured on paper 
tape for transfer to a computer file. 
All det.erminat.ions were performed in standard plastic tubes 
(Falcon plastics No. 2052). All dilutions of tracer, st.andardi:;, un-
knowns, NIRS and antiserum were made in a diluent buffer comprising 
0.05M sodium phosphate buffer pH 7 .4, 0.15M NaCl, O.OlM EDTA, 0.5% bov-
ine serum albumin (BSA), 0.1% sodium azide. 
54. 
Tube protocol:-. 
The double antibody method of Hunter (137) was used to separate 
antibody bound from free labelled ligandin. 
The components in appropriate dilutions were added to each 
stancia:rd and unknown :::amp!-:: tube in the following order:-
diluent buffer 
standard/unknown 
rabbit anti-liiandin antiserum (first antibody) 
i.-lIRS 
125 1-ligaodin 
This comprised the first incubation mixture. 
200 vl. 
200 vl. 




particular component was omitted the volume deficit was made up with 
diluent b·uffer. The tubes were inc\lbuted for 24 hours at 4°C. The 
second ant.ibody in the form of donkey anti-nbbit globulin (DARG )(100 
v1) was added to give a final incubation volume of 1 ml. Following a 
second 24 hour incub'.lti.on at 4°C the tubes were centrifuged at 2,000 xg 
for 30 minutes. The supernatants were decanted and after drainage onto 
absorbent. paper towelling the tubes were counted. 
Assay protocol·: -
Each assay included:-
4 Tubes containing only labelled ligandin (total counts). 
4 Tubes containing only second antibody to est.imate non-specific 
binding of label (NSB). 
4 Tubes containing label and both antibodies, but no standard or 
unknown to assess maximum binding of label in the absence of unlabelled 
antigen (B0). 
55. 
22 Tubes containing duplicate standard concentrations of unlabel-
led ligandin ranging from 0.3 to 500-600 nanograms per tube. This was 
the standard curve. 
Duplicate dilutions of a large pool of ligandin which had been 
aliquotted and frozen were used as internal standards. Two or three 
diluticns were used. Each aliquot was used once only. 
A variable number of unknowns in duplicate and in dilutions were 
assayed so that measurements in the sensitive part of the curve could 
be made. 
Determination of first antibody titre:-
This was determined by incubation of serial dilutions of rabbit 
anti-ligandin antiserum with constant amounts of 1251-ligandin 
according · to the standard assay protocol. The dilution selected for 
the assay was that dilution which demonstrated 50% of maximum binding · 
of the tracer in the absence of unlabelled antigen. This dilution was 
called the antibody titre. Serial bleeds 10 days after each booster 
were tested. 
Optimization of. the second antibody precipitation:-
This was achieved using serial dilutions from a large pooled stock 
of donkey anti-rabbit globulin (DARG) which were incubated with serial 
dilutions of NIRS in the presence of a constant · amount of 1251-
ligandin and a 1/ 1,000 initial dilution of first antibody according to 
the assay protocol outlined above. 
56. 
Optimization of assay incubatfon times:-
This was achieved by keeping the first incubation time constant 
and varying the second incubation time between 8 and 48 hours, and 
keeping the second incubation time constant at 24 hours and varying the 
first incubation time between 2 and 48 hours. 
Cross reactivity> with other proteins: -
Standard dilutions (1 mg/ml) of human albumin, myoglobin, cyto-
chrome C and rat ligandin were assayed by RIA. Results were expressed 
as .,ercentage cros& reactivi.ty, and are calculated by the formula:-
measured concentration x 100 
actual concentration 
Calculation of binding data: -
This was performed by an adaptation of the RIARUN Fortran pro-
gramme devised by llodbard and Lewald (138) which was run on a Univac 
series 1100 system computer. This programme fits the standard curve of 
the assay to a linciir function by the logit-log transform using the 
relationship;-
logit (Y) = a + b loge(X). 
Y = B/Bo, 
logit (Y) = loge (Y/1-Y';) 
X is the · dose of unlabelled antigen 
(bet h corrected for NSB) 
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DILUTION x 100 
Fig. 9 .1. Antiserum dilution curves of rabbit anti-human ligandin 
antiserum. On t:he ordinate is Fercentage ratio of antibody bound 
radioactivity to total radioactivity. On the ab,;cissa is !:he •Ulution 
of antiserum. Ser!.al dilutio"'.ls of consecutive bleeds from rabbit 410 
were incubated with fixed aciounts of 1251-lj_gandin accordir,g to 
standard assay protocol. \.Tith each bleed the 'titre', i.e. the 
dilution of antiserum which exhibits 50% of maximum bi~ding, rises. 
The affinity of the entiserum for the antibody was determined by 
Seate hard plot analysfa (139), also provided by the RIAR UN programme. 
Assessment of assay efficiency: -
This was performed by statistical analysis of several criteria of 
assaf perforr:iance, valt!cs fn· . which were provided by the RIARUN pro-
gramme. Assays with criteria falling more than two standard deviations 
from the mean were repeated. 
RES'JLTS AND DISCUSSION 
Determination of the first antibod y titre:-
The rising titre of antibody is shown for successive bleeds from a 
single rabbit is shown in fig. 9.1. The antiserum chos en (no. 410/ 
18/6) ex.hibited 50% of maximum binding of the tracer at an initial dil-
ution of 1: 3600 and · was used in this ccncentration in subsequent 
assays. 
Optimization of second antibody titre:-
Optimal binding was achieved when NIRS was used in dilutions of 
1:200 to 1:400, and DARG was used in dilutii:ms of 1:12 to 1:20 (fig. 
9.2). 
Optimization of incubation times (fig. 9.3):-
Twenty four hours was chosen for first and second antibody incub-
ations. These times provided the optimum between %BIT and convenience. 
Although after 48 hours of second incubation %BIT was approximately 10% 
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Fig. 9 .2. Optimization of second antibody precipitation. Ordinate 
and abscissa are as for fig. 9.1. The dilutions of DARG and NIRS which 
gave maximum b:I nuing were determined by holding the concentration of 
the one constan~ 3nd varying the concentration of the other using stan-














Fig. 9 .3 Optimization of incubation times. Ordinate and absc!.ssa 
areds!:.'.lr fig. 9.1. The maximum binding of 1251-ligandin under 
standard ass;!y conditions 'liic s assess ed in the absence of star.dard or 
unknown. Each i~cubation period was held constant at 24 hours while 
the other was varied. 
48 
A typical standard curve obtained by the addition of increasing 
amounts of unlabelled ligandin to tubes containing constant amounts of 
anti-ligandin antiserum and 125 I-labelled ligandin is shown in 
fig. 9.4. The curve is sensitive in the low nanogram range. 
Assc .... sment .of assay pe.,.formnnce :-
Precision car1 be defined as the reproducibility of an assay and is 
a measure of the variation observed between repeated determinations of 
the same sample within and between assays. This is different from ac-
curc:.cy. which is the degree . to which the measured value approximates 
the true valuf'. Accuracy is related to the spccifity of an assay and 
is considered later. 
Precision is affected by many factors. e.g. errors in dilutions. 
pipetting · errors and counting errors. Dilution errors were minimised 
by avoiding doubling · dilutions fo r the stanctard curve and unknowns. 
Pipetting errors were allowed for in the calculation of binding data by 
assig ning a coefficient of variation of 0.01 to pipetting volumes . 
This was performed automatically by the RIARUN programme. Counting 
errors were minimised by allowing at least 10,000 counts to accumulate 
minimised by allowing at least 10. 000 counts to accumulate per tube. 
Counting errors are equal 'to the square root of the counts. and there-
fore for a count of 10,000 is 1%. Only the NSB tubes had less than 
10,000 counts, but since NSB accounted for less than 2% of the counts 
this error was insignificant. 
Precision of a competitive binding assay such as RIA also varies 
according to the dose level being measured. Precision is best in the 
mid-range of the curve, and falls off at the extremes. 
59. 
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Fig. ~.4. Standard curve of the ligandin RIA. On the ordinate is 
the percentage ratio .")f antibody bound radioactivity to radioactivity 
bound in the absence of unlabelled ligandin . Also shown are dilution 
curves of human and rat hepatic cytosol. The dilution curve of rat 









Precision was monitored by use of internal standards. Between 
assay variability was nssessed by measuring two dilutions of a stock 
solution of ligandin (internal standards). Two dilutions were used to 
give an estimate of precision at two points on the curve. The mean (±_ 
S.E.M.) of a 1:2000 dilution of the stock solution was 10.0 (+ 0.2) 
ng/t ... be (CV == 0.08), s:1d for a 1:1000 dilution mean (+_ S.E.l\i.) was 
23.7 (±_ 0.12) ng/iube (CV== 0.3). 
Within assay varic.bility was assessed by repeated measurement of a 
single sample in a single assay. Mean for 20 replicates was 1.05 (±_ 
0.06~ ng/tube (CV =· 0.3). . 
Other ind.ico2s upon which precision depends were: -
LD50 (dose at 50 % response) 
Slope of lhe standard curve 
40.6 + 0.94 % (mean + SEM) • 
17.3 + 0.48 (mean±. SEM). 
-1.13 + 0.02 (mean + SEM). 
Sensitivity can be defined a s the minimal detection limits of the 
assay, i.e. the least concentration of unlabelled ligand which can be 
differentiated from a sample containing no . unlabelled ligand. This 
depends on the confidence limits of both estimates, and is best descr-
ibed by a statistical function, e.g. standard deviation or standard 
error. It is obvious then that sensitivity . depends to a large extent 
on precision. Also important is the fact that the definition of sens-
itivity is most useful when it refers to _the original sample rather 
than the amount of ligand in the assay tube. If an assay can detect 1 
ng for an incubation volume of 200 0 1 of sample then assay sensitivity 





























For this assay the minimal detectable concentration over 20 assays was 
2.9 ±. 0.3 ng/n1 (mean±. S.E.M.), i.e less than 1 ng/tube. 
Specifity is defined as the degree to which an assay will detect 
substances other than that for which the assay was . designed. Lack of 
specificity can be considered under the headings of immunological cross 
reactivity. and 
1
non-s pecific binding. 
lmmunolgical cross reactivity can occur for three reasons. A hom-
ogenous antibody population may react with identical sites on proteins 
other than those intended, ·e.g. the -subunit of all the glycoprotein 
hormones is identical. The antiserum may contain populations of anti-
bodies directed against similar but not identical sites on other pro-
teins. Finally the purified protein used fm inoculation may contain 
minor contaminants which may nevert!",cless be highly immunogenic. Imm-
unological cross reactivity may be tested for by measuring possible 
cross reacting substances in known concentration in the assay in the 
abser;ce of unlabelleci antigen. Human albumin, myoglobin and cytochrome 
C have negligible cross reactivity in the assay (table 9 .1). Rat liver 
cytoso~ exhibits partial cross reactivity at a non-identical antigenic 
site. This results in non-parallel dilution curves, i.e. curves of 
different slopes, representing antigens of different affinity for the 
antibody (fig. 9.3)(see below) 
Non-specific binding refers to non-immunological binding of the 
tracer, and is caused by adsorption to surfaces e.g. tubes, especially 
. if these are made of glass, or to non-specific binding to DARG, NIRS or 
carrier protein. Non-specific binding in this assay .was assessed by 
incorporation of the NSB tubes containing tracer, but no antibody or 
61. 
unlabelled ligand. Ov~r 20 assays NSB was 1.5 + 0.1 % (mean.:_ S.E.M.). 
The sensitivity of a binding assay such as RIA is affected by many 
factors described above. However these are all secondary. The prime 
factor affectii-tg a binding assay is the association constant of binding 
- thP Ka, which is a reflection of the affinity of antibody for nnti-
gen. Binding affinity is assessed by Scatchard plot analysis (139), 
which is the graphic relationship of the ratio of bound ligand: free 
ligand vs concentration of bound ligand. The affinity constant, Ka, is 
given by the slope of the curve. Scatchard plot analysis vf the 
ligandin-antiligandin reaction shows at least two populaFons of bind-
ing sites, represented by an exponential decay curve, which can be fit-
ted to tv:o linear curves, each of different slope. Antisera although 
monospecific are not monoclonal, and contain several populations of 
antibodies directed against several sites on the antigen, each with its 
own Ka. Under these circumstances the Scatchard plot is not linear. 
Scatchard plot analysis is provided by the RIARUN programme. Cal-
clunted values for 10 consecutive assays are Ka = O. 72 + 0. 04 x 
1011 L/Mol (mean+ s.E.M.). 
Antibody ,combining sites, designated as Q, can also be determined 
from the Scatchard plot and is given by the Y- :;ntercept. For 10 cons-
ecutive assays Q = 0.12 + 0.01 x 10-10 Mol/L (mean .:_ S.E.M.). It 
is important to note that the Scatchard plot calculated here is subject 
to several assumptions, not the least of which is that the mass of lab-
elled antigen is known with accuracy. Because of these assumptions the 
data derived from the plot are at best only approximations. 
62. 
Based on the successful RIA for rat ligandin a RIA for the cat-
ionic human G SH-T's has been developed. The double antibody technique 
used here gives good separation of antibody-bound from free antigen. 
The standard curve developed allows measurement of concentrations of 
less than lng/tube, and in addition is adequately precise. There was 
negb.gible cross reaction with other human proteins. Data concerning 
other possible interfering substances will be presented later. Unlike 
many other RIA procedures this assay is characterised by low non-
specific binding, perhaps attributable in part to the presence of bov-
ine berum albumin ir, the ass.ay diluent. 
The natt· re of the antigen-antibody reaction fa such that at the 
extremes of the dose-response curve the standard deviation of the res-
ponse is greater than in the mid-range. Therefore the dose response 
curve is most sensitive in its midranr,e. For this assay the sensitive 




LIGANDINAEMIA IN LIVER DISEASE 
The value of diagnostic enzymology in liver disease has been discussed 
(see chapt. IV). 
Some difficulty arises when one attempts to correlate the results 
of new tests with liver cell necrosis. because there is no "gold stan-
dard". There is no absolute indicator of necrosis. short of E·, er bi-
opsy. which is no·, ethically justified in acute hepatitis, and cannot 
be performed done as frequently as would be required in chronic hepat-
itis. Even liver biopsy may yield false informa tion because of sampl-
ing error. Therefore the results of new tests can only be compared, in 
a prospective study, to existing tei::ts, or to clinical parameters. and 
the question asked, 'is this test of use in predicting; fulminant hep-
atitis; chronic hepatitis; or recovery from acute hepatitis; at an 
earlier stage than those cu1·rently available. 
There are several reasons for investigating ligandin in the blood 
as a test for hepatic necrosis. In experimental animals the measure-
ment of ligandin by RIA has been shown to be more sensitive than SGOT 
in detecting necrosis (84). Secondly. since ligandin is a smaller mol-
ecule than either SGPT or SGOT. and since it is largely cytoplasmic in 
location, its rate of release might expected to be more rapid than SGOT 
or SGPT. Finally since ligandin is present in such large amounts in 
liver the magnitude of the rise in serum may be very large. All of 
these factors would tend to increase sensitivity. Concomitant with the 











might be caused by a variety of minor stimuli. 'l'he advantages of RIA 
over measurement of enzyme activity have been discussed, but in this 
instance the particular advantage is that RIA is not affected by haem-
olysis, which interferes markedly with determination of SGOT. In add-
ition the RIA may be performed on stored serum, which is not possible 
for ~GOT. 
This study · therefore was undertaken to examine serum ligandin in 
human liver disease and to determine if measurement of scrum ligandin 
was an index of necrosis or had diagnostic or prognostic value. 
METHODS 
Validation of measurement of ligand in in serum:-
1. Reccvery from serum:- Unlabelled ligandin in concentrations of 10 
and 100 ng / ml were added to serum from normal volunteers and from pat-
ients with acute viral hepatitis, with and without hepatic encephalo-
pathy. Serum was assayed for lig andin by RIA before and after add-
ition of purified liganr:lin. 
covery of ligandin. 
Results were expressed as percentage re-
2. Interference by drugs:- Penic illin, digoxin, gentamycin vnd furo-
semide in conc.entrations of 1, 5, and 10 \lg/ml were added to unlabelled 
ligandin (35 and 24 ng /ml). The samples were assayed for ligandin by 
RIA and results expressed as percentage recovery. 
3. Molecular size of immunoreactive ligandin in serum:- Three ml of 
serum from normal volunteers and from patients with acute h<:patitis was 
chromatographed on Sephadex G-100, column size 1.5 x 90 cm developed in 
O.OlM sodium phosphate buffer, 0.15M sodium chloride, pH 7 .4, by pump-







fractions were assayed for ligandin by RIA. Molecular weight markers 
were u_sed as before to calibrate the column. 
4. Immunoreactivity:- This was assessed by serial dilution of serum 
from normal volunteers and patients with acute hepatitis. The diluted 
samples were assayed for ligandin by RIA, -and the slope of the dilution 
curv~s compared to the. slope> of the standard curve using the Rodbard 
programme (91). 
5. Storage of serum:- Aliquots of serum from patients with acute hep-
atitis were allowed to stand at room temperature, at 4°C, and at -20°C 
for 6> hours, 12 hours, 24 ho':1rs, and 2 weeks. The sample_s were assayed 
before and aft2r storage. Results were expressed as % recovery. 
6. Normal concentration in serum:- Serum from 34 normal volunteers 
was assayed for ligandin by RIA. Results were expressed as ng/ml. 
Virology:-
Hepatitis A virus infection was detected by measuring anti HA V IgM 
antibodies (HA VAB, Ahbott). Hepat itis B virus infection was determined 
by measuring HBsAg (AusRIA II, Abbott). Some patients contrac ted hep-
atitis during an outbreak of hepatitis · A in a military camp. Anti HAV 
IgM was not determined in all of these patients but for the purposes of 
analysis they were regarded as having had hep&.titis A. 
Glutamic oxaloacetic transaminase: -
This was assayed using a Centrifuchem rotary spectrophotometer. 
The reagents werea-ketoglutarate, aspartate, reduced NADH, malate de-
hydrogenase and lactic dehydrogenase. The reaction was allowed to pro-













dogeno_us pyruvate to lactate. Any change in absorbance after this time 
was assumed to be due to NADH oxidation associated with the SGOT cata-
lysed conversion of oxaloacetate to malate. Results were expressed ns 
U/L, and the normal range was less than 12 U/L. 
Path,ot Selection:-
1. Acute Vira:l Hepatitis:- All patients who were referred to Groote 
Schuur Hospital Liver Clinic over a two year period with a diagnosis of 
hepatitis were included. In addition sera from a furthe r 13 patients 
atten ding the Infec: ious Dis.eases Section of Harari Hospital in Salis-
bury, Zimbab•.-.e were examined. 
Diagnosis was made on clinical grounds, and confirmed by finding 
elevated transaminase activity in the serum. Patients who had symptoms 
suggestive of acute hepatitis, but who did not have elevated transamin-
ases or serum bilirubin served as symptomatic controls . 
Serial blood sa mples were t ak en during the illness and during con-
valescence. These v:e;:-e annlyst.!d for SGOT and for ligandin by radio-
immunoassay. Correlation between ligandin and SGOT was es tablished by 
the Spearman rank correlation coefficient (140). 
2. Chronic active hepatitis:- Patients with suspected chronic active 
hepatitis were subjected to needle biopsy of the liver for diagnostic 
purposes. Patients with established cirrhosis were excluded from the 
study. At the time of biopsy and before therapy was started, blood was 
taken for SGOT and ligandin estimation. Serial ligandin and SGOT est-
imations were performed during the course of the disease. Some pat-
ients underwent second or third biopsies when SGOT and ligandin estim-
ations were again performed in the immediate pre-biopsy period. 
67. 









RECOVERY OF LIGANDIN FROM SERUM 
added ligandin mean% recovery 
27 ng 95% 




Table 10 .1. Recovery of Hgandin from serum of normals and pat-
ients with jaundice due to acute hepatitis. Serum was assayed by RIA before an:i after the addition of a fixed amount of iigandin. 
Biopsy appearances were graded by two observers. without knowledge 
of the patientr; clinical or biochemical status. The severity of necr-
osis and the degree of inflammation were scored separately on a scale 
from O - 3. The separate scores were then added together. A score of 
0 indicated no disease, a score of 1 - 2 indicated mild disease, 3 - 4 
indica~ed mo<lerate disedse, and 5 - 6 indicated severe disease. This 
system was adopted in an attempt to separate out the effect that necr-
osis per se might have on serum Jigandin. Correlation between histo-
logical severity and serum ligandin and SGOT was assessed w::.th the 
Speurman rank corr~lation coefficient. 
3. Other mseases:- Patients referred routinely to the Groote Schuur 
Liver Clinic and who required a liver biopsy. had blood withdrawn at 
the time· of biopsy for ligandin and SGOT er;timation. Patients with 
non-hepatic diseases, with no evid".!nce of coincidental liver disease 
were also studied, and served as non-hepatic controls . 
RESULTS 
Validation of measurement of serum ligandin :-
1. Recovery of exogenously added ligandin:- These results are shown 
in table 10.1. · More than 95% of added ligandin was recoverable from 
serum of normal volunteers, and patients with acute hepatitis. 
2. Interference by drugs:- Recovery of ligandin was not influenced by 
addition of four commonly used drugs in pharmacolo~ical concentrations. 






















4.83 + 0.25 
4.63 + 0.12 
4.50 + 0.10 
4.90 + 0.20 
4.83 + 0.12 
4.87 + 0.15 
4.77 + 0.12 
4.90 + 0.10 
4.77 + 0.23 
4.73 + o.i5 
4.70 + 0.10 














Table 10.2. Recovery of ligandin from serum after the addition of four commonly used drugs. Ugandin recovery was complete in all instances. 
DILUTION 
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Fig. 10.1. Comparison of ill:munochemical discplacement curves of lig-
andin in the serum of patients and the standard curve of the ligandin 
RIA. On the ordinate is the percentage ratio of antibody bound radi_o-
activity to radioactiv-ity bound in the absence of unlabelled ligand:fo. 
On the abscissa (log scale) is t~:? amount of unlabelled ligandin or 
dilution of sample. 
3. Molecular size of immunoreactive ligandin :- Following gel filtr-
ation of normal serum. or serum from patients with acute hepatitis no 
immunoreactivity was detectable in the eluant fractions. The concentr-
ation of ligandin in normal serum is too low to permit detection after 
the dilution which accompanies gel filtration, but even high concentra-
tion<> were not detected. 
4. Immunoreactivity:- Ligandin concentration in normal serum was too 
low to permit serial dilution. Di!ution curves, constructed by assay-
ing r,:;erial dilutions of serum from patients with acute hepatiti.B with, 
and without hP.patic encephalopathy. were parallel to the assay standard 
curve (fig. 10.1). 
5. Serum ligandin in normal volunt~ers:- This was 3.78 ~ 3.57 ng/ml 
(mean~ S.D.)(range O - 12 ng/ml). Since 12 ng/ml was the highest re-
corded value in normal volunteers, this was taken as the upper limit of 
normal, being slightly more than 2 standard deviations from the mean. 
6. Storage of serum:- Serum could be stored e.t room temperature for 
12 hours with9ut loss of activity. At twenty four hours activity was 
reduced by 30 - 50%. At -20°C serum could be stored for at least two 
weeks with out loss of activity. 
Acute Viral Hepatitis:-
Eighty patients were included in this study. Sixty eight pat·-
ients fulfilled the criteria for the diagnosis of acute viral hep-
69. 
UNIVARIATE STATISTICS 
Statistic Group l Group 2 
Ligandin Mean 65.l 36.7 
s.n. 235.0 59.7 
Skewness 7.4 2.5 
K•.1rtosis 64.4 5.9 
No of obs. 158 101 
SCOT Mean 134.0 219.l 
s.n. 271.0 320.0 
Skewness 3.9 1.8 
Kurtosis 18 .1 2.4 
No of obs 135 87 
Table 10.3. Univariate statistics for ligandin concentration 
and SGOT activity in acute hepatit ls. All values of ligandin 
and SGOT during the illness were used to obtain these statis-
tics. 
atitis. All except 3 of these recovered clinically within 6 weeks. 
These 3 had a prolonged course and are considered separately. One pat-
ient had a relapse or a second infection two months after the initial 
episode of hepatitis. Virological studies were not available for the 
second illness. 
There were 24 epi,;oder, of hepatitis A and 20 episodes of hepatitis 
B. In the remainder hepatitis B was excluded although a definitive 
diagnosis was not made because the appropriate serological tests were 
not available. Most of these patients were suspected of having hepat-
itis A because they contracted the disease during an epidemic of hepat-
itis A. Uni·.fariate statistics (table 10.3) suc-gested that the hepat-
itis B group was different to the rest of the patients and so this 
group was analysed separately. The non-B gro'..lp was called group I, and 
the HBsAg +ve group was called gr01.1p n. 
Frequency of elevated values of ligandin and SGOT over the dur-
ation of the study in each group was assessed by establishing a ratio 
of the number of clE:vated to normal ligandin values, and a similar 
ratio for SGOT for each patient. A sign (+ or -) was assigned to the 
difference between the ligandin and SGOT ratio in each patient, and the 
sign test was ' applied to these results. This showed that in group I 
SGOT was elevated more frequently than ligandin (p< 0.01) during the 
period of study, but in group II there was no difference between the 
number of days that ligandin was elevated, and the number of days that 
SGOT was elevated. These results were confirmed by the Wilcoxon match-
ed pairs sign test. 
A further 12 patients were referred for suspected hepatitis but 
serum transaminase activity did not rise and the diagnosis was exclud-
70. 
ACUTE VIRAL HEPATITIS 
Group 1 Group 2 
Ligandin SGOT Ugandin SGOT 
ng/ml U/L ng/ml U/L 
WEEK 1 mean 339 384 103 524 
range 0-2398 13-1880 0-300 114-1103 
WEEK 2 mean 53 159 42 391 
range 0-352 17-810 0-160 6-1332 
WEEK 3 mean 17 84 43 393 
range 0-99 4-974 0-166 12-1044 
WEEK 4 mean 6 36 27 100 
range 0-17 5-171 4-108 8-360 
WEEK 5 mean 5 21 23 47 
range 0-12 1-50 0-97 2-126 
WEEK 6 u{ean 8 13 11 60 
range 0-17 1-25 0-27 1-94 
WEEK 7 mean 4· 16 10 · 25 
range 0-7 1-22 0-22 12-42 
WEEK 8 mean 12 6 14 
range 1-11 6-30 
WEEK 9 mean 6 
range 0-17 
WEEK 10 mean 7 
range 0-16 
Table 10.4. Acute viral hepatitis. This table shows the mean 
ligandin concentration measured by RIA, and mean SGOT activity 
during each week of illness. The range of values for ligandin 






ACUTE VIRAL HEPATITIS 
Group 1 Group 2 
Ligandin SGOT Ligandin SGOT 
% % % % 
WEEK 1 80 (n=20) 100 (nalO) 75 (n-16) 100 (n=l5) 
WEEK 2 47 (n•47) 100 (n=39) 73 (n .. 11) 80 (n=lO) 
WEEK 3 35 (n .. 46) 85 (n .. 40) 62 (naal3) 92 (n.;13) 
WEEK .', 18 (ns22) 90 (n .. 20) 83 (n=-12) 90 (n=lO) 
WEEK 5 0 (n=- 8) 62 (n= 8) 40 (n .. 15) 60 (n,,;15) 
WEE.K 6 - 50 (n= 8) 50 (n= 4) 
WEEK 7 ...._ 38 (n= 8) 80 (n= 5) 
WEEK 8 0 (na 5) -20 (n= 5) 

















ACUTE VIRAL HEPATITIS MEDIAN LIGANDIN AND SGOT 
Croup 1 Group 2 
.Ligandin SGOT Ligandin SCOT 
ng/ml U/L ng/ml U/L 
WEEK 1 123 96 38 440 
WEEK 2 11 75 17 338 
WEEK 3 s 34 19 120 
WEEK 4 s 21 19 70 
WEEK 5 6 20 9 24 
WEEK 6 3 13 
























The corrdation between ligandin nnd SGOT was assessed in each 
group. In group I rs (Spearman rank correlation coefficient) = 0.62 
(p< 0.01). In group II rs = 0.5f (p< 0.01). If only values of lig-
andin above 96 ng/ml, i.e more than 8x normal, are considered then in 
group I for ligandin ar.d S<iOT rs = 0.86, (p< 0.01), but in group II 
·there is no correlation between ligandin and SGOT, rs = 0.04, 
(p> 0.10). 
Thirteen patients in group I had sufficient data to correlat-:- SGOT 
anci ligandin. In 3 of the ihirteen ligandin was positively and signif-
icantly correlated with SGOT (rs = 0.89 to rs = 0.96, p< 0.05). In 
the other 10 patients rs = 0.20 to rs = 0.90, (p> 0.05). 
In group II in 9 patients there was sufficient · data for ligandin 
and SGC>'T to be correlated. In only one patient was ligandin signific-
antly correlated with SGOT (rs = .o. 75, p< 0.05). In the other 8 pat-
ients rs = -0.60 to rs = 0.85 (p> 0.05). Both in group I and group 
II small numbers of p11ired meaGurments in some patients pr.evented sig-
nificance from being reached, rather than lack of correlation, since 
with the Spearman rank correlation if n=5 then rs must equE:l 1.0 for 
significance to be achieved. 
The mean, range and percentage of elevated values per week a1•e 
shown in tables 10.4 and 10.5. Since neither ligandin nor SGOT were 
normally distributed the medians given in table 10.6. 
In group I in the first week of illness 80% of all ligandin values 
were elevated (mean 339 ng/ml, range O - 2398 ng/ml). All SGOT values 
in the first week were elevated (mean 384 U/L, range 13 - 1880 U/L). 
71. 














In the first week of illness, in the first sample taken, only one pat-
ient did not ha.ve an elevated ligandin concentration. 
In week 2 100% of SGOT estimations, but only 47% of ligandin est-
imations were elevated (SGOT mean 159 U/L, range 17 - 810 U/L), ligan-
din mean 53 ng/ml, range O - 352 ng/ml). In week 3 SGOT was raised in 
85% (ll'ean 84. U/L, ranz~ 4 - 974 U/L). Ligandin was raised in 35% of 
samples (mean 17 ng/ml, range O - 99 ng/ml). By week 4 mean ligandin 
was within the normal limits, although 18% of values were still ele-
vated. Mean SGOT in week 4 was 36 U /L (range 5 - 171 U /L), and 90% of 
val\.;;s were still el(?vated. After week 4 the numbers of estimations 
within each time period are small, but mean ligandin remained within 
normal limits, while mean SGOT only fell to normal in week 6. 
In group II during the first week of illness 75% of ligaQdin 
values, and 100% of SGOT values were elevated. All patients had at 
least one elevated ligandin level. Mean ligandin was 103 ng/ml (range 
0 - 300 ng/ml), and mean SGOT was 524 U/L (range 114 - 1103 U/L). In 
week 2 mean ligandin ~·:as 42 ng/ml (range O - 160 ng/ml), Seventy three 
percent of values were elevated. Mean SGOT in week 2 was 391 U /L 
(range 6 - 1332 U/L)·. Eighty percent of values were elevated. Mean 
ligandin fell to normal by week 6, but mean SGOT was not within normal 
limits by week 8. In this group elevated values of ligandin and SGOT 
continued to be detected throughout the study period. 
Graphs from six patients in group I are given in fig. 10.2. In 
this group in each patient ligandin concentration returned to normal 
before or with SGOT activity. Graphs from 4 patients in group II are 
shown in fig. 10.3. In Group II in three patients ligandin elevation 
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Fig. 10 .2. Comparison of the disappearance curves of ligandin and 
AST (SGOT) in the serum of 6 patients with acute non-B hepatitis (group 
I). - On the ordinate is t~e ligandin concentration and SGOT (AST) ac-
tivity, ar.'.! on the abcsissa is time in days a:ter the onset of symp-
toms. 
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Comparison of Che disappearance curves of ligandin and 
the serum of· 4 patients with acute hepatitis B (group 
and ab;cissa are as for fig. 10.3. 
In two patients a very high ligandin, greater thnn 1000 ng/m was 
associated with a return to normal levels within 10 days (fig. 10. 2a. 
10. 2c). Within two days ligand in concentration fell from greater than 
1000 ng/ml to less than 100 ng/ml. The excretion curves in these pat-
ients suggest a biphasic clearance of ligandin, with a initial rapid 
and i5bwer second pha:~ of clearance. The curves could be fitted to 
the function y = axb, with r = 0.76 and r = 0.98 respectively. Cor-
respondi~g SGOT clearance curves could be fitted to the same function 
with r = 0.97 and r = 0.93 respectively. 
The serum hali-life of l.igandin and SGOT was estimated from .these 
two curves (aasuming that no further release of ligandin occurred bet-
ween measurements). The half-life of ligandin for the initial rapid 
clearance phase was 8 hours, and 16 to 24 hours for the slower clear-
ance phase. Calculated half-life of SGOT was 16 hours for the rapid 
clearance phase. and 24 to 48 hours for the slow clearance phase. 
Frequency distributions of ligandin and SGOT with time were con-
stru~ted using the v,e~k of illn2ss as the unit of time because paucity 
of numbers did not permit analysis using days of illness as the time 
unit. Many patients had more than one estimation of ligandin and SGOT 
during a single week. The values at the beginning and the end of the 
week may have differed by· several orders of maE,nitude. All estimations 
from all patients within the time unit are included in the frequency 
distributions. which were then constructed as if all values were in-
dependent. This method serves for descriptive purposes, i.e. gives in-
formation about the pattern of ligandin and SGOT values during the ill-
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Frequency distribution of-- ligandin 
acute hepatitis B (group II). The 










and SGOT (AST) in pat-
histograms were cons-
in fig • 1 0 • 4 • 
quency distributions cannot be compared statistically, since the inc-
lusion of non-independent samples leads to unacceptable bias. 
Frequency distributions for ligandin and SGOT (AST) values for 
each week of illness are shown in fig. 10.4 & 10.5. In group I ligan-
din concentration showed a bimodal distribution. with a cluster of 
values at O - 24 ng/ml, a tail between 25 and 84 ng/ml, and then a sec-
ond cluster above 96 ng/ml. In weeks 2 to 5 the cluster at O - 24 ng/ 
ml becam~ larger. The tail betweP-n the two clusters elongated in weeks 
2 and 3 and then shortened and disappeared by week 6. The secoP1 clus-
ter, above 96 ng/ml, decreased in week 2, formed part of the tail by 
weeks 3 and<!, and then disappeared. From week 6 onwards distribution 
was unimodal, clustered around a normal lig:mdin concentration. 
In group II there was a similar frequency distribution, but the 
tail of intermediate values was less pronounced and the cluster of 
values above 96 ng/ml remained at least unt~ week 5. 
SGOT frequency distribution in group I also showed a bimodal dis-
tribution in weelc 1 r.nd 2. However the lower cluster of values was at 
24 - 48 U/L. compared to O - 24 ng/ml for ligandin. · The tail between 
the two clusters persisted until weelt 5, and the cluster above 96 U /L 
was stUl present in weeks 6, 7 and 9. The cluster of low values did 
not centre around normal SGOT levels until week 5. After week 5 the 
numbers of values was too small for analysis. 
In group II small numbers of SGOT estimations at each time peroid 
hamper analysis. In week 1 all values were above 96 ng/ml. In week 2 
a cluster about 12 ng/ml and a smaller cluster at 37-48 ng/ml appeared. 
The cluster around 12 ng/ml persisted in week 4 and 5, but the cluster 
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Fig. 10 .6. r.orrelation of serum ligand in concentration and SGOT 
(AST) activity •.dth histology in patients with chronic active hepa-
titis. Both initial and follow up biOj)SJ data are included. On the 
ordinate is the ligandin concentration and SGOT activity, and on the 
ahsciss~ is the severity of histological change. 
evidence of a tail of intermediate values developing by week 5. Anal-
ysis after week 5 could be done because of insufficient numbers in each 
class. 
All patients recovered without chronic sequelae. Of the 12 pat-
ients who did not develop hepatitis, none had elevated ligandin. Three 
patit::nts wit); prolonge:;1 he?atitis, with an illness of more than two 
months duration ' were not included in the above analysis. In these pat-
ients liga,ndin remained elevated for the duration of illness but never 
rose above 4 times normal. In the single patient who had a second bout 
of h~patitis a sing~e estim~tion of ligandin was available which was 
506 ng/ml. 
Chronic Active Hepatitis (CAH) :-
Sixteen patients were included in this part of the study. Two biopsies 
showed mild disease. Serum ligandin in these patients was O and 10 
ng/ml. SGOT was 31 and 88 U/L. 
Ten patients had mcdt::rate disease activity. In this group 4 patients 
had elevated ligandin levels at the time of biopsy (mean for the group 
10.4 ng/ml, range O - 23 ng/ml). All patients had elevated SGOT 
levels, mean 99 U/L, range 18 - 425 U/L. 
Four patients had severe disease. All had elevated ligandin 
levels (mean 51~8 ng/ml, range 27 - 69 ng/mi). Mean SGOT in this group 
was 79 U/L. All patients had elevated SGOT levels (range 46-114 U/L). 
Serum ligandin levels were correlated with disease activity (r :: 
0.78, p< 0.01), while there was no correlation between SGOT levels and 
disease activity (r6 = 0.29, p> O.lO)(fig. 10.6). 
75. 
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Fig. 10.7. Graph of the course of a single patient With chronic acive 
hepntitis over three years. Three biopsies t aken o·:er the course of 
the diseas e showed prog=essive improvement in the histological ~core 
Seven patients underwent repeat liver biopsy at which time blood 
was again taken for SGOT and ligandin. There were too few patients in 
this group to make statistical comparisons, but if these biopsies were 
added to the original 16 then for the correlation between ligandin and 
histological severity is still significant (rs= 0.71, p< 0.01). 
'?ig. 10. 7 shows th1? course of a single patient over three years of 
therapy. Initial biopsy showed severe chronic active hepatitis, and 
the final biopsy showed mild disease. The improvement in her condition 
is better shown by the ligandin vfuues, which show a tendency to norm-
ality. while the SG JT gives no indication of improvement. 
Other liver diseases:-
Twelve patients with metastatic liver disease were seen. Four 
patients had carcinoma of the stomach, none had elevated ligandin. One 
of two patients with carcinoma of the lung had a serum ligandin of 30 
ng/ml, but the other had normal levels. In six patients the primary 
site was unknown. Of these 5 had normal ligandin levels, and one had a 
minimally elevated level of 13 ng/ml. There was no correlation with 
SGOT levels, which were elevated in all patients. 
Six patients with extrahepatic obstructive jaundice were seen. 
Serum ligandin was not elevated in any of these r>atients, but SGOT was 
elevated in all patients. 
Twenty patients with cirrhosis were included - 4 with cryptogenic 
cirrhosis, and 16 with . alcoholic cirrhosis. None of these patients had 
elevated ligandin. None of 8 patients with alcoholic hepatitfa had 
elevated ligandin levels. In these patients SGOT was in the 1-ange 20 -
110 U/L. 
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Ligandin in the serum of 34 patients without liver disease selec-
ted at random from a hospital population was in the normal range in all 
cases. However in three patients who experienced cardiac arrest ligan-
din was elevated in the serum. The values recorded were 60, 84 and 191 
ng/ml. 
DISCUSSION 
Validation of measurem~nt of serum ligandin:-
Many substances may interfere with RIA's. Since jaundice is like-
ly k the conditions in whic~ ligandin measurement may be usefU1, i.e. 
liver disease, it was important to examine the effect of bilirubin on 
the recovery of ligandin from serum. Since patients with liver disease 
may have many serum biochemical abnormalities. only some of which are 
known, it was preferable to test recovery of ligandin from sera from 
these patients, rather than by adding bilirubin to purified ligandin. 
This study suggests that acute hepatitis, with and without hepatic en-
cephalopathy, has a :1egligible effect on the estimation of ligandin, 
since in these cases ligandin recovery is complete. 
Serum ligandin in patients with acute hepatitis dilutef' out in 
parallel to the , assay standard curve, indicating that the immunoreact-
ive material released from the liver is simil~r to native ligandin. 
This finding provides further evidence against the influence of in-
hibiting substances. 
None of the pharmacological agents tested interfered with the 
assay. However other agents might well interfere, and further drug in-
hibition studies may need to be performed. For practical purposes it 






























ticularly those with acute hepatitis were not on any therapy st the 
time. 
It is known that rat ligandin adheres to Sephadex. Bass (84) 
found in the rat that after loading approximately 1400 ng/ml to Scpha-
dex G-100 recovery was only 20%. Therefore failure to recover human 
ligan..tin after gel filtretion could be due to non-specific adsorption 
to Sephadex bea'd:s. 
Ohmi et al (92) found a normal concentration of ligandin to be 
less than 7 ng /ml. Tsuru et al (93) describe levels of less than 4 
ng/i;:! as normal. Bass (91) .in a preliminary study quoted 8.5 ng/ml as 
the upper level of normal. These figures are compatible with the con-
centration found in this study in normal volunteers. These concentr-
ations are much lower than those in the rat, (26 ng/ml)(84). The fac-
tors responsible for this difference between man and rat have not been 
investigated. 
Acute viral hepatitis:-
These results snggest that the release of ligandin and SGOT differ 
in some respects in acute hepatitis. Three possible conclusions may be 
reached; that ligandin is as good an indicator of hepatic necrosis as 
SGOT, that ligandin is a better indicator, or that SGOT is a better in-
dicator for hepatic necrosis. 
Ligandin and SGOT cannot be equally good indicators of necrosis, 
since the two measurements behave differently during the course of the 
disease. Th~ correlation between SGOT and ligandin when ligandin con-
centration is above 96 ng/ml suggests that at these levels ligandin and 
SGOT are indicators of the same phenomenon. Adachi et al (94) have 









also shown that correlation of GSH-T activity with SGOT and SGPT is 
better when these activities are markedly raised than when they are 
not. 
The correlation between ligandin and SGOT below ligandin concen-
trations of 96 ng/ml is not good, suggesting that at this stage of the 
disea~:e the release or <.:l~arance of SGOT and ligandin are different. 
The disappenrance curve of ligandin from blood is biphasic, in 
keeping with the pattern seen with other enzymes (68). This suggests 
that redistribution of ligandin ;,lays an important role in plasma 
clearance. 
The half-Ufe of ligandin in blood is shorter than the half-life 
of SGOT (assuming that the curves from which the half-life was calcul-
ated are true disappearance curves). This conclusion ic, supported by 
finding that the mean, median, and percentage of elevated values falls 
faster for ligandin than for SGOT. Adachi et al (94) using their assay 
for GSH-T activity also describe an early peak of GSII-T activity in 
acute hepatitis, paralleling SGOT activity, but which falls to normal 
before SGOT. Rats given CC14 release G SH-T activity early, before 
SGOT and SGPT. GSH-T activity returns to normal before transaminase 
activity' ( 83). , 
The lack of correlation of necrosis on hfatology with transamin-
ase levels has been well documenti:?d, and discussed previously (57,141). 
Since SGOT may remain elevated after apparent clinical recovery, the 
rapid return of ligandin levels to normal may indicate that ligandin is 
a better index of necrosis. However an alternative hypothesis is that 
if SGOT elevation indicates necrosis, and SGOT remains elevated longer 
than ligandin, this suggests that ligandin is undetectable at low 
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levels of necrosis. S:.ipportive evidence for this contention is provid-
ed by the finding that ligandin is not elevated in other liver diseases 
where necrosis is known to occur, e.g. mild chronic active hepatitis 
and alcoholic hepatitis. 
The bimodal distribution seen in the first week of illness can be 
inter.:reted as indicating a group of patients who have very active dis-
ease, i.e. those , with ligandin )96 ng /ml, and a group with milder dis-
ease or who are convalescing. With time the active group merges into 
the convalsecent group, represent.::d by the tail and those values clus-
tered around normal, while the convalescent group merges with th:: fully 
recovered pati~nts. This interpretation is consistent wit.h the known 
behaviour of the disease, and the fact that by the time the diagnosis 
is made, i.e. jaundice appears, in some patients maximum nec rosis may 
be past. · This interpretation, coupled with the short half-life of lig-
andin, explains the finding of nor mal levels of ligandin in some cases 
in the early stages of the disease. These patients have _already enter-
ed convalescence and are no longer releasing ligandin from the liver. 
SGOT values show a similar frequency distribution. The same in-
terp:::-etation can be applied to the SGOT frequency distribution. In 
this instance ~he convalescent group clusters at values higher than 
corresponding ligandin values, again suggesting that ligandin is clear-
ed earlier than SGOT. 
Ohmi and Arias (92) have suggested that necrosis in viral hepat-
itis is intermittent or progressive. Their conclusion is based on 
finding a marked difference in maximum ligandin elevation in the s.erum 
of patients with fulminating drug hepatitis, and fulminating viral hep-
atitis. In the former, where they suggest a single massive burst of 
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necrosis. the ligandin concentration was ranged from 680 - 5350 ng/ml. 
while in fulminant viral hepatitis. at the same stage of illness. the 
range was 8 - 780 ng/ml. 
Ohmi and Arias (92) have also found higher mean ligandin concentr-
ations in patients dying with fulminant hepatitis than in survivors 
wher~ studied at the sal"!"".l stat;e of disease (316 vs 47 ng/ml). They thus 
suggested that m(::asurement of ligandin could have a prognostic value. 
Results of this present study do not permit one to conclude that 
ligandin is more sensitive than t>GOT. but the finding that Hgandin 
retu!":is to normal mere rapid~y than SGOT in a group of patients who all 
recovered clir.ic:11ly suggests that ligandin is a better indicator of 
resolution that SGOT. This hypothesis can only be confirmed by finding 
that ligandin levels remain elevated in patients progressing from acute 
to chronic hepatitis. There were no such patients in this series, and 
so the suggestion that ligandin may provide a better index of recovery 
remains unproven. 
Chronic Active Hepa ti tis: -
The criteria for initiating steroid therapy in CAH are fiomewhat 
arbitrary. These include a transaminase level of more than 5x normal, 
and/or a globulin level that is more than 2x ele .. ated. Since the crit-
eria used do not correlate perfectly with disease activity as judged 
histologically, there will be some patients with disease severe enough 
to warrant treatment. who are not identified, and some patients with 
high enzymes who might be treated despite mild histological changes. 
While it is possible that biopsy sampling error could result in inaccu-
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racy, it is . widely ac~epted that the histological severity of the dis-
ease is more exact than any other criterion of activity. 
This study showed that serum ligandin concentration is often ele-
vated in moderate to severe chronic active hepatitis. The degree of 
elevation correlated significantly with the histological severity of 
dise~ '.;e. Th~re was no r.orrelation between SGOT and histological sever-
ity. In CAH maximum ligandin levels were 6 - 7x normal. 
Patients with milrl disease have normal or slightly elevated ligan-
din levels. Although necrosis does occur in mild chronic active hepat-
itis, ligandin is no~ suffici~ntly sensitive to detect this. This lack 
of sensitivity :-nay be useful. This group do not need therapy, but if 
conventional indications for therapy, such as the transaminase levels, 
were used, some would be treated. Ligandin identified this group with 
certainty~ 
Patients with moderate disease may have an eleva ted ligandin Some 
of these patients may require treatment. In this group ligandin levels 
do not differentiate between those who do, and those who do not require 
therapy. However, the SGOT also fails to differentiate between these 
two groups. 
Patients . with severe disease all have elevated serum ligandin 
levels. The magnitude of elevation is more than 2x normal. These pat-
ients all require therapy. Ligandin levels identified this group with 
accuracy. However if only the transaminases were considered, not all 
would have received treatment. 
In this study ligandin concentration correlated better with dis-
ease activity than did SGOT. Other series have reported that SGOT cor-
relation with disease activity was better than reported here (97). 
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This may be because of the small numbers in this series, leading to 
sampling from a non-representative group. 
Neverless these results strongly suggest that a larger study of 
ligandin in CAH is warranted, to determine whether ligandin indeed cor-
relat&s better with disease activity than SGOT. If these results are 
confirmed it would seem that ligandin may be a better test on which to 
base therapeutic decisions. 
Other diseases:-
Serum ligandin was not elevated in liver diseases other than acute 
and chronic hepatitis, specifically alcoholic hepatitis, obstructive 
jaundice, and cirrhosis. On the basis of the small series studied here 
one must be cautious of concluding that ligandin is never elevated in 
these coz:iditions. Elevated ligandin may be found in hepatocellular 
carcinoma, but as this forms part of another investigation these re-
sults will be reported later. 
Ligandin elevation is probably specific for liver disease. Only 
patients who had had a major episode of hypotensfon developed ligandin-
·aemia. Although it cannot be proved, it is likely that ischaemic 
damage · to the liver occurred and that this caused the release of ligan-
din. 
CONCLUSIONS 
It is possible to conclude that because ligandin is a smaller mol-
ecule than SGOT, and because it is present in the hepatocyte in greater 
concentration than SGOT, that it is released into serum as early as or 
earlier than SGOT. This has been well shown in experimental animals 
(83, 84). In man release occurs at least simultaneously with SGOT. 
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Both in man and experimental animals clearance from blood is rapid, 
with a half life less than that of SGOT. However contrary to expect-
ations, in man ligandin is less sensitive to minor hepatic injury than 
SGOT, and is not found in serum in our patients with alcoholic hepat-
itis or cirrhosis in whom the SGOT was mildly elevated. The reason for 
this insensitivity is not known. 
Ligandin estimation appears to be a useful indicator of severe ac-
tive hepatic disease (with the exception of alcoholic hepatitis), but 
is prr,bably inadequate for diagnosis of mild disease. Ligandin estim-
ation may thus find its place in the estimation of severity of disease, 
particularly in CAH, where it may be useful as a guide to therapy. 
CHAPTER XI 
LIGANDINURIA IN RENAL DISEASE 
In this chapter an attempt is made to study the pattern of ligan-
din e¥cretion in normal individuals and in patients with renal disease, 
with the aim of ~scertaining whether the measurement of urinary ligan-
din has any diagnostic significance or prognostic relevance. 
MET.tiODS 
Urine and serum samples were obtained from the following pat-
ients; 
1. Patients undergoing renal transplant from cadaver donors were 
studied in the immediate post-transpJant period, and throughout their 
three to four week stay in the intensive care unit. The diagnosis of 
post-transplant tubular necrosis was made if there was initial non-
function in the absence of a demonstrable cause, which recovered spon-
taneously without treatment, or if renal biopsy showed changes of acute 
' tubular necrosis (ATN). In some patients poor function persisted for 
more than two weeks, and evidence of rejection was found. In these 
' 
patients poor function in the first five days war. assumed to be due to 
tubular necrosis (119). 
2. Patients admitted with severe infections not involving the urinary 
tract, who were at risk for tubular necrosis, by virtue of a period of 
hypotension, or by virtue of severe infection alone. These patients 
were grouped into those showing no renal impairment, and those showing 
mild renal impairment which resolved with therapy. Renal impairment 
85. 
was defined as an abnormality of two of the following; serum urea, 
serum creatinine, and urine/plasma urea ratio. 
3. Patients with severe or prolonged hypotension due to myocardial 
infarction • cardiac arrest. or trauma. 
4. P~tients with acute tubular necrosis from other causes. In these 
patients the diagnosis of ATN was made by finding acute renal failure, 
I 
with a period of oliguria followed by a period of polyuria associated 
with recovery, following · a recognisable predisposing cause. Patients 
with non-oliguric acute renal f~ilure, or with suspected A TN but no re-
cognisable cause were excluded. 
5. Normal volunteers. 
Renal function was assessed by estimation of serum urea and creat-
inine. cr~atinine clearance. and urine:plasma urea ratio. Urea and 
creatinine were measured by standard autoanalyser techniques. Ligandin 
was measured in urine by RIA. 
Validation of measurement of ligandin immunoreactivity in urine:-
·1. Immunoreactivity of ligandin in urine. Urine of known concentr-
ation of ligandin was assayed in serial dilutions in the RIA. The 
slopes of the dilution curve were compared to the slope of the standard 
curve as before. 
2. Recovery of ligandin from urine. Known concentrations of ligandin 
were added to urine from normals and patients with acute and chronic 
failure. The samples were assayed before and after the addition of 
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Fig. 11.1. Serial dilutions of urine from a patient -;..'i.th ecute 
tubular necrosis, and following renal transplantation, compared \r.l.th 
the standard curve of the ligandin assay. Ordinate and abscissa are as for fig. 10.1. 
3. Molecular size of immunoreactive ligandin in urine. Urine from 
patients with acute tubular necrosis was chromatographed on G-100 Seph-
adex with molecular weight markers as before. 
4. Storage of urine specimens. Ligandin in known concentrations were 
added to aliquots of normal urine and allowed to stand at room temper-
ature. at 4°C. and at -20°c for 4, s. 12. and 24 hours, and at -20°C 
for 2 weeks. The samples were then assayed for ligandin immuno-
reactivity. 
RESULTS 
Immunoreactivity of urinary ligandin :-
Ligandin in the urine of patients with acute tubular necrosis and 
post renal transplant dil_uted out in parallel to the assay standard 
curve (fig. 11.1). Ligandin in normal urine was diluted below the 
limits of detection of the assay before sufficient points could be ob-
tained for adequate statistical comparison with the standard curve. 
Recovery of exogenous ligandin from urine: -
Recovery of added ligandin from normal urine was complete when 
either 1 ng or- 25 ng ligandin were added. Recovery from patients with 
ATN in whom endogenous ligandin excretion had ceased was 74% when the 
dose of added ligandin was 1 ng, and 100% when the dose of ligandin 
added was 25 ng. 
Molecular size of immunoreactive ligandin in urine:-
Following Sephadex G_-100 chromatography no immunoreactive ligandin 
could be detected in the eluted fractions when either normal urine. or 
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urine from patients with ATN with a known high concentration of ligan-
din in the urine, was applied to the column. 
Ligandin concentration in normal urine:-
Specimens of urine from 50 normal volunteers were examined. Lig-
andin concentration was 11 ng/ml .:!:. 10.25 ng/ml (mean .:!:. S.D.). The 
range was O - 38 ng/ml. The normal range was therefore assumed to lie 
between O and 40 ng/ml. The upper level thus was slightly more than 
three standard deviations from the mean. 
Storage of urinary ligandin :-
Urine ligandin could be stored at 4°C for 24 hours, or at -20°C 
for at least two weeks, ~ithout loss of immunoreactivity. Storage at · 
room temperature for 8 hours led to a 50% drop in ligandin recovery. 
Ligandinuria following renal transplantation:-
Thirty five patfonts were studied. Five patients were diagnosed 
as having unequivocal ATN. Of these, one patient had normal ligandin 
concentration in the urine on the first day. The other 4 patients had 
elevated levels of ligandin in the initial post transplantation urine. 
Ligandin concentration in these specimens was 72, 45, 50 and 3696 ng/ 
ml. Normal urinary ligandin concentrations were present in three of 
these patients on day 2, and in the remaining patient ligandin returned 
to normal on day 3. 
Eleven patients . were presumed to have ATN, in that the initial 
post transplantation function was poor, but did not recover at all, or 
only recovered with treatment for rejection. In 10 of these patients 
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ligandin excretion in the first five days was normal. In a single pat-
ient on the first day the ligandin concentration was 3236 ng/ml, and 
within normal limits the next day. 
Eighteen patients had no evedence of ATN in the immediate post 
tranplant period. In seventeen of these patients in the first 5 days 
the urinary ligandin was in the normal range. In one patient the first 
post transplant urine specimen showed a ligandin concentration of 4000 
ng/ml, on day 2 ligandin concentration was 200 ng/ml, and on day 3 was 
normal. In this patient the donor kidney suffered a prolonged cold 
ischaemic time of 48 hours · prior to transplantation, but functioned 
well once grafted. 
A single patient experienced hyperacute rejection on day 1. 
Nephrectomy on day 4 revealed a necrotic kidney: Urine ligandin con-
centration on day 1 was 1785 ng/ml, on day 2 was 356 ng/ml, and was 
normal on day 3. 
Ligandinuria following acute infection:-
In fifteen patients with severe infections who had no overt renal 
impairment ligandinuria was assessed for 5 days on treatment. Mean 
urinary ligandin concentration in these patients was 24.4 ng/ml (range 
0 - 147 ng/ml, median 19 ng/ml). Five patients showed elevated ligan-
din concentrations in the urine. One of these patients had ligandin-
uria for 4 days. but in the others only a single specimen contained 
elevated ligandin levels. There were no clinical features distinguish-
ing these patients from the rest of the group. 
In 12 patients with acute infection in whom renal function was 




18.8 ng/ml. This is not .significantly different from that seen in the 
previous group. A single patient in this group developed elevated lig-
andin in the urine for two days 
Ligandinuria associated with hypotension :-
Ten patients suffered prolonged episodes of hypotension followed 
by oliguria. Th ·causes were drowning (1). pulmonary embolus (1). rup-
tured aortic aneurysm (1). cardiac arrest (3). and acute myocardial in-
farction (4). Six of the ten patients had an elevated ligandin at some 
stage of their illness. Five of these patients died before the pre-
sence of ATN could be esta'blished. In this group mean ligandin con-
centration was 243. 3 ng / ml (range 80 - 590 ng /ml). In no instance did 
urinary ligandin remain elevated longer than 3 days. Neither the sixth 
patient in this group or any of those without ligandinuria developed 
ATN. 
Ligandinuria associated with acute tubular necrosis:-
Nine patient developed unequivocal A TN. The causes were drug 
toxicity (3), eclampsia (1), septicaemia (3), sunstroke (1) and intes-
tinal obstruction (1). Two patients were studied early in the course 
of their disease. In these patients the initial ligandin concentration 
in the urine was 158 and 174 ng/ml. In the other 7 patients the first 
available specimen was at least 4 days from the onset of the precipi-
tating cause. In these patients ligandinuria was not detected. 
Patients with acute glomerulonephritis (4), and chronic renal 
failure (9) had normal ligandin concentration in their urine. 
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Bass et al (111) expressed ligandinuria in terms of urinary creat-
inine. In man the excretion of several urinary enzymes has also been 
expressed in terms of urinary creatinine (105). Expressing human urin-
ary ligandin 'per mg urinary creatinine did not result in increased sen-
sitivity and this method has thus not been used. 
Only prolonged or severe hypotension or renal ischaenia appear to 
be associated with an elevated ligandin concentration in the urine. 
When it occurs ligandinuria is of short duration. This ir.akes the s~udy 
of ligandinuria in ATN diffi::ult, since patients ts·..ially only present 
when they get symptoms of renal failure, i.e. several days r-<ter the 
onset of the illness. Our data indicate that unless studied early, 
ligandinuria will not be detected in A TN. For the same r eason ligan-
d~nuria cannot be used to differentiate between A TN and other causes of 
acute renal failure. Further the oliguria which is a feature of the 
disease makes the collection of regular urine specimens difficult. 
Marked ligandinuria is associated with conditions causing a dras-
tic reduction in renal blood flow (cardiac arrest, post renal trans-
plant, ruptured aortic aneurysm, drowning). It is likely that ischaem·· 
ic necrosis of tubular cells is responsible for the release of ligandin 
into the urine. It is possible that release occurs from damaged cells 
as well, as not all patients with ligandinuria developed clinical1y 
significant A TN following the episode of reduced blood flow. 
Post transplantation ATN is thought to occur on the basis of renal 
ischaemia. In this situation, when ATN could be positively diagnosed. 
ligandin was elevated in 80% of patients. Of those patients in whom 
ATN was suspected, but not proven. only one patient had elevated urin-
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ary ligandin. Although rejection is said to occur from day 4 onward it 
is possible that the poor initial function in these patients was due to 
early rejection. 
It is notable that in the patient whose graft underwent prolonged 
ischaemia the first specimen recorded the highest level of ligandin in 
the whole series (4000 ng/ml). 
Rejection of the transplanted kidney is not associated with ligan-
dinuria. Although tubular damage is seen in this condition presumably 
the degree of damage is of too low intensity to cause a detectable re-
lease of ligandin. 
Cho et al (125) have used GSH-T activity in the perfusates of 
donor kidneys to predict whether ATN would develop post transplant. 
There was a significantly_ higher G SH-T excretion in the perfusates of 
those kidneys which developed post-transplant ATN. The test could be 
used with 100% predictability. The ultrafiltrates of these kidneys 
were also studied, and although a difference was found it was not stat-
istically significant. This current study however shows that even high 
levels of ligandinuria may not be predictive , of ATN. The differences 
between these results could be due to the fact that Cho et al used 
GSH-T enzyme•assay, whereas here ligandin was measured by the more sen-
sitive RIA. Secondly urine produced after transplantation is not. equi-
valent to ultrafiltrate or perfusate. 
Patients with systemic infections who develop decreased renal 
function do not have elevated urinary ligandin levels. It has been said 
that the decreased function in this situation is due to tubular dis-
ease. However on the basis of these results a functional disturbance 






















In some patients with systemic infection ligandinurio. was found 
without decrease in renal function. These episodes may have been rel-









Mercapturic acids were first described in 1879 when it was shown 
that "oromobcnzene and '.'.;hlorobenzene given to dogs were excreted as N-
acetyl (chlorophehyl)-L-cysteine and N-acetyl(bromophenyl)-L-cysteine. 
i.e. as conjugates of N-acetyl-L-cysteine (141.142). These N-acetyl-L-
cysteine conjugates were termed mercapturic acids (MA). 
Most of the exµerimenta,l work on MA biosynthesis and glutathione 
conjugation wr.s done in rats but other laboratory animals. e.g. rabbits 
and guinea pigs were used as well. The findings in different species 
differed only quantitatively, and were qualitatively similar. Cone-
lusions about the biosynthetic pathway were applicable to all species 
tested. 
Initially interest in the metabolic pathway for the formation of 
MA's focused on the crigin of the cysteine moiety. Possible sources 
included tissue protein, dietary cysteine, or glutathione (GSH). 
Dietary cysteine was eliminated from consideration for several 
reasons. Varying the timing of administration of food with respect to 
administration of bromobenzene did not alter tha rate of MA formation 
(143). The amount of MA excreted was proportional to the dose of pre-
cursor and not to the amount of dietary cysteine (144). Animals given 
a MA precursor and kept on a low protein diet continued to excrete MA 
but lost weight or ceased to grow (145,146). The latter could be re-
versed by dietary cysteine or methionine. These findings were inter-
preted as indicating that dietary cysteine was utilized to replenish 
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tissue thiols, rather than contributing directly to the mercapturic 
acid biosynthesis. . This wat confirmed when it was shown that only a 
small amount of dietary 35s-cysteine was incorporated into MA's 
when animals were given bromobenzene or naphthalene (147,148). 
Having ·excluded dietary thiols, tissue protein was thought to be 
the rr:ost likely source ,)f the cysteine group. Animals given a fixed 
dose of bromobcw~ene excreted MA in proportion to their weight (indir-
ectly therefore, in proportion to tissue protein) and glutathione when 
given in the diet did not increase MA for-mation (149). 
However from · 1934 onwards evidence suggesting that glut~.i;hione 
(GSH) could b~ the thiol donor began accumulating. (It h:i.d been point-
ed out that the tripeptide G SH, y-glutamyl-L-cysteinyl-glycir..e, con-
tains thrPe amino acids which are used in the metabolism of xenobiotics 
(150). The mercaptu1•ic acids contain cysteine; bcnzoic acid is exi::re;ted 
as hippuric acid (a glycine conjugate), r.nd phcnyJacetic acid is ex-
creted as the glulamine conjugate. It has not b~en shown ho\Vever that 
G SH i3 the source of the ~lycine in hippuric acid). 
,;,··,, 
When in 1934 Nakashima gave nap!!thalcne, which had been shown that 
year to be a 1"1A precursor, to rabbits, the GSH content of the lens. nnd 
liver decreaseq (151,152). In 1940 it was shown that the GSH conjugate 
of benzyl chloride (S-bem:yl G SE) when admini::tered to rats gave rise 
to the corresponding MA, N-acctyl-S-benzylcysteine, in the urine (153), 
suggesting that the G SH conjugate was an intermediate in MA formation. 
In the same yenr rabbits given brornobenzene were found to show a dec-
rease in liver G SH, which was proportional to the amount of bromophenyl 
MA formed (154). The finding that p-bromobenzylbromide and its GSH and 
cysteine conjugate all gave rise to the same MA, N-acetyl-S- (bromo-
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benzyl)-L-cysteine, provided further clues to the metabolic pathway 
(154). 
Administration in vivo of a number of MA precursors were shown to 
decrease liver G SH (156-158). Furthermore addition of dietary cysteine 
did not alter · the rate of MA production (157). Barnes et al placed the 
finai nail in the coffin ,lf the Ussue protein theory when they ·pointed 
out that the turnover rate of tissue protefo generated insufficient 
cysteine to maintain MA production, while the turnovc1· rate of GSH was 
capable of sustaining MA synthesb ( 158). 
At about the ·ti.me that GSH was being shown to be involv1:.~ at an 
early stage in MA biosynthesis, progress was also beine: made in the 
elucidation of the last step of this pathway. Stekol. who did much of 
the early work, and others showed that administration of S-cysteinyl 
derivatives of MA precusors to dogs, rats, rabbits and man, resulted in 
the formation of the corresponding MA (159-161). 
Elucidation of the metabolic pathway of mercapturic acid formation 
proceeded rapidly. In 1951 bromobenzene was shown to decrease G SH in 
liver and kidney (162), and liver and kidney homogenates were shown to 
convert S-benzylhomocysteine to the N-acetyl derivative (163). 
Further i!}formation on the intermediate steps was provided by the 
demonstration that a cysteinylglycine derivative of a MA precursor 
could be cleaved, with the release of glycine, by a peptidase .(cystein-
ylglycinase) which was found in rat liver, kidney, &nd pancreas (164, 
165). In 1960 Booth et al (166) showed the formation of a GSH con-
jugate of naphthalene by rat liver slices using chromatographic com-
parison with synthetic compounds. This was the first direct evidence 
of GSH conjugation as the first step in MA biosynthesis. This group 
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also showed that kidney homogenates converted the GSH derivative to a 
cysteine derivative which was then acetylated by liver slices or by 
kidney homogenate (166). Following administration of MA precursors 
several other GSH conjugates were demonstrated in rat liver slices. 
homogenate or bile (165.167-170). 
Evidence for participation of an enzyme in the conjugation react-
ion was first presented by Booth et al in 1960 (165). when they found 
that the addition of rat liver supernatant increased the rate of con-
jug&tion of the epoxide derivative of naphthalene to GSH. Only th2 GSH 
conjugate was formed in increased amount. The formation of the cysteine 
and N-acetyl-cysteine derivatives was unchanged. This effect was de-
stroyed when the supernatant was boiled. Eighty two percent of the en-
zyme ac~ivity resided in · the cytosol (171). Activity in the liver was 
much higher than in . other organs (liver > heart > kidney > lung > 
spleen). 
The enzyme was partially purified. using its catalytic activity 
with 3.4-DCNB and GSH as a marker. No other thiol would substitute for 
• GSH. These workers also described enzyme catalysed GSH conjugation to 
alkyl hruides, epoxides, bromsulphophthalein (BSP). iodobenzene, phen-
anthrene. naphthalene and chloronaphthalene. The last four substrates 
required the addition of microsomes and NADPH before conjugation 
occurred. implying that microsomal oxidation preceded conjugation. 
Simultaneously in the United States. Combes and Stakelum were able 
to show that the reaction between BSP and GSH was catalysed by an en-
zyme present in liver cytosol (17 2). No co-factors were required and 
the reaction was specific for GSH. This specificity for GSH has. since 
been documented repeatedly (173-175). They also suggested that the 
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Fig. 12.1. Mercapt.uric acid biosynthesis. R-X is an 
electrophilic substrate. 
substrate is conjugated to the SH group of GSH in thioether linkage 
(176,177). 
The presence of conjugates of GSH, cysteinylglycine, cysteine and 
N-acetylcysteine in the bile of rats dosed with naphthalene, and the 
failure to demonstrate the presence of y-glutamyl-S-cysteine deriv-
atives led Boyland to propose the scheme shown in fig. 12.1 (178), 
which has now been accepted as the pathway of MA biosynthesis. 
Five forms of glutathione S-transferase (GSH-T) activity were de-
scribed in the organs of rats and other laboratory animals over the 
next few years, each ascribed to a separate transferase or group of 
transferases, and named according to the chemical nature of the sub-
strate used. These were the aryl, alkyl, aralkyl, epoxide and alkene 
transferascs. The enzymes involved were diffe~entiated from each other 
on the basis of substrate specifity, pH and temperature optima, organ 
distribution and precipitability in acid, ethanol, and on heating. 
The first GSH-T to be characterized was described because of its 
ability to catalyse the reaction of the form depicted in fig. 12. 2.1 
.071), and given the name of GSH S-aryl transferase (179). This same 
enzyme .was found to catalyse the conjugation .of other polychloronitro-. 
benzenes to G SH, sometimes with replacement of the nitro group instead 
of the halogen, e.g. 2,3,4,6 tetrachloronitrobenzene (180). It was 
thus evident that the enzyme had fairly broad specificity. It soon be-
came apparent however, that this was not _the only enzyme catalysing 
conjugations to GSH, and that several enzymes must exist. 
The second G SH-T to be described was G SH S-alkyl transferase and 
was isolated on the basis of its ability to conjugate iodomethane and 
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CH31 + GSH = CH3-SG + H+ + 1-
methyl iodide 
(12.1) 
This enzyme was also shown to be active with several other ali-
phatic halides (181). It was shown to be different from the previously 
described aryl transferase. 
Since the original description of MA's it has been recognized that 
MA's derived from certain halogenobenzenes and polycyclic aromatic 
hydrocarbons are acid labile. These have been t1irr,1ed premercapturic 
acids. and are of the form of dihydrohydroxy MA's. e.g. N-acetyl-S-
(1. 2-dihydro-2-hydroxy-1-naphthyl )-L-cysteine or N-acetyl-S-·( '.I. 6- di-
hydro-6-hydroxy-5-benzanthracyl)-L-cysteine. Cold mineral acid treat-
ment would yield N-acetyl-S-(1-naphthyl)-L-cysteine or N-acetyl-S-(5-
benzanthracyl)-L-cysteine (fig. 12.3). The term "premercapturic acid" 
is misleading and unnecessary as these are in fact mercapturic acids 
(1). 
It was suggested that these acid labile MA's were probably formed 
from intermediate epoxides (182 .183). Supporting evidence was obtained 
when it was shown that conjugation with iodobenzene required the pre-
sence of microsomes and NADPH (171). and confirmation came with the de-
monstration that the conjugation of benzanthracene and phenanthrene oc-
curred via these suggested epoxide intermediates (167,169). 
Tho first attempt at characterization of these GSH-epoxide conjug-
ating enzymes responsible took place in 1965 (174) when, using the sub-
strate 2,3-epoxypropyl phenyl ether, the epoxide GSH-T activity was 











































































































































































































































































































































Since then a vast number of epoxide substrates have been described 
including many reactive intermediates of stable hydrocarbons formed as 
a result of microsomal oxidation. 
The first report of GSH conjugation to a-a unsaturated compounds 
was in 1967 (184). These compounds occur widely in nature and are used 
in the plastics industry. The enzyme .::atalysing this conjugation was 
isolated using its ability to conjugate GSH to diethyl maleate as a 
marker (fig 12.2.3)(184). It was subsequently shown that at least six 
enzymes, differentiated from eac~1 other by heat inactivation, ammonium 
sulphate solubility. enzyme _inhibitors and by the tissue distribution 
of activities in liver and kidney. were responsible for reactions with 
several a-a unsaturated carbonyl compounds (185). Among these were al-
dehydes, ketones, lactones, nitriles~ These six enzymes, the GSH S-
alkene transferases were shown by similar techniques to be different 
from the previously described GSH-T's (184,185). 
A fifth form of enzyme which catalysed GSH conjugation to aralkyl 
halides, e.g. benzylchloride (fig. 12.2.4), was described in 1969 
(186). This enzyme. called G SH S-aralkyl transferase, was shown to be 
different to the other transferases. Yet another enzyme, conjugating 
GSH to aralkyl sulphate esters, (fig. 12.4.1) was shown to be dis-
similar to the G SH S-aralkyl transferase reactive with benzyl chloride 
(187). 
At this stage it was noted that the transferases had not been 
shown to catalyse conjugation with any endogenous substrates. Although 
G SH conjugates of several endogenous substances were known to occur in 
vivo, it had not been shown that the G SH-T's catalysed the conjugation 











+ G SH 
N02 
1- ch loro-2,4-d initrobenzene 
Fig, 12.4. Reactions of glutathione used to purify the GSH 
S-transferases; (1) reaction with menaphthyl sulphate used to purify 
GSH-T M; · (2) reaction with epoxynitrophenoxy prop,rne used to purify 
GSH-T E; (3) reaction with chlorodinitrobcnzene used to purify GSH-T 
AA. Iodomethane was used to purify GSH-T B, and dichloroni trobenzene 
was used to purify GSH-T A and GSH-T C~ 
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the presence of ATP and liver homogenate (188) and it was speculated 
that this was the first step in the synthesis of isovalthine (S-(1-
carboxyisobutyl] cysteine). Other endogenous S-substituted -car boxy 
cysteines have been found (189-191). but their origin is obscure. 
Maleic acid conjugates of GSH and cysteine do occur (191-192), (S-(1,2-
dicarboxyethyl]-cysteine) but again little is known of their origin. 
Maleic acid conjugation to GSH occurs spontaneously. Maleic acid is 
not a good substrate but the presence of liver cytosol docs catalyse 
the reaction to a small extent (184). 
Recent work with the rat has suggested that in some species lipid 
hydroperoxides may be maj,Jr endogenous substrates for some of the 
GSH-T's. 
Work on the biosynthesis of MA's had at this stage produced an em-
barrassingly large number of seemingly separate enzymes. At least 10 
different enzymes catalysing GSH conjugation had been identified using 
only a small percentage of the compounds known to be MA precursors, 
with the possibility that investigation of other substrates would yield 
further enzymes. Thus far all studies utilized preparations that were 
probably, by modern criteria, not pure. Each preparation may have con-
tained varying amounts of other GSH-T's. Work with highly purified en-
zymes began when Fjellstedt et al were able to purify an enzyme capable 
of conjugating GSH to 1,2-epoxy-3-(p-nitrophenoxy)propane (fig. 12.4. 
2)(193). The enzyme was homogenous with respect to gel electrophoresis 
and analytical ultracentrifugation. However in the early stages of 
purification there were at least two other proteins with epoxide GSH-T 
activity. These could be separated on CM-cellulose. The purified en-
zyme was reactive with a wide range of epoxide substrates, but not with 
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arene oxides. It was also shown that the three peaks of epoxide G SH-T 
activity seen on elution from CM-cellulose each. when purified to homo-
geneity. had overlapping substrate specificities {194). 
At about the same time, a G SH-T active with aralkyl substrates had 
been purified to apparent homogeneity by Gillham (195). Purification 
was followed using conjugation of GSH to menaphthyl sulphate as a 
marker (fig 12.4.1). 
Clarification came when Jakoby's group demonstrated that there 
were at least se,vr.m GSH-T's in rat live:..· (127.196.197). The two prev-
iously described GSH-T's (19.3, 195) were designated GSH-T Mand E re-
spectively (menaphthyl sulpluite and epoxide GSH-T). Since it was known 
that GSH-T E was the first peak eluted from CM-cellulose. the GSH-T's 
were named in reverse order of elution from CM cellulose. GSH-T A, B, 
c. n. E (197). GSH-T M was lost in the purification process. Sub-
sequently, when the more sensitive substrate l-chloro-2, 4-dbitro-
benzene (CDNB) was used the seventh GSH-T. GSH-T AA was found eluting 
after GSH-T A (197). With the exception of GSH-T Dall t he rat GSH-T's 
been purified to homogeneity. GSH-T B was purified using its ability 
to conjugate iodomethane to GSH (127), GSH-T A and C by their ability 
to conjugate 3,4-dichloronitrobenzene (DCNB) to GSH (127,196) and G SH-T 
AA by its ability to conjugate CDNB to GSH (fig. 12.4.3)(197). Each 
pure prqtein had wide overlapping substrate specifity with the other 
GSU-T's. 
Simultaneously Mannervik and colleagues purified two rat liver en-
zymes with aryl GSH-T activity using DCNB as substrate {198). Their 
enzymes, designated GSH-T I and II, were later shown to be identical to 




time Hayakawa et al using a sensitive radiochemical assay isolated and 
purified a GSH-T from sheep liver active with several arene oxide de-
rivatives of polycyclic aromatic hydrocarbons. Their purification sys-
tem was ver~ similar to that of Fjellstedt et al (200). They concluded 
that their preparation was identical to that of Fjellstedt and the 
failure of the latter to show arene oxide activity was probably due to 
the lack of a sufficiently sensitive assay (200). 
It was then shown that rat GSH-T B was identical to ligandin (13). 
a major intracellular binding protein, which h!id been previously char-
acterised (see chapter I). 
In man, using a purifK:ation scheme simila!" to that used in the 
rat, five G SH-T's were purified to homogeneity and designated a. 13. y, 
6 and t:, on the basis of increasing 'isoelectric points (16). 
At this stage it is necessary to consider a few questions of sem-
antics. Jakoby has pointed out (201) that the terms aryl. alkyl, ep-
oxide, alkene and aralkyl GSH-T, are misleading since they do not refer 
to single enzymes. but to a combined activity contributdd to by several 
enzymes. He suggested that the enzyme activity be specified by sub-
strate, for example 'GSH-T activity with iodomethane' (201). Therefore 
having previously dealt with these terms in their historical contest, I 
will avoid their use except where necessary to refer to earlier papers. 
Jakoby also pointed out that enzyme kinetics and association constants 
of binding derived from experiments on cytosol containing mixtures of 
these enzymes are of little value, being the summation of the 





PURIFICATION OF GLUTATHIONE S-TRANSFERASES 
The earlier methods of purification used n combination of ion ex-
change chromatography, ammonium sulph11te precipitation and adsorption 
chromatography. The 100, OOOxg supernatant from rat liver can ·be app-
lied to DEAE cellulose so that GSH-T M remains o_n the column (194), but 
the other G SH-T's pass through unhindered (127). The dialysed redis-
solved precipitate frcm an ammonium sulphate fractionation of the pool-
ed eluent is then chromatographed on CM-cellulose. GSH-T D and E ap-
pear in the initial wash after which the other G SI!-T's are eluted sequ-
entially with a KCl gradient (12). Further purification of each GSH-T 
is by adsorption chromatography with hydro:xyapatite. 
A similar scheme is used for the purification of human G SH-T's. 
The cationic GSH-T's do not bind to the first DEAE-cellulose column and 
are collected in the initial wash (16). Since the original reports 
many other methods for purification have been described, mostly using 
the above techniques in various combinations. 
More recently purification techniques have included affinity 
chromatography with a variety of ligands. Kraus used G SH coupled to 
aminododecyl-cellulose to purify a G SH-T able to conjugate hexachloro-
cyclohexane (HCH) to G SH (202). Gu then berg and Mannervik were able to 
purify a GSH-T from rat lung using GSH coupled to agarose by a hexyl 
spacer (203). GSH coupled to agarose with 1,6-diaminohexane as a 
spacer has also been used. GSH-T B did not bind to the affinity gel 
and appeared in the initial wash. GSH-T AA was eluted with a salt 
gradient and G SH-T's A and C were partially separated with a G SH dis-
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placement (204). BSP coupled to Sepharose 4B has been used to purify a 
porcine GSH-T, called ligandin (205). A BSP-GSH conjugate coupled to 
agarose (Sepharose 4B) has been used to purify an insect GSH-T (206) 
and rat ligandin (207). Human GSH-T has been partially purified using 








The GSH-T's are widely distributed throught the plant and animal 
kingdoms ( 209-215). The lowest known organisms found to have G SH-T 
activity are bacteria. Strains of Salmonella typhimurium used in the 
Ames mutagenicity test are able to catalyse the conjugation of CDNB and 
G SH (209-210). Protozoa also have G SH-T's. The GSH-T's of Trypanosoma 
cruzi have beer. i•urified. In this organ:Sm the G SH-T's may play a part 
in resistance to drugs (211-212). 
In plants the G SH-T'., are similarly highly conserved (213-215). 
The ability of corn, sorghum and sugar cane to resist the effects of 
the herbicide atrazine correlates with the levels of the G SH-T 
catalysing its conjugation to GSH (216). A similar GSH-T responsible 
for conjugation of fluorodifen (p-nitrophenyl a. a. cc trifluoro-2-nitro-
p-tolyl ether) has been isolated from peas (217) and peanuts (218). 
G SH-T from the corn root has been claimed to conjugate S-ethyldipropyl-
thiocarbamate (EPTC) sulfoxide and GSH (215) and to be enhanced by the 
EPTC antidote dichloracetamide. however the existence of this enzyme 
has been disputed ( 219. 220). Non-enzymatic conjugation of G SH to 
several herbicides has been reported (2~0). 
G Sil-T's have been found in various species of insect e.g. the wax-
moth larvae (206), grass grub, housefly. cockroaches (221,222) and loc-
usts (173,223). The insect GSH-T's have been shown to metabolize 
organophosphorus insecticides such as methyl and ethyl parathion, diaz-· 
inon and malathion (224,225). a- Hexachlorocyclohexane is also meta-
bolised by GSH conjugation, as are other polychlorobenzenes (226). 
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While there is some correlation between insecticide resistance and GSH-
T levels (227) the G SH-T's are probably not the main mediators of re-
sistance (228). GSH-T activity can be separated from another GSH-
dependent enzyme, DDT dechlorinase (229,230), which is thought to be 
unrelated. 
''"'1'~,m, .. . 
GSH-T activity has been found in six spec5es of earthworm (Lum-
bricidae). Worm homogenates subjected to isoelec~ric focusing have 
shown ·species specific profiles of enzyme activity (231). 
The gill, hepatopancreas (,~quivalent of t~e liver), and excretory 
gland of crabs and lobsters have GSH-T activity (232,2:!4), as does cyt-
osol prepared from whole mnlluscs (233). 
BSP binding on gel filtration is absent in elasmobranch and tel-
east fish (234) 1 several of which hav.e GSH-T actiyity with epoxide sub-
strates (233), suggesting that BSP is poorly bound to the GSH-T's in 
these species. The rainbow trout takes up BSP avidly, and is able to 
form BSP-GSH conjugates (235). Tadpoles lack a mechanism for BSP up-
take and have no Y protein as determined by gel filtration. In con-
trast the adult frog and all land animals studied are able to take up 
BSP and have Y protein (234). GSH-T activity has been demonstrated in 
the livers of snakes (236) 1 lizards (179) 1 · chickens (237) 1 several 
species of wild birds (179,238,239), laboratory rodents of all kinds 
(240-242) and apes (243). The hepatic GSH-T's of hamsters (242), 
guinea pigs (244) and monkeys (245,246) have been purified and char-
acterised and as in the rat and human have been shown to consist of 
forms with overlapping substrate specificity. A pig liver 'ligandin' 





'': ., ..... 
The G SH-T's are widely distributed within the mammalian body. In 
the rat liver they comprise about 10% of the soluble proteins (247, 
249). Ligandin accounts for about half of the G SH-T concentration, 
i.e. about 5% of the soluble liver protein. Ligandin is localised to 
the cytoplasm of the hepatocyte and is not found in the Kupffer cells. 
Staining by immunofluorescence and immuooperoxidase techr.iquei: is more 
intense in the centrilobular area (99) and nuclear staining is also 
demonstrable (99,248). 
In man the G SH-T's compi:ise 2-3% of the . soluble hepatic protein 
(249). Using an immunopero.xidase technique the distribution of ligan-
din in the liver in man has been shown to be similar to the rat (250). 
Systematic investigations of the distribution of GSH-T activity 
using a va·riety of substrates have spawn the liver to have the highest 
concentrations of the enzymes in all animal species studied (171,243, 
251,252). Other sites · of relatively high activity are kidney, lung and 
intestine. GSH- T activity has also been found in heart, spleen, intes-
tine, placenta, lens, erythrocytes, white cells, whole blood, testis, 
ovary, adrenal, skin, sperm, semen and brain (31,32,251,253-259). In 
the human kidney ligandin is localised to the proximal tubules and to a 
lesser extent in the thick descending limb of Henle (250), while in the 
rat ligandin is found only in the pars convoluta of the proximal tubule 
( 260). G SH-T enzyme activity in the rat is limited to the proximal 
tubules and the loops of Henle (261). Ligandin measured by radio-
immunoassay has been found in significant amounts in rat liver, kidney, 
intestine, testis, ovary and adrenals, and in smaller amounts in heart, 
skeletal muscle, brain, stomach and colonic mucosa, lung, pancreas, 







Rat hepatoma cells in culture show a line of immunological iden-
tity with purified ligandin when tested by immunodiffusion. In addit-
ion there was another precipitin line which showed only partial iden-
tity with purified ligandin. Cytosol from other rat and hybrid cell 
lines showed either partial identity or no cross reactivity at all with 
the purified ligandin (263). In adult rat hepatocytes in culture 
hepatocytes in culture ligandin is only produced during the early lag 
phase and the stationary phase of growth, and was markedly decreased 
during the proliferative phas& (264). Other mammalian cell lines have 
also been sh
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GSH-T's purified from different organs of different species have 
been reported to have molecular sizes ranging from 39,000 to 80,000 
daltons (table 15 .1). However these differences may be due to method-
ological artefacts rather than biological variation. A comparative 
study of the G SH-T's from hoasefly. rat and mouse showed that on gel 
filtration the elution volume · of the G SH-T's depends critically on the 
buffers used and the presence of stabilisers such as glycerol unfl EDTA 
(both used in the Jakoby method of purification) (266). GSH-T activity 
from all three species had an identical elution volume in any given 
system, but the molecular weight varied from 43,000 daltons in a Tris 
buffer with potassium chloride to 53,600 daltons in Tris buffer without 
potassium chloride. Crude enzyme and highly purified enzyme had the 
same elution volume indicating that molecular size did not change dur-
ing purification (266) • 
It is generally accepted that rat liver GSH-T's are between 45,000 
and 47,000 daltons in size, and that the human GSH-T's are slightly 
larger at 48,000 daltons (199). The GSH-Ts have all been shown to be 
dimers, irrespective of tissue of origin (table 15.1 & 15.2). 
Rat liver G SH-T's:-
In addition to the seven rat liver GSH-T's (AA, A, B, C, D, E and 
M) a more acidic GSH-T with a pl of 6.6 has been detected by isoelec-















GSH-T M, but has not yet been shown to do so. The physicochemical 
characteristics of rat liver ligandin have already been discussed. The 
other rat liver G SH-T's have not been as well studied. 
Until recently the G SH-T's were thought to be limited to the cyt-
osol, but reports of GSH-T activity associated with mitochondrial and 
microsomal fractions (267-270) led to the isolation of three GSH-T's 
from rat liver mitochondrial matrix (271). Unbroken mitrochondria had 
little activity (272). Mitochrondrial G SH-T's have been estimated to 
contribute about 7% of the mitochrondrial protein and are thought to 
account for approximately 7't of total hepatic glut!nhione G SH-T ac-
tivity (268). 
Microsomal G SH-T's do not appear to be adsorbed to the membranes • 
but are thought to be an integral part of the membrane. They resist 
separation despite several procedures designed to remove loosly bound 
proteins from membranes (273). Unlike cytosolic GSH-T's the microsomal 
GSH-T's are activated by agents r eacting with sulfhydryl groups. In 
the absence of the sulphydryl reactive agents, N-ethylmaleimide or iod-
acetamide, activity of the microsomal GSH-T's was 5-iO% of the total 
G SH-T activity. but in the presence of these agents microsomal activity 
increases to 30% of total G SH-T activity. Whether the sulfhydryl group 
was on the G SH-T molecule or on a neighbouring molecule has not inves-
tigated (274). Membrane bound GSH-T activity in decreasing order is as 
follows: rough endoplasmic reticulum, microsomes, smooth endoplasmic 
reticulum. Other membranes have little activity ( 272). Membrane 
GSH-T's were found to resemble the cytosolic GSH-T's A, B and C, but 
are not inducible with phenobarbitone. Others have found GSH-T ac-






Rat GSH-T's in other tissues:-
Ligandin has been purified from rat kidney and shown to be immuno-
logically similar to the liver enzyme and to have similar enzyme ac-
tivity (131). Rat renal Y protein has three bands on SDS-PAGE, Ya, Yb 
and Ye (18). Rat renal GSH-T activity can be separated into three 
peaks using isoelectric focusing (136). The most basic peak with a pl 
of 9.0 is immunologically similar to ligandin. The second peak (pl 
8.5) was only poorly recovered on refocusing and could not be assessed 
further. The third peak focusing at pl 7 .o was different from any of 
the hepatic GSH-T's separated in the same way. By compa~ing the 
elution profile of liver cytosol from CM-cellulose with the elution 
profile of kidney cytosol under identical conditions, Scully and Mantle 
(276) showed that the kidney contained a small amount of GSH-T AA, a 
considerable amount of GSH-T Band a third form, GSH-T X, which eluted 
from CM-cellulose at a higher ionic strength than G SH- T C did in the 
correspo~ding liver cytosol analysis. This peak probably corresponds 
to the peak at pl 7 .O described above. They were unable to demonstrate 
a GSH-T corresponding to GSH-T A or C, both of which migrate as YbYb in 
SDS-PAGE. The Yb subunit detected by Bass et al in kidney cytosol is 
therefore as yet unexplained. 
A testicular protein with GSH-T activity has been purified (277). 
On SDS-PAGE it consists primarily of a 25,000 daltons subunit running 
with the mobility of Ye. There is very little of the Ya subunit, in 
fact in some purifications it does not appear (262,277). This protein 
has been shown to cross-react with antibodies to rat liver ligandin and 
112. 
to have similar enzyme activity with CDNB and has therefore been called 
ligandin, but it lacks a high affinity binding site for bilirubin. 
Using elution of cytosol from CM-cellulose, rat testis has be:en 
shown to have. a considerable amount of G SH-T AA and C. less G SH-T A and 
only a small amount of GSH-T B (276). The subunits of each GSH-T des-
cribed in testis correspond to those described in liver. Of interest 
is the fact that the YcYc dimer corresponds toGSH-T AA and the GSH-T B 
is a YaYc dimer. To date no YaYa dimer has been shown in the testis 
(276). In this separation procedure there is no G'.:'.H-1 with subunits 
corresponding to those described for testis ligandin, i.e. mostly Ye 
with about 10% Ya. The protein purified by Bhargava et al may tlms not 
be homogenous and may comprise a mixture of GSH-T B and GSH-T AA. 
Purification of the pulmonary transferases showed similar profiles 
to the liver enzymes (277) using similar purification techniques, but 
using hexyl-GSH affinity chromatography a peak of activity with CDNB 
was found which was not present in liver (203). 





Only rat GSH-T A and M have been subject to investigation of their 
reaction mechanisms. Gillham (195) has presented evidence that for 
purified G SH-T M, the reaction mechanism with 1-menaphthyl sulphate is 
of the form termed Ordered Bi Bi, which can be represented thus: 
E = enzyme 
B = second substrate 
Q = second product. 
E +A ::. EA 
EA + B = EAB = EQ + P 
EQ = E + Q 
A = first substrate 
P :: first product 
GSH-T A has been investig ated by two groups with conflicting 
results. The NIH group (196) proposed a mechanism whereby at low subs-
trate concentration (GSH less than 0.1 mM) the reaction could be des-
cribed by a Ping Pong mechanism where the first product leaves the en-
zyme - first substrate complex before addition of the second substrate 
(right hand wing of fig. 16.1). At higher concentrations of GSH 
(greater than 0.15 mM) an ordered sequential mechanism is operative 
(left hand wing of fig. 16.1). Here G SH adds on first, followed by the 
second substrate. This is the nature of the reaction which is likely 
to occur . in vivo since the physiological concentration of GSH in the 
liver is about 5 mM. 
Mannervik and Askelof however dispute the Ping Pong mechanism and 
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equations of the form applicable to a Ping Pong pathway and a random 
sequential pathway show that using the same substrate as before. the 
random sequential model fits the experimental data better than the Ping 
Pong model ( ~78-280). This issue is not resolved. Binding of subs-
trates to GSH-T A is hyperbolic, with a 2:1 stoichiometric ratio (subs-
trate:enzyme). At higher ligand concentrations there is a weaker. pro-
bably non-specific binding (281). 
Mechanism:-
A wide range of compounds have been described as substrates for 
the G SH-T's. Criteria used for detection of such substrates include 
detection of enzyme catalysed formation of G SH adducts in tissue prep-· 
arations and bile, and the detection of rnercapturic acids in the urine. 
W0rk with purified enzymes has involved a more restricted range of sub-
strates. 
An essential requirement for a compound to be a substrate for the 
GSH-T's · is that it must have a lipophilic centre. This is a pre-
requisite for binding to the enzyme (282,283). The leaving group of 
the substrate may be a halide, sulphate, nitro, or methyl group. Glu-
tathione may add on across the oxirane ring of an arene oxide, or aryl-
halide epoxide, or it may add on across the ethylenic bond of an a13un-
saturated compound. The electrophilic domain may be a carbon, nitrogen 
or sulphur atom. The compound can be aliphatic. aromatic or hetero-
cyclic. The wide variety of substrates utilised by the GSH-T's are the 
subject of several reviews (1, 2, 3, 284-286). The dealkylation and de-
arylation of phosphoric acid triesters, many of them organophosphate 




222,226,287). More recently some of the GSH-T's have been shown to 
have glutathione peroxidase (G SH-Px) activity (288) and to be respon-
sible for the soluble A 5 3-ketosteroid isomerase ( A 53-KSI) ac-
tivity in the liver (see later)(289). 
Many substrates conjugate to G SH at an appreciable spontaneous 
rate, making the enzymatic catalysis difficult to detect. Consider-
\ 
ation of the reaction with organic nitrates and thiocyanates led to the 
formation of a hypothesis of enzyme mechanism which is now generally 
accepted. It was proposed (290) and subsequently demonstrated (283) 
that the diverse reactions of · the G SH-T's can be explained on the basis 
of nucleophilic attack by the enzyme bound Gs- thiolate ion on an el-
ectrophilic centre on the second substrate. 
The enzyme may increase the nucleophilicity of bound Gs-, in a 
manner analagous to the behaviour of cysteinc thiols in protein (291), 
but there is no definite evidence for this. Currently it is thought 
that the sole effect of the enzyme is to bring GSH into suitable appos-
ition with the hydrophobic substrate (292). If the ele<;trophilic group 
is sufficiently reactive and suitably apposed to the G SH moiety the 
reaction will occur. Hydrophobic molecules which lack an electrophilic 
centre may theoretically bind to the enzyme at the same site and act as 
a competitive inhibitor, and indeed this does occur. Many of the 
nonsubstrate ligands bound by the GSH-T's fall into this category. 
Conversely a polar molecule with an electrophilic domain would not be . 
expected to be a substrate. For example, disulphide interchange (eqn 
16.1) is a special example of nucleophilic attack on sulphur (282). 





This reaction is not catalysed by the G SH-T's if R and R' are pol-
ar groups, but if these polar groups are blocked. as with hydrophobic 
derivatives of L-cystine and G SSG. the G SH-T's do catalyse the reac-
tion. 
Similarly maleic/fumaric acid isomerization is not catalysed by 
the n SH-T's. but more hydrophobic analogues e.g. maleylacetone and 
maleylacetoacetio acid do undergo G SH-T catalysed isomerization (282). 
Diethyl maleate does not undergo isomerization. but is subject to thio-
ether formation with GSH, which is also catalysed by the GSH-T's. 
Therefore the reason that some nucleophilic reactions of G ::;H are 
not catalyzed may be due to poor binding of the second st•.bstra te. One 
can thus propose that any compound containing a sufficiently clectro-
philic centre and a sufficiently hydrophobic domain is a potential 
G SH-T substrate. This mechanism cam explain all the known forms of· 
GSH-T activity:- organic nitrate reductase, GSII peroxidase, t,53-KSI 
and prostaglandin isomerase. 
The GSII-T's are not good catalysts by enzyme standards, but what 
they lack in efficiency is made up in versatility. They comprise a 
low affinity, high capacity system, ideally suited to handle the vs.st 
array of subst.rates presented to them. 
Despite the wide array of known substrates only a small number are 
required to study the rat GSH-T's. GSH-T AA and Bare similar catalyt-
ically and may be structurally related, but AA is inhibited to a much 
greater extent than GSH-T B by indocyanine green. Both GSH-T A and C 
have aryl GSH-T activity (198), but GSH-T A is inactive or nearly so 
with alkene substrates. GSH-T B can be distinguished from GSH-T A and 






has high activity with 1. 2-epoxy-3-(p-nitrophenoxy)propane. and only 
GSH-T M has appreciable activity with menaphthyl sulphate. 
GSH Peroxidase:-
The presence of enzymes catalysing the reaction 
(16.2) 
has been known ~or some time. One such enzyme is G SH peroxidase (GSH-
Px)(293) which has been demonstrated in a variety of tissues. The re-
action catalysed is 
(16.3) 
This enzyme is also able to use organic hydroperoxides as sub-
strates. Cumene hydroperoxide is a commonly used example. 
The enzyme has a molecular size of 84,000 daltons. and comprises four 
identical -subunits and four molecules of selenium. However another en-
zyme active with organic hydroperoxides and not wit:h H202, which 
was not a seleno-enzyme. was found in rat brain and liver cytosol 
(294,295). Suggestions that some of the GSH-T's had similar kinetics 
and inhibition kinetics led to the demonstration that in the rat part-
ially purified GSH-T's (288). and purified GSH-T B and AA were able to 
catalyse the r~action (296. 297). The reaction is presumed to occur via 
the formation of an intermediate sulfenic acid of GSH. i.e. GSOH (187). 
GSH + ROOH = GSOH + ROH 





Similar findings have been obtained in rabbits and giunea pigs 
(298,299). The reaction occurs by nucleophilic attack by GS- on the 
hydroperoxide. G SH-T. or the non-seleno enzyme G SH peroxidase ac-
118. 
tivity, accounts for 23-38% of peroxidase activity in rat adrenal, 
liver, kidney, brain and fat, and 91% in testis. Spleen, heart, lung 
and intestinal epithelium have no non-seleno enzyme G SH peroxidase ac-
tivity (300). This implies that the GSH-T of these tissues do not have 
GSH-peroxidase activity. Apart from GSH-T Band AA none of the other 
GSH-T's have been reported to have GSH-Px activity. There is consider-
able species variation, ranging from 45% of total GSH-peroxidase ac-
tivity accounted for by the G SH-T's in the hamster liver to 100% in the 
guinea pig liver. Eighty four percent of human hepatic GSH-peroxidase 
activity is non selenium depE;!ndent (300). 
Burk et al (296) also showed that purified GSH-T B had GSH per-
oxidase activity and that this activity could be induced by phenobarb-
itone and in selenium deftciency. The isolated perfused liver from se-
lenium d·eficient rats was able to produce G SSG when perfused with 
t-butyl hydroperoxide (301). These results indicate a possible physio-
logical function for the non selenium dependent GSH-Px activity pro-
vided by the GSH-T's (see later). 
Organic nitrate reductase (E.C. 1.7.99.4):-
Hepple and Hilmoe in 1950 (302) showed enzyme catalysed formation 
of inorganic nitrate and reduced G SSG from GSH and nitroglycerine or 
erythritol tetranitrate. 
RCH20NO + 2GSH = RCH20H + HN02 + GSSG (16.6) 
Ohkawa et al (303) showed that the general reaction 
RCH2SCN + 2G SH = RCH2SH + G SSG + HCN (16. 7) 
was catalysed in mice and housefli~s by a group of soluble enzymes and 





1:D,5 - 3-KETOSTEROIO fi -3-KETOSTEROIO 
Fig. 16 .2. Isomerization of uS 3-keto steroids to !.'. 4 3-keto 
steroids. In liver cytosol this reaction may be catalysed by GSH-T. 
ed these two reactions to be catalysed by purified GSH-T's A. AA, B, C, 
lh and 6 ( 283. 290). Theoretically since the G SH-T's catalyse thioether 
formation there is a presumed disulphide intermediate (eqn. 16.8) which 
is unstable and decomposes (eqn. 16.9) to form the product (283,290). 
RSCN + GSH = RSSG + HCN (16.8) 
GSH + RSSG = GSSG + RSH 
Similarly. for organic thiocyanates 
RCHONO + GSH = GSN02 + RCHOH 




The presence of the intermediates was confirmed by adding a non-
substrate thicl to the incubation mixture, whereupon the concentration 
of GSSG formed was decreased (283) to an extent that could not be ex-
plained by disulphide interchange of the form:-
GSSG + RSH = GSSR + GSH (16.12) 
ti5-3-Keto steroid isomerase (E.C. 5.3.3.1):-
The isomerizatior. of tif> steroids to t14 (fig. 16.2) in steroid 
• producing tissues is catalysed by an enzyme occurring in the microsomes 
requirlng NAD+ and NADH (304,305). However in rat liver cytosol an 
enzyme with similar activity, dependent on GSH, was found (306), which 
was identified as GSH-T B (289). Other rat GSH-T's were less active. 
All the basic human GSH-T's had activity to varying degree (289). No 
intermediate conjugate has been found and GSH is not consumed. This 
subject is discussed further in consideration of the interaction of 








Fig. 16 .3. Prostaglandin A1 - glutathione conjugate. Conjugation 
occurs at the cyclopentenone ring. 
, 
Prostaglandin (PG) Metabolism:-
Several PG derivatives may form GSH conjugates. PGA1 conjug-
ation with GSH is catalysed by the GSH-T's (307). The formation of a 
GSH adduct of 15-keto PGF2a is inhibited by the presence of PGA1 
(308). PGA1 is conjugated to GSH at the cyclopentenone ring. (fig. 
16.3), whereas the 15-keto PGF2a• is conjugated at the 15-C position. 
This latter conjagation is also presumed to be catalysed by the 
GSH-T's. 
A preparation from sheep lung with GSH-T activity resembling lig-
andin in substrate specificity. molecular size. subunit's and pl was 
shown to catll1.yse formation of PGD2. PGE2 and PGFz:i from PGH2 
(fig. 16.4)(309,310). Rat liver GSH-T's also catalysed the reaction to 
form PGF2a• but formatio_n of PGD2 and PGE2 was more variable. No 
No GSH adduct could be demonstrated. This reaction was not catalysed 
by GSH peroxidase (the seleno-enzyme). 
A preparation of bovine vesicular gland microsomes was able to 
catalyse the conversion of PGH1 to PGE1. This enzyme also required 
GSH but has not been characterised (311). 
Slow reactive substance of anaphylaxis (SRS-A) is a GSH conjugate 
of hydroperoxyeicosatetraenoic acid (HPETE) (fig. 16.~). The parent 
compound undergoes initial epoxidation at the &-7 position and is sub-
sequently conjugated to GSH. It is not known whether this reaction is 
catalysed by the GSH-T's or occurs spontaneously (312). 
Despite the above findings the exact role of the GSH-T's in PG 
metabolism is not known. 
121. 
























Fig. 16 .4. The glutathione S- transferases and prostaglandi.n meta-bolism in a sheep lung preparation. (1) 15-hydropero:,;y PGH2. (2) IS-hydroxy PGHz. The isomerization to form PGD2 is possibly not a specific enzymic isomerization, but may be a non-spec~fic reac~ ion which occurs in the presence 0{ protein e.g. albumin _ 
' '\ 
OOH 
COOH ' I 
Fig. 16.5. Molecular structure of slow reactive substance substance 
of anaphylaxis A. ( SRS-A). This is a GSH conjugate of hyd:-operoxy-




In addition to their activity as enzymes (GSH-transfcrase, · pros-
tagl::rndin isomerase, ~5-3-ketosteroid isomerase, organic nitrate re-
ductase, GSH peroxidase) the GSH-T's as a group also bind a wide range 
of ligands which do not undergo GSH conjugation or other GSH-trans-
ferase mediated modifications. All the rat and the cationic human 
GSH-T's have this activitY: (table 17.1)(41). Binding affinities for 
the ligands vary. The binding activity of ligandin is the best 
studied. Ligandin was originally conceived of as an organic anion 
binding protein. It soon became apparent that the major requirement 
for binding is hydrophobicity. and like binding to albumin in the 
serum, binding to ligandin is non-specific. This binding may serve in 
part to solubilize hydrophobic molecules in cytosol, much as albumin 
does in the serum (313). Tables 17.2 to 17.5 list some of the non-sub-
strate ligands which have been shown to bind to ligandin. A variety of 
methods have been used to study binding, including circular dichroism 
(20), equilibrium dialysis (42,314), bilirubin difference spectroscopy 
(315), fluorescence quenching (41) and binding to the Y peak on gel 
filtration (8). It should be noted that binding to the Y peak includes 
binding to all the GSH-T's, and not to ligandin alone. 
The chemistry of non-substrate binding to ligandin has been dis-





Table 17 .1. 
' DISSOCIATION CONSTANTS FOR SOME RAT & HUMAN GSH-T'S 
'.. 
' 
: ligand !n for GSH-T- <no 
AA A B· C a B y 6 £ 
Bilirubin 100 15 2 2 65 110 34 18 34 monoglucuronide 4 2 3 6 5 5 diglucuronide 40 23 10 20 33 121 
indocyanine green 100 3 3 1 20 20 Haematin 4 2 0 .1 7 10 l(j 
:: 








Table 17 .2. 
LIGANDS BINDING TO PURIFIED LIGANDIN 
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Table 17.3. 
LIGANDS BINDING TO LIGABDIN 







Porphyrins and Derivatives 
Bilirubin 
Haematoporphyrin 
Coproporphyrin I & III 




































LIGANDS BINDING TO LIGANDIN 








2-vH oestradiol-GSH conjugate 
Oestrone glucuronide 
Diethylstilboestrol 








































































N.B. Recently evidence has appeared showing that within the Y peak on gel filtration there are several binding pro-teins unrelated to ligandin, and therefore these data will have to be interpreted with caution (521). 
GSH-T A has been shown to have a single binding site for bili-
rubin, but the other rat GSII-T's have not been investigated in this re-
spect (41). 
Bilirubin binding to the cationic human GSH-T's (ligandin) is com-
plex. There are two binding sites~ The GSff-T-bilirubin complex is 
catalytically active, but at pH 6. 5 slowly loses catalytic activity. 
In the presence ,of GSH, catalytic activity decreases more slowly and to 
a lesser extent (316). These studies only considered the cationic 
GSH ... T's. 
Covalent bindjng: -
In addition to non-covalent binding, ligandin and the other 
GSH-T's are able to bind covalently to certain highly reactive com-
pounds, "Such as the oxidation products of 3-methyl cholanthrene (3-l\tC) 
and benzo(a)pyrene (BP)(26,317). GSH-T A and Bin the absence of GSH 
will bind covalently to CDNB (196,199). Aminoazodye carcinogen binds 
covalently to ligandin via the thiol groups of cysteine (23). The maj-
ority of the cysteines reside on the Ye peptide, and therefore it would 
be expected that Ye would be the site of covalent binding, and indeed, 
the activated carcinogens 3-MC and dimethylaminoazobenzene (DAB) bind 
to Ye in vivo (26). Ethacrynic acid also binds covalently to the 
GSH-T's. This is the only described instance of a compound binding co-




A large number of compounds which inhibit the GSI-1-T reaction have 
been identified, some of which are listed in table 17 .6. Examples of 
competitive, non-competitive and uncompetitive inhibition have been de-
scribed. It is difficult to identify physiologically important in-
hibit:;rs from the wealth of data available. Two aspects are worth men-
tioning. Firstly organic solvents in which many of the substrates are 
dissolved for laboratory studies, are themselves inhibitors (319). 
This is of importance inasmuch as substrates used by different inves-
tigators may be dissolved ~ different solvents, thereby making com-
parisons of results difficult. 
The second point of interest is the fact that metals, metallic 
salts and organometallic _compounds may inhibit GSH-T activity (320, 
321). Further it is known that several metals and their salts may de-
crease hepatic GSH, and a GSH conjugate of cadmium chloride has been 
described (322-325). The mechanism of reaction is unknown, nor is it 
known if this reaction is catalysed or spontaneous. 
Other known inhibitors include radiographic contrast media (326), 
non-substrate ligands, such as bilirubin and indocyanine green (41), 
and steroid sulphates (327). Product inhibition has also been reported 
(175,185,195,198). 
124. 
Table 17 .6. 
INHIBITION CONSTANTS FOR RAT GSH-T'S WITH CDNB AS SUBSTRATE 
ligand Ki for GSH-T {.vM) 
AA A B C 
Bilirubin 7 2 6 2 
Indocyanine green 100 0.02 3 0.01 
3,6-dibromsulphophthalein 180 22 12 30 




Rat live·r GSH-T's are similar in size and have a wide overlap of 
subst."."ate sp_ecifity. The individuai G SH-T's have amino acid analyses 
which are sufficiently similar to suggest that there may be a common 
origin, but the number of separate gene products are unknown. Based on 
their belief that GSH-T AA is a YcYc dimer and that GSH-T B consists of 
both a YaYc and YaYa dimer, Scully and Mantle (276) have proposed. that 
a single gene product gives rise to a YcYc dimer, which is broken down 
to the Yb and Ya subunits by several peptidases variably present in 
different organs. Currently available immunological evidence suggests 
that ligandin is not that closely rel&ted to the other G SH-T's. Since 
conversion of Ye to Ya occurs in the presence of enzyme inhibitors such 
as EDTA, and since degradation occurs in highly purified preparations, 
the action of a peptidase is unlikely. However trace amounts of con-
taminating proteolytic enzymes in an otherwise pure preparation could 
be responsible for breakdown. An alternative hypothesis is that YaYc 
is the gene px:oduct, and with aging or following phenobarbitone induc-
tion~ spontaneously loses a .:!:_30 amino acid peptide from the C-terminal 
end of the Y-chain, to give YaYa. More recently work on the mRNA for 
ligandin has shown that phenobarbitone induction produces an excess of 
Ya mRNA as compared to Ye mRNA (328). This suggests that Ya and Ye are 
separate gene products, that only Ya is inducible, and is in agreement 
with the findings of Bass et al ( 26 2). 
125. 
G SH-T A and C have similar amino acid analyses. are immuno-
logically identical. and are possibly the products of a single gene. 
which have undergone post-translational modification. Antibodies to 
rat liver GSH-T's B and E react only with the eliciting antigen. and do 
not react with other G SH-T's. 
In the human the five cationic G SH-T' are immunologically and 
structurally similar and are thought to be the products of a single 
gene. The relationship of the cationic GSH-T's to the anionic GSH-T's 
is at present not established. Analysis of a large number of human 
liver homogenates on starch gel electrophoresis showed three groups of 
GSH-T's. which were assf:ligned to three genetic loci. named GST 1. 2 and 
3 (329). GST-1 was represented by an group of three anodally migrating 
isoenzymes. This group was not always present. Hardy-Weinberg equi-. 
. 
librium could be achieved if these isomers represented products of a 
locus with three alleies. two functional and one nul allele. This 
group would correspond to GSH-T u. Similarly a cathodally migrating 
group of GSH-T's could be shown to be consistent with a locus with two 
alleles, (GST-2). This would correspond to the cationic GSH-T's. A 
third locus, GST-3, represented by an anodally migrating GSH-T. but 
faster moving .than GST-1, was the product of a single allele. and may 
represent GSH-T w. The implication of these studies is that each mono-
mer is coded for by a different allele. This work requires confirm-






Of the GSH-T's, only ligandin has been studied to any extent as an 
individual protein. For the most part changes in enzyme concentration 
have been detected by following changes in enzyme activity with one or 
other substrate. Such measurements may be of physiological signifi-
cancP., but they do not ?"eflect changes in individual GSH-T levels. 
A sex difference in concentration of the G SH-T's in the liver has 
been noted several times (179, 330-334). Aryl, aralkyl, epoxide and al-
kyl activities are lower in the female (330), but using the ratio of 
activ_ity of CDNB and DCNB ~nd immunoprecipitation as a guide to ligan-
din concentration others have found the male liver to have less ligan-
din than the female (331). 
Hypophysectomy and thyroidectomy both increase ligandin concen-
tration in the rat liver, apparently by stabilising the protein, there-
by decreasing the rate of catabolism (335). In these studies ligandin 
was measured immunologically, but others, using the combination of im-
munoprecipitation, and the ratio of activity with CDNB and DCNB have 
shown that hypophysectomy decreases ligandin in the female liver but 
has no effect in the male (331). These conflicting data can only be 
resolved when studies measuring the concentration of individual GSH-T's 
immunologically, or by e.g. isoelectric focusing, are performed. 
Hypophysectomy decreases aryl hydrocarbon hydroxylase activity in 
the testis. This could be reversed with follicle stimulating hormone 
(FSH) and luteinizing hormone (LH). Similar changes were seen with 
cytochrome P-450 and epoxide hydrase, but GSH-T levels, using benz-
pyrene-4, 5-oxide as the substrate, were unchanged, either by hypophy-
sectomy or by replacement with FSH and LH (336). 
127. 
Male gonadectomy results in a decrease in liver aryl hydrocarbon 
hydroxylase, epoxide hydrase, and GSH-T activity. but in ovariectomised 
animals there was no change. Only a single epoxide substrate. styrene 
oxide, was used to determine GSH-T activity (332). 
Ovarian ' epoxide metabolising enzymes change during pregnancy and 
lactation. GS.H-T activity increases during pregnancy and lactation and 
returns to normal 30 days post lactation (256). GSH-T activity in 
other organs did not change during this period, and there was no change 
with oestrus (256). 
In the rat kidney variable male: female G SH-T activities ha¥e been 
found, depending on the substrate used (333). 
Serum G SH-T activity with epoxide substrates was also found to be 
higher in the male. 
From the above results it is not possible to come to any con-
clusions about the hormonal control of the GSH-T's, but it seems that 
thyroid hormone, and the pituitary. may play a part in the regulation 
of the GSH-T's. The pituitary may exert its efect via TSH. The role 
of sex hormones or their trophic hormones in the induction of GSH Tac-
tivity cannot be assessed because studies have not separated the con-
tribution of in_dividual GSH-T's to net enzyme activity. The GSH-T's 
not subserving epoxide conjugation, e.g. GSH-T a. have not been assess-
ed in this respect. 
Ontogeny:-
At birth G SH-T activities in many organs are low relative to the 




the liver this maturation parallels the ability of that organ to take 
up organic anions (334, 337-348). In the rat liver G SH-T B, Y protein, 
BSP conjugation, aryl and epoxide G SH-T activity all reach adult 
levels at about 30-35 days of life (337.339.344). GSH-T activity is 
detectable at' 18-21 days of foetal life (338,342.349). Karavanova et 
al (:t~O) have shown that ligandin immunofluorescence is present in more 
cells and is intense in the late foetal rat liver. In the first post-
partum week the number of +ve cells decrease markedly. and persist only 
around the central vein. From day 7 post-natally the number of pos-
itive .cells increase to adult numbers. which are reached at lfi - 18 
days. 
Low levels of ligandin in the newborn primate are thought to con-
tribute to the development of 'physiologic jaundice' (351). Uridine 
diphosphoglucuronide transferase. the major enzyme responsible for 
bilirubin conjugation, is also low in neonates and this could also play 
a role in the physiological jaundice of the newborn (352,353). 
A single study has shown that GSH-T levels do not change with sen-
escence. and although epoxide hydrase levels increase. benzpyrene bind-
ing to DNA also increased with age (354). 
In the ~teroid producing tissues the picture is somewhat dif-
ferent. In rat testis. activity with epoxide substrates is present at 
birth, and increases markedly at puberty (344). In rat ovary this ac-
tivity is first detectable at day 12. increasing to a maximum at day 35 





Drug induction (table 18.1 - 18.3) :-
Some hepatic GSH-T activity. like the some microsomal mixed func-
tion oxidases and other cytosolic drug metabolising enzymes, are sub-
ject to induction by xenobiotics. Inducers of the MFO's can be class-
ified into three groups. Phenobarbitone, which causes an increase in 
liver 'weight and prolifei'ation of the endoplasmic reticulum induces the 
cytochrome P-450 group of enzymes. Other members of this group of in-
ducing agents include some polychlorobiphenyls and other insecticides. 
3-Methyl cholanthrene (3-MC) and other polycyclic aromatic hydrocarbons 
indu.!e the so called cytochrc;,me P-448 group of enzymes. This induction 
is not accompanied by endoplasmic reticulum proliferation or increase 
of liver weight. 2,3, 7 ,8-Tetrachlorodibenzo-pdioxin (TCDD) and bcnzo-
(a)pyrene (BP) are other. examples of this group of inducers. Pregnen-
olone 16. -carbonitrile (PCN) represents a third class of inducing 
agents in which the substrate specifity of the induced enzymes is 
different from the two previous groups. 
Induction of thP. GSH-T's has been shown with members of all three 
groups. However the response in various organs differs markedly. 
In the mouse induction by polycyclic aromatic hydrocarbons is con-
trolled by the Ah Caryl hydrocarbon) locus. This locus also controls 
induction of uridine diphosphoglucuronyl transferase and at least two 
other cytosolic· enzymes, all concerned in the metabolism of polycyclic 
aromatic hydrocarbons. Discussion of this system is beyond the scope 
of this review (see ref 355). However it is known that in the mouse 
induction of the GSH-T's is not controlled at this locus (356). 
Measurement of induction has been mainly by measurement of GSH-T 


























Pb, 3-MC, TCDD, DAB, PCB's, BHA 
. Rifampicin, Ethoxyquin, DDT ,PCN 
Pb, 3-MC, Ethoxyquin, BHA 
Pb, TCDD, PCB's, 3-MC 
BHA, Ethoxyquin, Pb, 3-MC, BPO 
Rifampicin 
PCB, Pb, PCN 
Pb, 3-MC, BHA, Ethoxyquin 
Pb, PCN, 3-MC, DDT, TCDD, TSO 
TSO 
Transferase C TSO 
Table 18.1. Induction of glutathione S-transferase in rat liver. 
Abbreviations:-
Pb- phenobarbitone 





























































zyme activity can be subserved by two or more enzymes. the changes in 
activity measured after induction may reflect changes in several 
G SH-T's. Induction has also been studied by plasma clearance . and/or 
biliary excretion of bilirubin in vivo (357. 358). and in vitro by dye 
binding to Y . protein on gel filtration (359). While such studies may 
be useful in the elucidation of the functional role of the G SH-T's they 
are insufficient ' to describe the magnitude of changes in individual 
GSH-T's. Very few studies have measured the individual GSH-T's di-
rectly (by immunological methods or semiquantitatively on ion exchange 
or IEF columns). In add it.ion the variety . of dosage schedules used 
makes comparison between studies difficult. However some points do 
emerge. 
Phenobarbitone indu9tion results in an increase in the YaYa and 
Yb Yb dimers in rat liver (22. 262). There is some controversy over 
whether the YaYc dimer can be induced. Bass et al (262) were unable to 
show an increase in the Ye monomer on PAGE-SOS, whereas Hayes et al 
(22) showed induction of GSH-T A (Yb Yb). but not GSH-T C (also Yb Yb), 
and induction of both YaYc and YaYa. Pickett et al (328) have shown an 
increase in translatable mRNA for Ya with phenobarbitone adminis-
tration. Ye mRNA was only slightly induced. 
Phenobarbitone causes induction of ligandin at all ages (339). 
Using trans-stilbene oxide GSH-T A, B, and C could also be induced in 
rat liver. Specific activity of GSH-T A and C were unchanged, but 
specific activity of GSH-T B was doubled (360). This study did not in-
vestigate which dimer (YaYa or YaYc) was induced. Ethoxyquin and 
t-butyl hydroxyanisole have also been shown to induce GSH-T's (361). 






chlorobiphenyls rifampicin and dimethyl aminoazobenzene. and polycyclic 
aromatic hydrocarbons such as 3-MC, TCDD and dichlorodiphenyltrichloro-
ethane (DDT). and a long list of insecticides (179,247.330. 341, 346-348, 
357. 362-379). Tables 18.1 to 18. 3 lists some the agents which have 
been used to induce GSH-T activity and concentration in the rat. 
~n extrahepatic tissue the findings are less dramatic. Parental 
phenobarbitone induces renal GSH-T's but the response is less than in 
liver. This has been shown measuring GSH-T activity (333,362,366), and 
ligandin by RIA (18). TCDD induces ligandin in the kidney (131) but 
3-MC treatment only result~ in induction of aryl and aralkyl activity 
(333). Epoxide GSH-T activity does not appear to be induced in the 
kidney (333). It is not possible to say which GSH-T's are induced in 
the kidney. DDT and P~N could not be shown to induce renal ligandin 
measured by radial immunodiffusion (131) but this has not been tested 
by the more sensitive radioimmunoassay. Dietary enzyme inducers e.g. 
Phenobarbitone and 3-MC however, fail to stimulate renal GSH-T activity 
(366). 
Rat intestinal GSH-T's have been the source of several interesting 
observations. Immunoreactive ligandin is increased by phenobarbitone 
from 6.7 ug/mg protein to 10.1 ug/mg, a magnitude of rise too small to 
have been detected by immunodiffusion (18). Parenteral enzyme in-
ducers, 3-MC, benzo(a)pyrene (BP) and phenobarbitone, increase enzyme 
activity only in the middle and distal intestine, the proximal intes-
tine being unaffected (370). Others have shown activity more proximal-
ly (255). Activity in the jejunal surface and crypt cells could be in-
duced with phenobarbitone (255). However if these drugs are adminis-





the substrate used to test activity and depend also on the inducing 
agent used (366). These results imply that the route of administration 
is very important in induction of drug metabolising enzymes. Ingested 
drugs. whic~ must pass through the liver before reaching the systemic 
circulation, are sufficiently metabolized to alter the induction pat-
tern, and drugs gaining access to the circulat!on through other portals 
of entry e.g. skin 01:: lungs or parenterally. may have an entirely diff-
erent effect. 
Rat lung GSH-T activity with benzpyrene-4,5-oxide is not inducible 
by phenobarbitone. pregnenolone carbonitrile. 3-MC or cigarette smoke 
(243). However a more sensitive radioassay using styrene oxide has 
shown induction by cigarette smoke but not by 3-MC up to 10 days after 
exposure ( 380). Mouse lung epoxide G SH-T activity does not respond to 
3-MC or phenobarbitone (381). Agf!in, only activity in whole cytosol 
was measured, and not the individual proteins. 
3-MC does not cause induction of GSH-T activity in mouse skin 
(382). 
The testes have been little studied but in the hypophysectomized 
rat the G SH-T activity with epoxide substrates does not change nor does 
it change witli the administration of FSH and LH to these animals (336). 
Membrane bound and organelle associated G s·H-T's are not induced by 
with any su~stances studied so far (271,273). but their activity is in-
creased several fold in the presence of sulphydryl reagents (274). 
Experiments on vitamin A deficient rats have yielded conflicting 
results. Chhabra et al (383) failed to show any induction of GSH-T ac-
tivity in the liver. lung and intestine following prolonged vitamin A 




G SH-T activity in the liver and kidney in vitamin A deficiency. Only 
enzyme activity and parameters of BSP metabolism were measured. The 
contribution of the individual GSH-T's was not assessed (384,385). 
Low doses of vitamin C have been shown to reduce G SH-T activity 
(386). The significance of this finding is unknown. 
\;Ombined vitamin E and selenium deficiency results in an increase 
in GSH-T activity in liver, testis and brain. Since Vit A and Vit C 
are important antioxidants and play a part in the prevention of lipid 
peroxidation, it is suggested that the ultimate inducer is a lipid 
hydr.:,peroxide or some othe~ product of lipid peroxidation (387). 
134. 
CHAPTER XIX 
PHYSIOLOGICAL ASPECTS:- DETOXICATION 
The GSH-T's are a ubiquitous. highly conserved system. . The 
physiological function of these enzymes is not well defined. Although 
man} chemicals can be shown to undergo GSH conjugation most are purely 
of research interest. Among the known substrates are many environ-
mental pollutants and therapeutic drugs. It is not known to what ex-
tent the GSH-T's are physiologically important in the detoxication of 
most of these agents. 
Toxic xeuobiotics may cause cell necrosis (e.g. paracetamol and 
bromobenzene). Other xenobiotics may be carcinogenic, such as the 
polycyclic aromatic hydroc_!lrbo~s (PAH) e.g. benzo(a)pyrene, bcnz(a)an-
thracene· (BA) and 3-methylcholanthrene (3-MC). Carcinogens also have 
cytotoxic activity. Study of the mechanism of cell damage in either 
case has revealed to some extent the role of the GSH-T's in detoxific-
ation. 
The organs rich in GSH-T's are strategically situated at the por-
tals of entry to the body and thus uniquely placed to deal with toxins, 
the lung for inhaled toxins, the intestine for ingested toxins, and the 
liver sitting astride the portal system, through which must pass all 
toxins which elude metabolism by the intestinal mucosa. The lung.of 
course, also filters the entire systemic circulation, and is the first 
capillary bed encountered by metabolites leaving the liver. Further-
more the testis and ovary have high levels of GSH-T activity (256,336). 
Even the vas deferens and the epididymus have unexpectedly high GSH-T 










Fig. 19 .I. Oxidation of benz(a)anthracene (1) and benzo(a)pyrene (2) 







tals of entry to the body guarded, but other sites particurlarly vul-
nerable to deleterious injury, the gametes and the developing foetus, 
may be protected. 
Detoxification of carcinogens:-
Carcinogens are ingested, inhaled or otherwise gain entry to the 
organism in an inert form. However their metabolism by the cytochrome 
P-450 group of enzymes results in the formation of highly reactive in-
termediates, which in the case of polycyclic aromatic hydrocarbons are 
epoxides (arene oxides)(389~391). 
The polycyclic aromatic hydrocarbons may be converted to either K 
region or non-K region arene oxides (fig. 19 .1) (169. 392-399). The 
arene oxides may then uridergo one of the following metabolic transfor-
mations; enzymatic hydration to the dihydrodiol by microsomal epoxide 
hydrase; enzymatic reduction to the parent compound by epoxide reduct-
ase; spontaneous isomerization to the phenol; reaction with cell pro-
tein; GSH conjugation; spontaneous or enzymatic (fig 19.2)(389,400) • 
· Binding to microsomal protein is covalent and irreversible and would 
render . the epoxide inactive. The protein is also denatured. Even 
though K region arene oxides are more stable than non-K arene oxides, 
they are better alkylating agents and more likely to undergo reaction 
with protein or GSH (391). The non-K arene oxides, although they do 
react chemically and enzymatically with G SH are not good substrates for 
for the GSH-T's (391,395). 
The dihydrodiol may follow one of two paths. It may be conjugated 
to glucuronide and be excreted, or in the case of the non-K region 
arene oxides, the dihydrodiol may undergo a second epoxidation at the 
13.6. 
ARENE OXIDE 
Fig. 19 .2. 
GSH-T 





Metabolic fate of an arene oxide (epoxide). 
' 
olefinic double bond of the dihydrodiol by the same microsomal mixed 
function oxidase, to form the diol epoxide (fig. 19.3)(391,401). Al-
though the K-region arene oxides are mutagenic they are not necessarily 
the ultimate 9arcinogens. This honour probably belongs to the diol ep-
oxides. These molecules are not good alkylating agents as such, and 
are therefore less reactive with GSH. They do however, react with DNA 
and nucleic acids (391). 
Benzo(a)pyrene (BP) forms K region epoxides which are conjugated 
to GSH by purified GSH-T A, C and E. GSH-T Bis not very active with 
epoxides ( 40 2). In the isolated perfused· rat liver G SH conjugates 
formed the major biliary metabolites of BP (403,404). In the perfusate 
the concentration of the dihydrodiol was much higher than the thio-
ether. Within the liver itself formation of th<~ GSH conjugate and the 
dihydrodiol occurred at approximateiy the same rate. In the intact 
animal GSH conjugates predominated in the bile. Although the dihydro-
diol was rapidly formed it required glucuronidation, a relatively slow 
process, for excretion. Both pathways therefore are important in de-
• toxication, but the G SH pathway is the major excretory pathway (405). 
In rabl:>it lung GSH-T activity was less than in the liver, and accounted . 
for 15% of the metabolites of BP. The lung has little epoxide hydrase 
activity. Only water soluble products (conjugates of GSH, sulphate and 
glucuronic acid) were able to leave the perfused lung. Lipophilic 
metabolites such as the diol epoxides accumulated in the lung (406). 
Calculation of kinetic constants of pulmonary benzpyrene metabolism 
suggested that GSH-T was more active than epoxide hydrase in metabolis-
ing benzpyrene. The lung could clear most of the benzpyrene oxide pre-
sented to it in a single pass (407). In organs other than the liver 
137. 
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Fig. 19.3. }folecular structure of the diol epoxide of benzo(a)pyrene. 
epoxide hydrase activity is low, and in these organs as in the lung the 
G SH-T's are probably more important in the metabolism of epoxides and 
arene oxides. 
Evidence has recently been presented that as well as conjugation 
to epoxides, benzpyrene quinones undergo G SH conjugation cataylsed by 
rat liver G SH-T B ( 408). 
Although some work has suggested that binding of benzpyrene to DNA 
is influenced more by nuclear epoxide hydrase than GSH-T (409), others 
have provided more direct evidence that the presence of G SH plus cyto-
sol or purified G SH-T B reduces the binding of benzpyrene metabolites 
to nuclear DNA. Prior depletion of GSH increased nuclear binding of 
benzpyrene metabolites. GSH conjugates are formed in roughly inverse 
proporti~n to the extent of binding (410). This work was performed in 
vitro and does not take partitioning into intracellular compartments 
into account. 
Dietary antioxidants used as food preservatives are known to be 
antimutagenic, although until recently the mechanism was not known. 
· BHA (2(3)-tert-butyl-4-hydroxyanisole) or ethoxyquin (1, 2-dihydro-6-
ethoxy-2, 2, 4-trimethyl quinoline) added to the diet of rats and mice 
decreased the mutagenicity of benzo(a)pyrene metabolites in the urine 
of animals fed benzpyrene (361,411). These dietary antioxidants were 
shown to induce the levels of GSH-T activity with several substrates 
(361). Epoxide hydrase activity was also increased (412). This is 
due to increased synthesis of the enzyme ( 413). The mechanism whereby 
antioxidants exert their antimutagenic effect is therefore thought to 
be by induction of GSH-T and epoxide hydrase which results in more 
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bolites in u_rine was also decreased by addition of purified G SH-T A and 
B and by cytosol. This protection was not seen if G SH was absent from 
the assay system (361). 
Benzo(a)pyrene also forms K region and non-K region epoxides (395, 
414). Both have the potential to form dihydrodiois. but in the pre-
sence of GSH and cytosol the K region arene oxide is preferentially 
converted to the GSH conjugate. The 8,9-diol can be converted to the 
vicinal diol epoxide (an ti-benzpyrene-8, 9-diol-10-11-oxide) ( fig 19. 3) 
which can then undergo enzyme catalysed GSH conjugation (415). 
Aflatoxin B1 (fig. 19.4), the carcinogenic form of aflatoxin 
which has been implicated in the causation of hepatocellular carcinoma 
in Africa and the Far East, is excreted by rats mainly as a GSH conjug-
ate (416). Aflatoxin is ·metabolised to an epoxide (417) and this is 
probably the site of GSH conjugation. Binding of aflatoxin to DNA is 
inversely proportional to hepatic G SH levels (418) and can be decreased 
by cytosol (419). This inhibition of binding is GSH specific and is 
enzymatic, i.e. is destroyed by boiling. Although there is no direct 
- evidence for GSH-T involvement in the prevention of DNA binding this 
work ia highly suggestive. In the early studies of GSH-T these cri-
' teria, loss of activity on boiling and an absolute requirement for GSH 
were regarded as good evidence for GSH-T activity. GSH-peroxidase ac-
tivity would also fulfill these criteria. 
A cytosolic protein which resembles ligandin and mouse skin !!_-pro-
tein has been shown to bind to 3-MC. When this protein is incubated 
with liver cell nuclei 3-MC is translocated into the nucleus (420). 











protein it is probably not ligandin, but perhaps in this work 3-MC is 
being bound by one or more G SH-T's. 
Many other polycyclic aromatic hydrocarbons, some carcinogenic, 
some necrogenic, are substrates for the GSH-T's. but these have not 
been ;,tudied systematic1:tlly. 
Other relevant carcinogens studied although less completely inc-
lude vinyl chloride and dimethylaminoazobenzene. Both form GSH conjug-
ates. vinyl chloride via an epoxide intermediate (421), and dimethyl-
amincazobenzene via N-demethylation followed by sulphation (422). The 
metabolism of vinyl chloride provides an example of an alternative 
pathway of meta·oolism of a GSH conjugate. 
The Ames test for mutagens has been used to study the relationship 
between !he G SH-T's and ·carcinogenesis. The Ames system involves the 
use of a strain of Salmonella typhimurium which is unable to synthesize 
histidine. Some strains in addition have increased cell wall permeab-
ility. These organisms are grown on a histidine deficient medium in 
the presence of the mutagen that is being tested. Mutagenic activity 
• manifests as a reversion in the mutated histidine operon, allowing the 
bacteria to synthesize histidine again. Each revertant will produce a 
colony. Mutagenic activity is expressed as the number of revertant 
colonies per plate, after correction for the spontaneous reversion rate 
(423,424). Mutagenicity correlates with carcinogenicity (425,426). 
CDNB is mutagenic in this system, but its effects can be reduced by 
addition of the S9 fraction (9,000 xg centrifugation) containing cyto-
sol and microsomes. The inhibition of mutagenicity is inversely cor-




ed with with G SH levels ( 209). As G SH-T levels rose in phenobarbitone 
induced animals mutagenicity decreased. 
The role of the G SH-T's in the Ames test is controversial. To 
some extent this depends on the mutagen used. CDNB mutagenicity is 
reduced by the GSH-T's. but epoxide induc_ed mutagenicity is only mini-
mally affected (209,427). 
It has also been pointed out that in situations where ligandin 
concentration is increased within the cell. such as hypophysectomy, 
thyr.0.idectomy or phenobarbitone administration there is a decrease in 
aminoazodye induced carcinog"enesis ( 428). However these manoeuvres may 
have many different effects on different intracellular proteins. To 
attribute the reduction in carcinogenicity to the effect on ligandin 
alone is all oversimplification. 
Detoxication of cell toxins:-
Paracetamol (acetaminophen) and bromobenzene provide .possible ex-
amples of the role of the GSH-T's in prevention of cell necrosis. Par-
, acetamol is metabolised by the liver to glucuronides and sulphates pri-
marily, . and as a minor pathway undergoes N-hydroxylation and conjuga-
tion to GSH. The reactive intermediate has not been identified, but it 
is able to bind to tissue protein (429,430). There is evidence to sug-
gest that conjugation is catalysed (431). but the GSH-T's have not been 
definitely implicated. With paracetamol overdosage the sulphation and 
glucuronidation pathways become saturated and the G SH pathway becomes 
more important. Toxicity only occurs after liver GSH is depleted, when 















Bromobenzene undergoes P-450 metabolism to an arene oxide (433. 
434). which can also bind to tissue protein. Again depending on dose 
the amount excreted as mercapturic acid varies. The higher the dose 
the more GSH conjugation, and therefore mercapturic acid for::nation. 
Tiss ... <.? protein binding only occurs when the intracellular G SH is dep-
leted ( 435). 
With both these agents the extent of necrosis is related to tissue 
protein binding. Pretreatment which decreases the GSH concentl"ation 
(eg .iiethyl maleate) increases necrosis (436). while addition of cys-
teine. a GSH precursor. decreases necrosis · (437.438). Although it is 
known that brumobenzene oxide is a substrate for the G SH-T's it is not 
clear to what extent the GSH-T's are responsible for conjugation, and 
to what ~xtent conjugation is spontaneous. 
Detoxication by binding :-
All the G SH-T's. are able to bind non-substrate ligands to differ-
ent degrees (41). Binding was originally described for ligandin in 
· terms of organic: anion binding (BSP, indocyanine green, Rose Bengal). 
However the list ·of non-substrate ligands bound by the G SH-T's is very 
much more extensive • 
Experimental data demonstrating detoxication by non-substrate 
binding are lacking. Most studies have concerned organic anion binding 
and transport but as these are not strictly detoxication pro.:!esses they 
will be considered later. 
It has been shown that ligandin has a role in the prevention of 
bilirubin toxicity. Bilirubin. like many other endogenous end products 










toxified by conjugation to glucuronic acid and excreted in the bile. 
Under situations of bilirubin excess this excretory system may be over-
loaded, or the excretory system itself may be at fault, and toxicity 
may occur. .This is particularly a problem in the neonate, in whom the 
blood-brain barrier has not yet developed, and may result in kernict-
erus. Bilirubin can also be shown to uncouple oxidative phosphoryl-
ation in the mitochondria. This effect can be reduced by the presence 
of ligandin (439). In the liver, even in great excess of bilirubin, 
mitochondrial respiration is normal, but in the CNS defects in oxid-
ative phosphorylation are observed with bilirubin excess. 
much higher G SiJ-T activity in liver than in brain. 
There is 
Dimethylaminoazobenzene is N-hydroxylated by the mixed function 
oxidases and then undergoes sulphate esterification by the soluble 
sulphotransferases to form the active metabolite. The active meta-
bolite binds covalently to ligandin (440,441), but also undergoes GSH 
conjugation (442). The GSH conjugate is non-covalently bound (441). 
The major hepatic ar,1ir.oazodye binding protein moves with the electro-
. phoretically slower moving 'h2' fraction, has a sedimentation coef-
ficient .of 5S, and hence was called the slow h 25S azoprotein (443 
445). This protein has a molecular size of 80, 000 daltons and consists 
of two apparently identical subunits. However aminoazodyes are also 
bound, albeit with lesser affinity. by two other proteins in the cyto-
sol, aminoazodye binding protein A (which is probably identical to Z 
protein or fatty acid binding protein) and ligand in C 4,446.447). 
On the other hand polycyclic aromatic hydrocarbon binding was 
first studied in the mouse skin, using benzo(a)pyrene. An electro-








which has since been purified from skin and liver ( 449). This protein 
has similarities to ligandin; molecular size of 40.000 daltons; two 
similar subunits of 20.000 daltons; and a sedimentation coefficient of 
3.5. but the pl (8.3) is lower than for ligandin (8.9). and the amino 
acid analyses are diffc:.•ent. This ~-protein in its currently purest 
available form has GSH-T activity, but has been shown to be different 
from ligandin (450,451). Either this protein is not pure and is con-
taminated with a G SH-T or else it is itself a G SH-T • 
. : 3-MC however is known . to be bound to ligandin (7). The molecule 
can be bound non-covalently in its native state, but after activation 
by microsomes is much more tightly bound. It can also undergo GSH-T 
catalysed conjugation ( 392). 
The· effect of this binding activity is not clear. It maybe a form 
of detoxication, but equally well non-covalent binding to ligandin may 
provide a mechanism for intracellular transport of hydrophobic mole-
cules. These hypotheses need to be tested. 
Covalent binding to the GSH-T's has been discussed. Jakoby has 
pointed out that since some carcinogens are non-covalently bound pre-
ferentially to the GSH-T's they would therefore preferentially undergo 
covalent binding to the GSH-T's (199). This has been demonstrated re-
cently. BP-4. 5-oxide is bound to four cytosol fractions. all of which 
have GSH-T activity. Approximately 8-10% of the water soluble meta-
bolites are protein bound, of which binding to ligandin accounted for 
nearly 50% (317). 
In some instances this binding to proteins is thought to protect 
the cell, in that the carcinogen is trapped and inactivated and ex-
cretion may be facilitated. Covalent binding is a form of irreversible • 
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detoxification. Where covalent binding is to a non-essential protein, 
such as the GSH-T's, especially in view of their high concentration in 
the cell, this may indeed be so, but essential regulatory proteins pre-
sent only in small amounts may also be covalently bound. Since co-
vnlenc bindir>g irreversibly damages protein this may be deleterious. 
The covalent binding of activated metabolites to the GSH-T's also 
inactivates the G SH-T irreversibly. They are no longer able to bind 
non-substrate ligand_s or to act as enzymes (317). This form of detoxi-
catit,.1 has been viewed as a sort of molecular suicide ( 45 2). 
Despite ~trong evidence of the importance of the GSH-T's, work in 
model systems has suggested that the efficiency of the G SH-T's may be 
severely limited by their. cytosolic location, which, it is postulated, 
would make them inaccessible to lipoohilic xenobiotics. The active in-
termediates of xenobiotics are formed in the endoplasmic reticulum and 
for reasons of solubility are likely to remain in the hydrophobic mem-
brane environment rr.thcr than diffuse into the aqueous cytosol. How-
ever the increase in polarity conferred by oxidation may make this 
argument less relevant. Similarly this arguement does not take into 
account that protein bound xenobiotics are water soluble, and therefore 
xenobiotics bound to the GSH-T's may be at home in the cytoplasm. 
The experiments on which these arguments are based used the Ames 
test and showed that if the drug activating system (microsomes) are in 
direct contact with the target (bacteria) the presence of cytosol does 
not result in inactivation of the active metabolite, whereas inactiv-
ation is greatest when the metabolite has to cross the cytosol to reach 
the target bacterium (269). Furthermore, others have shown, based on ,a 




hydroxylated metabolites of BP would be expected to be bound to the 
membranes (453). These models, of course, may not be representative of 
the situation within the cell. Since the endoplasmic reticulum is in 
contiguity with the nucleus it is conceivable that activated metabol-
ites could be translocated along the membranes by lateral diffusion end 
not be conjugated by the cytosolic transferases. In this situation the 
presence of membrane transferases would be essential. It has been sug-
gested that for epoxides at least the G SH-T's are not involved in the 
reduction in mutagenicity in !~e Ames test (454,455) This too may not 
apply in vivo as othe!' evidence already discussed suggests that the 
G SH-T's are important in epoxide metabolism (456). 
f For the most part conjugation to G SH is a detoxifying step as with 
m:-st phase II reactions. but with bifunctional haloalkanes metabolic 
activation may result from conjugation. l, 2-Dichloroethane, which is a 
waste product of the plastics industry. and 1, 2-dibromoethane are 
mildly mutagenic, but their mutagenicity can be greatly increased after 
activation by liver cytosol. This activation was shown' to be G SH de-
pendent and G SH specific and to be catalyzed by G SH-T A and C but not 
B. It seems that the S-(2-chloroethyl)-L-cysteine moiety was respon-
sible, the hypothesis being that since 1, 2-dichloroethane is a bifunc-
tional alkylating agent (2 halide groups) conjugation to on(; molecule 
of GSH resulted in a highly reactive compound, a half sulphur-mustard 
(eqn 19~1)(457,458). Similar findings pertain to dibromomethane and di-
iodomethane (458). 
CH2(Cl)CH2Cl + GSH = CH2(Cl)CH2SG (19.1) 
A further example of metabolic activation mediated by the G SH-T's 




(290). This may be the mechanism whereby the organic thiocyanates 
cause toxicity. 
Bilirubin metabolism:--
The role of ligandin in bilirubin metabolism has been partly de--
fined. Unconjugated bilirubin, bilirubin monoglucuronide and bilirubin 
diglucuronide, all bind to rat and human G SH-T's (16, ~1. 460). Multiple 
dye dilution studies in isolatr:1 perfused livers frol" no~·mal rats, rats 
pre""treated with phenobarbitone or rats thyroidcctomized to increase 
Ugandin levels have been used to derive rate constants for t:1e influx 
of bilirubin into the cell and efflux from the cell back into plasma. 
Mathematica1. analysis of data derived from a compartmentalized model 
ehowcd that ligandin is responsible for limiting efflux of bilirubin 
from the liver into the blood (460). 
Bilirubin, like many xenobiotics, is hydrophobic and requires to 
be rendered more water soluble before excretion can occur. The mech-
anism whereby this is achieved is by conjugation with glucuronide, cat-
alysed by UDP-glucuronyl transferase, a phase II 'drug metabolising' 
enzyme. Both mono- and diglucuronides are formed. The controversy 
regarding the mechanism of of bilirubin diglucuronide formation will 
not be discussed here. The GSH--T's in man and the rat bind all three 
bilirubins with varying affinity (41). It has been shown that bili-
rubin accumulates in the liver, and that 64% of the intrahepatic bili-
rubin pool in the rat is conjugated, mostly as monoglucuronide. The 
high concentration of the GSH-T's in the liver cell is thought to be 
partly responsible for this accumulation (461). The role of Z protein 
in bilirubin metabolism has not been well defined. 
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CHAPTER XX 
PHYSIOLOGICAL ASPECTS OF TRANSPORT AND STORAGE 
Organic anion transport:-
There are several lines of evidence to support the contention that 
the GSH-T's also play a role in organic anion transport in the cell. 
Organic anion transport systems are well described in the liver 
(BSP, indocyanine green), kidney (penicillin, para amino hippuric acid) 
and intestine, i.e organs where GSH-T concentrations are high. The 
GSH-T's are known to bind organic anions. Of course, the simple demon-
stration that the GSH-T's bind organic anions, and are present in those 
organs where organic anion transport systems exist is not sufficient 
evidence for a role in organic anion transport. Such evidence requires 
that alterations in GSH-T concentration affect, or are associated with, 
changes in organic anion transport. 
It has been shown that drugs which inhibit BSP clearance also in-
hibit GSH-aryl transferase activity. e.g. radiographic contrast media 
(462). 
Phylogenetic and ontogenetic evidence:-
In the newborn, where the concentration of ligandin and the other 
GSH-T's has been shown to be very low (338,339) BSP clearance is re-
duced (8). Phylogenetic studies have shown Y protein to be absent in 
those species in which the liver is unable to take up BSP (234). Y 
protein is absent in most aquatic species and in the tadpole. It makes 
its appearance in the frog (234) and is present in all air breathing 
vertebrates studied. The presence of Y protein and its binding activity 
thus correlate with terrestial life. Perhaps animals living in an 
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aquatic environment do not need a highly developed system to handle 
hydrophobic molecules. Aquatic species do however have GSH-T's (233). 
Since in man and the rat all the G SH-T's can bind organic anions they 
may all be potentially involved in organic anion uptake, but it is pos-
sible . i:hat in the marine species the G SH-T do not bind organic anions. 
Phenobarbifone treatment, which increases cytosolic GSH-T's, also 
increases cytosolic BSP binding (359) and enhances plasma clearance of 
BSP, dibromsulphophthalein and indocyanine green (357,463). Fasting 
reduces ligandin and Z protein and decreases hepatic organic anion up-
take (463). There is a high degree of inverse correlation between the 
plasma BSP half-life and the liver ligandin content in the fasted and 
phenobarbitone pre-treate~ fasted states. Kinetic studies with pheno-
barbitone· have shown that the increases in the first order rate cons-
tant of transport from plasma to liver (K1), hepatic BSP and ICG con-
tent, and increased relative storage of BSP correlate with increased Y 
protein (358). Other. chemicals, including agents such as 3-MC and BP 
have similar effects. In most instances changes in Y protein are 
mirrored by changes in hepatic organic anion uptake. but thyroid hor-
mone deficiency (hypophysectomy or thyroidectomy) increased Y protein 
but decreased K1 indicating that other factors must also play a role. 
Other kinetic studies on isolated perfused livers suggested that 
phenobarbitone pre-treatment increased the rate constant for dibromo-
sulphophthalein transport from hepatocytes to bile and decreased the 
reflux rate from cells back to plasma (464). 
In view of the role of ligandin and the G SH-T's in bilirubin meta-
bolism, i.e. regulating the efflux back into plasma. one must consider 
that the GSH-T's may play the same role for organic anions. 
149. 
·.- ,. -~--.-.' . -~_,.,.._ .... ,>. -~- .,_.,.,.,_, •• ,__, ..... , .•. .. '-. -~. . .. ,.·. . '"". ·.,. 
' 
Binding of bile acids is an example of a naturally occurring org-
anic anion which binds to the GSH-T's. Ligandin has been shown to bind 
lithocholic acid (22), cholic acid (465,466) and chenodeoxycholic acid 
(466). In rat liver cholic acid is bound in the presence of GSH mainly 
to a YbYb dimer with enzyme specifity similar to GSH-T C (467), but 
other GSH-T's also bind cholic acid (465). In the absence of GSH bind-
ing to GSH-T C does not occur (465). 
There are certain similarities in the binding of bile acids to al-
bumin and to ligandin. Chol_ic acid binds to a single site on both pro-
teins, whereas chenodeoxycholic acid and lithocholic acid are :.probably 
bound at two sites (466). However despite clear evidence of bile acid 
binding to the G SH-T's the physiological role of the G SH-T's in bile 
salt and bile acid metabolism is remains unclear. 
The question of anion entrance into the cell, by facilitated dif-
fusion or as a result of a membrane carrier will not be discussed here 
(see ref. 468). 
Extrahepatic organic anion transport:-
The possible involvement of ligandin in renal organic anion trans-
port was first suggested by Kirsch et al (131). These workers examined 
the inhibition of penicillin binding to renal ligandin and showed that 
BSP and probenecid decreased penicillin binding and delayed plasma 
clearance. Penicillin is cleared by the kidneys and is known to share 
an uptake pathway from proximal tubular lumen to cell with probenecid. 
Others have shown that para amino hippuric acid. acetyl salicylic acid 
(ASA) and furosemide added to kidney cytosol were eluted from Sephadex 
G-75 at the elution volume of GSH-T activity (469,470). Para amino 




transport pathway in the proximal cells, all inhibited the GSH-T reac-
tion. These data suggest that the renal GSH-T's may play a role in up-
take of organic anions. However manoeuvres to alter renal GSH-T levels 
or organic anion transport, such as 3-MC induction, NH4 induced acid-
osis and penicillin treatment. showed that GSH-T activity and organic 
anion transport varied independently (345). In the rat maturation of 
the two activities were independent, although in the rabbit the two 
matured simultaneously ( 345). In mice enzyme activity was similar in 
both sexes but organic anion transport was greater in the male (345). 
It is possible that not all the renal G SH-T's bind organic anions. 
Each may respond differently to the various inducing agents. To fully 
evaluate the role of the GSH-T's in renal organic anion transport the 
G SH-T's will have to be studied individually. 
Intestinal organic anion transport has been little studied, but an 
anatomical dissociation between organic anion transport and GSH-T ac-
tivity measured with CDNB has been shown (471). Organic anion uptake 
was maximal in the midportion of the intestine, whereas GSH-T activity 
was greatest in the duodenum and jejunum. 
Thus evidence exists for both a storage function and possibly also 
a transport function for the GSH-T's. Bilirubin is stored in the 
liver, and organic anions may also be stored. In the kidney and intes-
tine, where transport is a more important function than storage, the 
evidence suggests that if the GSH-T's do play a role, they are not the 







PHYSIOLOGICAL ASPECTS:- PORPHYRIN METABOLISM 
Ligandin in the rat has been shown to bind with relatively high 
affinity to a number of compounds involved in haem metabolism (472). 
Haem is one of the most tightly bound of all non-covalent ligands (Ka 
.:!:_1071/mol)(473). When labelled O -amino laevulinic acid is given to 
rats the label appears in the liver associated with at least five pro-
tein peaks on gel filtration (474). The relative amount of radio-
activity in each peak changes as the animals are sacrificed at greater 
intervals after dosing, but at 10 and 20 minutes the ligandin peak 
located immunologically (and which includes the other GSH-T's) is the 
major peak. The radioactivity in the other peaks increased at GO 
minutes at the expense of ligandin ( 4 75). However recovery of haem 
from the peaks was incomplete at all stages, implying that haem precur-
sors or .haem breakdown products were also bound. If haem labelled 
mitochrondria, haem labelled microsomes or labelled haemin is added to 
cytosol the binding pattern is different (474). However there is still 
a major peak of binding eluting at the same elution volume as ligandin. 
Acceleration of haem synthesis or of the catabolism of haem alters the 
pattern of binding (475). Ketterer et al (475) speculate that since 
some hepatic haem must be passed from the mitochondria where it is syn-
thesized to the endoplasmic reticulum, where it is incorporated into 
haemoproteins, e.g. cytochrome P-450, ligandin could be involved in 
this process, either as a transport protein or by providing a stable 
intracellular haem pool, particularly since the Ka is so high. 
152. 
:· 







It is interesting that the differences in binding affinity of por-
phyrins parallel the differences in their hydrophobicity ( 4 7 4). The 
more hydrophobic porphyrins are more tightly bound. providing further 
evidence that the nature of bindir.g to ligandin (and the other G SH-T's) 
is hydrophobic. Binding of all the porr,~1yrins i·~ inhibited 'Jy BSP sug-
gesting that they all bind at the same site on ligandin. At higher 






PHYSIOLOGICAL ASPECTS:- PEROXIDE METABOLISM 
The recent demonstration that the G SH-T's act as a non-seleno G SH-
peroxidase suggested a role in detoxication of an endogenously produced 
toxin. Under a~robic conditions life depends on enzymes which m.eta-
bolise r:?active toxic oxygen intermediates. Superoxide anions, singlet 
oxygen and the peroxide radical are inevitable products of oxygen m•:ta-
bolism and are all toxic. C"!llular defence against t nese free radicals 
is mediated by superoxide dismutase, catalase and GSH-Px (see fig. 
22 .1). Vitamin E also has an anti-oxidant function. 
The non-seleno GSH-peroxidase does not utilise H202 as a sub-
strate, but is able to catalyse reduction of organic hydroperoxides 
such as cumene hydroperoxide, t-butyl hydroperoxide, and lipid hydro-
peroxides (294,295,476). 
The physiologic importance of this reaction can be judged from 
several lines of evidence. GSH-T's account for 100% of GSH-Px activity 
in the guinea pig liver and 84% in the human liver ( 289. 299. 276). In 
selenium deficient rats the proportion of GSH-Px activity subserved by 
the G SH-T's increases and this is paralleled by an increase in G SH-T 
activity with CDNB (295,296,310). Vit E deficiency also results in in-
duction of GSH-T activity. It has been postulated that the inter-
mediate endogenous inducer may be a lipid peroxide but there is no · 
evidence to support this hypothesis (387). Indirect evidence for a 
role for the GSH-T's in protection against lipid peroxidation has been 
provided by following the production of malondialdehyde as a measure of 
























GSH added reduced malondialdehyde production. This protective activity 
copurified with the GSH-T's through several stages of purification. At 
least two G SH-T's were shown to be protective, but the mechar.ism has 
not been investigated (477). The seleno-enzyme did not provide any 
protection in this system ( 4 77). 
A soluble G SH dependent factor limiting peroxide formation has 
been described. It has been shown that this factor reacts with cumene 
hydroperoxide and fatty acict hydroperoxides, but not with membrane 
lipids, which are phospholipids (478). This factor was shown not to be 
G SH-Px (the seleno-enzyme)(478). 
A GSH-T partially purified by affi~ity chromatography did not pre-
vent lipid peroxidation or react with preformed lipid hydro peroxides. 
However the G SH-T used in this study was not characterised, or shown to 
have non··Se dependent GSH-Px activity. Since non-Se dependent GSH-Px 
activity is probably restricted to G SH-T B and AA, and these may not 
have been included in the test system, the results of this study are of 
doubtful significance (478,479). 
It seems therefore that the G SH-T's may be an important system for 
detoxifying lipid peroxides, perhaps in some species more important 
than the seleno-enzyme. Morrisey and O'Brien (480) have postulated 
that the physiological substrates for the seleno enzyme are H202 
and fatty acid hydroperoxides. Phospholipids may require to be dephos-
phorylated before the seleno enzyme can act upon them. The G SH-T's may 
have as their physiological substrates, fatty acid hydroperoxides, and 
phospholipid hydperoxides. If this is so then the membrane bound 







PHYSIOLOGICAL ASPECTS:- THYROID HORMONE METABOLISM 
Lichter et al studied the binding of labelled triiodothyronine 
(T3) and thyroxine (T4) to liver cytosol in vivo and in vitro 
(481). T3 bound to four peaks on gel filtration including the Y peak 
containing the GSH-T's. Binding was inhibited by BSP and bilirubin. 
However in vivo binding to Y was less than in vitro. Maximal binding 
was to a peak with the mob_ility of albumin, but its identity was not 
definitely determined. 
T4 in vitro did not bind to the Y peak, but bound mainly to the 
albumin-like peak. In vivo however, binding to the Y peak accounted 
for 33% of protein bound T4. The difference between the in vivo and 
in vitro findings could not be ascribed to binding of metabolites. The 
binding pattern did not change with time. Homozygous Gunn rats which 
were hyperbilirubinaemic had decreased hepatic T3 uptake compared to 
the phenotypically normal heterozygotes. Presumably, increased bili-
rubin binding by ligandin inhibited T3 binding. Phenobarbitone pre-
treatment which induces ligandin also increases thyroxine binding to 
the liver (482). All this suggests that ligandin binding of thyroid 
hormones may be physiologically important. T4 and T3 can undergo 
conjugation with glucuronide and sulphate in the liver and kidney (and 
possibly other tissues). The excretion of T4-glucuronide is inhibit-
ed by BSP (483). It is not known if these conjugates bind to ligandin 
these conjugates bind to ligandin or whether the inhibition with BSP is 






Other thyroid binding proteins have been described in liver and 
kidney cytosol (484-486), but these correlate more closely with the 
non-ligandin binders in terms of molecular size, and reported binding 
affinities are different to those of ligandin. 
Smith and Litwack do not consider ligandin to be a thyroid hormone 
receptor (486), ·but point out that the hormonal effects of the thyroid 
hormones have a delayed onset and that the existence of long-lived in-
termediates has been postulated (487). Could ligandin be responsible 
for storing these intermediates and thus delaying \heir action? They 
also discuss the interesting point that in amphibia thyroid i,~1rmones 
are responsible for changes in enzymes which occur at metamorphosis. 
Thyroxine stimulates tail absorption and limb growth and th~ appearance 
of urea cycle enzymes which shift nitrogen metabolism from the produc-
tion of a!Tlmonia in the aquatic stage to urea in the adult stage. y 
protein and organic anion uptake are absent in the tadpole but is abun-
dant in .the post-metamorphosis liver (234). The interaction between 
the appearance of ligandin and the shift in nitrogen metabolism and how 















PHYSIOLOGICAL ASPECTS:- STEROID METABOLISM 
The interaction between the G SH-T's and the steroid hormones is 
poorly understood. Several steroids and/or their metabolites have been 
shown to bind to ligandin. The question has been asked 'is ligand~1 a 
steroid receptor in the liver'? The arguments agaillst this being so 
have been elegantly summarized by Smith and Litwack (486) and are, in 
short: 
The tissue distribution of ligandin does not correlate with the 
magnitude o: response of those tissues to steroids. 
The binding affinities of the steroids for ligandin do not para-
llel the potency of those steroids. 
All the steroids which bind ligandin do so . with an affinity far 
less than the binding affinity of other known receptors. 
Ligandin concentrations in the liver and kidney are too great and 
require too large a concentration of hormone for saturation to allow 
sensitive mod:tlation of hormone effect. 
Since active steroids and their metabolites bind to ligar.din with 
approximately · equal affinity they probably compete for binding. 
Using immunohistochemical techniques the distribution of ligandin 
in steroid producing tissues has been shown to be linked to the hormone 
producing cells, the interstitial cells of the testis, the cortex of 
the adrenal ·medulla and the theca granulosa cells of the ovary (250, 
488). Others have shown G SH-T epoxide metabolizing activity in both 
spermatogenic and interstitial cells (256). Ligandin does not have 
much epoxidc G SH-T activity and may be absent from spermatogenic cells. 
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The demonstration that several rat and human GSH-T's have A5-
3KS1 activity (289) raises the question of whether there is a role for 
ligandin in steroid synthesis. A5-3KS1 was first shown in the bac-
terium Pseudomonas testosteroni and has since been purified and 
crystallized from that source (304). This enzyme has no G SH-T acti-
vity. In mammals, in steroid producing tissue, the enzyme exists as a 
microsomal enzyme, molecular size .:!:_80,000 daltons and is involved in 
testosterone synthesis as well as synthesis of gluco- and mineralc."'.:or-
ticoids. Since these hormone:; are not produced by ·.:he liver it is un-
likely that the hepatic A 5-3KS1 activity has any role in steroid syn-
thesis. However no work defining a physiological role for this acti-
vity has yet been reported. 
Looked at from another point of view. it is likely that steroid 
hormones affect · the G SH-T levels. It has been shown that there is a 
male/female difference with respect to G SH-T and ligandin concentration 
(339). Gonadectomy in the male rat results in decreased levels of 
GSH-T activity with styrene oxide in the liver, but ovariectomy leaves 
levels in the liver unchanged (332). There is no explanation for these 
findings, but it is likely that the sex hormones or related trophic 
hormones are involved. Glucocorticoids have been shown to induce GSH-
epoxide transferase activity in neonatal and young rats up to 12 days 
of age (489). Activity in the foetus was not inducible when pregnant 
rats were treated with dexamethasone. 
The binding of cortisol and other steroid metabolites to ligandin 
may have several effects. Binding may be required to facilitate trans-
port of conjugated hormone into the bile canaliculi for excretion. Al-




steroids and their metabolites into plasma (cf. bilirubin). A third 
alternative is that since the association constants for steroid meta-
bolites and ligandin are higher than the corresponding Ka's for albu-
min, ligandin may have a role in uptake into the hepatocyte, and may 
also, in a me.nner analo;;ous !o that of albumin in the plasma, determine 
the amount of free steroid, and to a greater extent the amount of free 
metabolite, available for interaction with the receptor or other intra-
cellular proteins. 
The GSH-T's may play another role in steroid removal, by catalys-
ing conjugation. A GSH conjugate of oestradiol 175 has been described 
(490). The reaction is presumed to occur via an epoxide intermediate. 
Although this particular . conjugation is non-enzymatic, oestradiol 176 
disulphate has been shown to inhibit several GH-T1s both competetively 
and non-competetively ( 327). The physiological significance of this is 
unknown. 
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GLUTATHIONE S-TRANSFERASES IN HUMAN TISSUES 
INTRODUCTION 
(i SH-T enzyme activity has been shown to be present in most tis-
sues. Quantitation of GSH-T's in human organs has been limited to 
studies of enzyme activity only, and has shown considerable interin-
dividual variation. To what extent this variation is due to changes in 
indiv~dual GSH-T's is not known, nor is the nature of the GSH-T's in 
most organs is unknown. 
This chapter considers the quantitation of ligandin in human tis-
sues and also deals with the separation of the different GSH-T's in 
these organs in an attempt to elucidate some of the qualitative changes 
that may underly quantitative differences in enzyme activity. 
METHODS 
Preparation of tissue for assay:-
Human tissue was obtained within 12 hours of death from patients 
dying by violetice. Tissue was either used immediately or was stored at 
-70°C until used. All procedures were performed at 4°C. 100.000 xg 
Supernatants were prepared from 25% homogenates in O. 25M sucrose in 
distilled water if destined . for isoelectric focusing. or in O.OlM 
sodium phosphate buffer pH 7.4, 0.15M NaCl, 0.25M sucrose if destined 




Molecular size of immunoreactive ligandin:-
Cytosol from kidney, liver, testis, adrenal and lung were chro-
matographed on Sephadex G-100, column size 90 x 1.5 ems. The column 
was poured and developed in O.OlM sodium phosphate buffer. 0.15M NaCl. 
pH 7 .4. Elution was by pump driven upward flow at a rate of 20 ml/ 
hour. Fractions of 4 ml were collected. Protein content of the eluate 
was measured spectrophotometrically at 280 nm. Ligandin concentration 
was measur~d by RIA and GSH-T enzyme activity with CDNB as beforP.. The 
coluw.n was calibrated with !Darker proteins to allow the estimation of 
molecular size of the immunoreactive peaks. · These were transferrin 
(70,000). albumin (63,000), ovalbumin (48,000), cytochrome C (13,000). 
Blue dextran marked the void volume. 
Immunoreactivity of tissue ligandin : -
Serial dilution of cytosol from liver, kidney, adrenal, testis, 
pancreas, stomach, duodenum, ileum, colon, salivary gland, lung, thy-
roid, heart, spleen, skeletal muscle, bladder and prostate were assayed 
for ligandin by RIA. Dose response curves were constructed and linear-
ised by the logit/log transform. The slopes of the transformed curves 
were compared to the the slope of transformed standard curve of the 
assay using the RIARUN programme as before. 
Concentration of ligandin in tissue:-
Ligandin was measured at a dilution of 1: 16 in cytosol from pan-
creas, colon, ileum, stomach, salivary gland, spleen, prostate, lung. 
brain,heart. thyroid, bladder and muscle, and in a dilution of 1:100 in 
cytosol from liver, testis, kidney, adrenal and duodenum. Cytosol pro-
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tein was measured by the Lowry method (128). Results were expressed as 
ug/mg supernatant protein. 
lsoelectric focusing:-
This was performed in an LKB 4101 IEF column using a stepwise suc-
rose density gradient. The water used to cool the column was passed 
through a coil immersed in water at 4°C. Anolyte was 0.5M H3po4 
and catholyte was 0.15M NaOH. The pH range 6.5 - 1.0.5 was created 
using a 1:1 ratio of ampholyt_e pH range 6.5 - 9 and pH range 8 - 10.5. 
The pH range 4 - 8 was created using a 1: 1 ratio of ampholyte pH range 
4 - 6.5 and pH range 5 - 8. Final ampholyte concentration in all cases 
was 3%. 
Cytosol was applied to the column as part of the gradient after 
50% of the column had been filled. Focusing time was 16 hours. The 
volume of cytosol used in each instance and the pH range are given in 
the legend to the figures. 
At run completion the column was drained by pump at a flow rate of 
2 ml/min. Two ml fractions were collected. pH was measured immediate-
ly. The fractions were also assayed for GSH-T activity with CDNB, and 
for ligandin by RIA. 
Assessment of relative contribution of each group of GSH-T to 
total activity was by estimation of the area under the curve. 
Assessment of red cell GSH-T activity:-
The contribution of red cell G SH-T contamination to anionic G SH-T 





,o t TESTIS 
0 ·8 2 0 ·2 







0 ·4 ti (') ADRENAL 4 S! 0 -2 
c( .. 





0 ·2 >- 2 
c( 
z 0 ·1 N 
c( z 
Cl ·1 UJ 
..J 




0·20 ' LUNG 
0·15 
0 ·10 l 
0 ·1 -
• 0 · 05 i 
C ·e 0 · 3 KIDNEY .... E 0 ' E .,. 
::i. , 10 C 
I M 
1 8 
2 0 ·2 
> )( 
!: 
> ,s z 
I- 0 
0 









UJ 20 30 40 so 60 
FRACTION NO. 
Fig. 25.1. Sephadex G-100 chromatography of cytosol from (1) kidney and lung, (1) adrenal and testis. Ligandin imraunoreactivity \r.lS meas-ured by RJ.A, and _enzyr:ie activity was :::easured with CDNB as substrate. 
IMMUNOREACTIVE LIGANDIN iN NORMAL TISSUE CYTOSOL 
Organ Concentration Specific immunoreactivity No. of 
µg/ml cytosol ~~/mg cytosol protein samples 
Uver 375.1 23.2 2 Kidney 119 .8 12.8 3 Testis 118.0 19 .7 1 Adrenal 86.9 13.~ 2 Duodenum , -26 .7 2.8 1 
Ovary 8.8 1.50 1 Colon 2.8 0.38 1 Pancreas 2.4 0.26 1 Lung 1.9 0 .17 1 Stomach 1.5 0 .16 1 Brain 1.0 0.28 1 
Salivary gland 0.8 0.08 1 Heart 0.6 0.07 1 
Muscle 0.6 0.04 1 Prostate o.5 0.05 1 Bladder 0.5 0.08 1 Thyroid 0.4 0.06 1 
Ilii:um 0.2 0 .02 1 
Table 25 .1. Concentration of immunoreactive .1,igandin in the cytosol from human organs. · A single · provided specimens of each 
-tissue examined. Additional tissue was available for liver, kid-ney, and adrenal. In these instances the mean . concentration of ligandin in al -'- specimens is given. 
was measured at 410 nm. All absorption at this wavelength was assumed 
to be due to haemoglobin haem. • Using the known concentration of G SH-T 
in red cells (31) the contribution of red cell GSH-T to tissue anionic 
G SH-T activity was calculated. 
RESULTS 
Molecular size of immunoreactive ligandin:-
Elution profiles from Sephadex G-100 for 4 tissues are shown in 
fig. ~5 .1. Enzyme and immunoreactivity eluted at approximately the 
same elution v~lume, namely 1.4 - 1.6x the void volume, but the curves 
were not superimposable. Purified hepatic ligandin eluted at 1.5x the 
void volume. 
By comparison with molecular weight standards G SH-T activity eluted at 
a molecular weight of 47. 500 daltons, with the ~ntire peak eluting bet-
ween 39,500 and 54,600 daltons. 
lmmunochemical displacement curves:-
Dose response curves constructed from serial dilutions of cytosol 
were parallel .to the assay standard curve for each tissue tested. 
These results are displayed graphically in fig. 25.2 and fig. 25.3. 
Concentration in human tissues:-
Table 25.1 shows the concentration of immunoreactive ligandin in 
cytosol expressed per mg supernatant protein. A specimen of each tis-
sue examined was obtained from a single donor. Additional specimens of 
liver, kidney, adrenal and lung were also obtained. The highest con-
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Fig. 25 .2. :immunochemical displacement curves of cytosol from human organs compared with the standard curve of the ligandin RIA. Ordinate and abscissa are as for fig. 10.1. 
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Fig. 25 .3. l:mnunochemical "displacement curves of cytosol from human organs compared with the standard curve of the ligandin RIA. Ordinate and abscissa are as for fig. 10.1. 
GLUTATHIONE S-TRANSFERASE IN NORMAL HUMAN TISSUES 
GSH-T specific ligandin specific 
activity activity immuno- activity Organ reactivity 
umol/min/ml umol/mg protein ng/ml µ .g/mg protein 
Uver II 5.83 0.42 182409 13.2 Kidney II ~.10 0.44 126471 19.8 , Ovary II i .66 0.28 8761 1.5 
Uver III 19.97 1.15 567846 33.0 kidney III 8.34 1.03 211482 76.1 Adrenal Ill 3.04 0.48 6.4512 21.0 
Uver IV 14.02 
lung IV 1.45 
Uver V 16 .48 
Kidney -v 9 .13 
Adrenal V 10.87 
Table 25.2. Glutathione S-transferase activity with CDNB and ligandin immunoreactivity in normal human organs. The roman numerals refer to tissue from a single donor. 
IMMUNOREACTIVE LIGANDIN IN NOR}lAL TISSUE CYTOSOL 
Organ Cationic Neutral Anionic 
GSH-T % GSH-T % GSH-T % 
pl above 9.0 pl 6.0 - 6.9 pl 3.6 - s.2 
Uver 1 . 99 1 ICidney 1 66 34 
Adrenal 1 28 3 69 
Uver II 97 trace 3 ICidney II 78 22 
Ovary II 13 6 87 
Uver Ill 100 
Kidney Ill 76 24 
Adrenal III 93 7 
Uver IV 72 28 
Lung IV 8 92 
Uver V 63 37 
Testis V 33 26 41 Adrenal V 24 50 26 
Lung V 11 5 84 


















































amounts present in kidney, adrenal, testis and ovary. When more than 
one specimen of tissue was available for assay up to a 4 fold differ-
ence in ligandin concentration (expressed per mg protein) was seen. 
GSH-T activity and ligandin immunoreactivity in tissues are compared in 
table 25.2. 
lsoelectric focusing. (IEF) :-
Cytosol from five individuals was subjected to isoelectric focus-
ing. Enzyme activity in the eluted fractions was initially assessed 
with CDNB, 3,4-dichloronitrobenzene, p-nitrobenzyl chloride and etha-
crynic acid. Use of · these additional substrates did not increase de-
tection of extra GST peaks, in several column runs, and therefore 
elution was followed by GST activity with CDNB alone • 
Recovery following IEF in all organs was 31-62% (mean 42%). IEF 
was able to resolve GSH-T activity into cationic (pl > 7.5), neutral 
(pl 6.0 - 6.5), and anionic (pl < 5.7) groups (table 25.3). 
Liver cytosol from 5 individuals was subjected to lEF (fig. 25.4) • 
The cationic GSH-T's were present in all specimens, constituting bet-
.ween 63 - 100% of activity. Up to four peaks of activity were clearly 
separable, but in two livers only a single peak was detected (fig • . 
25.4.5 & 25.4.6). 
Neutral GST activity was present in three liver specimens, ranging 
· from a trace (fig. 25.4.2)to 37% of total activity. The anionic GST's 
were present in 2 specimens (fig. 25.4.1 • 25.4.2), but accounted for 
no more than 3% of activity • 
Kidney cytosol from 3 donors was studied (fig. 25.5). In the kid-
ney cationic GSH-T activity accounted for 66-88% of activity, up to 
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Fig. 25.4. IEF of normal liver cytosol. In the focusing range pH 3 -10 or pH 6.5 - 10.5 1 ml of cytosol was applied to the column. In the focusing range pH 4 - 8 3 .5 ml of cytosol wa::; applied. The elution profile of GSH-T activity with cmrn is show.1 in all spe cimens. llllillunoreacti,..ity is shown for liver II, III aud V. In all ca ses i rumunorcactivity wa::; confined to the cationic region. 
3. 
0 ·6 12 2 ,000 
LIVER II 








3 0 ·3 6 6000 
>-
I-
E > I 











20 30 40 50 
FRACTION NO. 
1 
1·2 4. 17·5 
1·0 12 15 
t C .E 0 ·8 10 12·5 ':::,.. 
0 
E 
Cl. 0 ·6 8 10 
>-
E I-
~ 0 ·3 6 7·5 ci,' I-
C: 0 
< 
UJ I z 
~ 
0 ·2 a. 4 5 0 
>- z 
N < z (!) 
UJ 0·1 2 2 ·5 ...J 
10 20 30 40 50 60 
FRACTION NO. 
Fig. 25.4. IEF of normal liver cytosol. In the focusing range pH 3 -
10 or pll 6.5 - 10 .5 l ml of cytosol was applied to the colur;m. In the 
focusi:':; rar.ge pH 4 - 8 J .5 ml of cytosol was applied . The elution 
profile of Gc.ll-T activity "; th CDNB is shown in all specimens . 
I=unorea('.ti vity is shown for liver II, III and V. In all cases 












































Fig. 25. 4. IEF of normal 11 ver cytosol. In th:! focusing range pH 3 -
10 or pH 6.5 - 10.5 l ml of cytosol was applied to the column. In the 
focusing range pH . 4 - 8 3.5 ml of cytosol was applie c!. The elution 
profilr, of GSH-T ac ti vi ty with CDNB is shown in all specimens. 
Immunoreacti vity is s :•o.•n for 11 ver II, III and V. In all cases 






























:, 0 -5 
.it' 






































Fig. 25.5. IEF of normal kidney cytosol. In the focusing range 
0 
60 
- 10 or pH 6 .5 - 10 .5 1 I:J.l of cytosol was applied to the column. 
the focusing range pli /~ - 8 3 ,5 ml of cytosol was applied, The eh 
profile o:: GSH-T activity with CDNB is shown i n all specimens. Imo 
reactivity is shown for kidney II aud. III. In all cases immuno1 
tivity was confined to the cationic region. 
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Fig. 25.5. IEF of normal kidney cytosol. In the focusing rang e pH 3 
- 10 or pH 6.5 - 10.5 1 ml of cytosol was applied to the column. In 
the focus ing range pH 4 · - 8 3.5 ml of cytosol was applied. The elution 
profile of GSH-T activity with CDNB is shown in all specimens. I mmuno-
reactivity is shown for kidney II and III. In all casei; i mmu noreac-
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Fig. 25.5. IEF of normal kidney cytosol. In the focusing range pH 3 
- 10 or pH 6.5 - 10.5 l ml of cytosol · ~ms applied to the column. In 
the focusinz range pH 4 - 8 3.5 ml of cytosol was applied. The elution profile of GSH-T activity with CDNB is shown in all specimens. Immuno-











the kidney did not correspond to the cationic peaks in the liver of the 
same individual. 
Neutral GSH-T activity was present in only one kidney (fig. 
25.5.4), but could not be clearly separated fromcationic GSH-T acti-
vity. Anionic GSH-T activity was present in all specimens, accounting 
for 9 - 34% of to~_al activity. A single major peak was present in each 
case. 
Adrenal gland from 3 patients was available for study (fig. 25.6). 
In the adrenal the relative contribution of the cationic GSH-T's varied 
from 24 - 28% (fig. 25.6.1 & 25.6.3), to 93% (fig. 25.6.2). Neutral 
GSH-T activity was present in all specimens, contributing from 3 - 50% 
of total activity. The anionic species in adrenal was absent in one 
specimen (fig. 25.6.2), but contributed up to 69% of activity in the 
others. 
Lung from two donors was studied (fig. 25. 7). In both samples the 
major GSH-T activity (84 and 92%) resided in the anionic GSH-T peak, 
focusing at pH 4.3 and 4.7 (fig. 25.7.1 & 25.7.2 respectively). Only 
traces of cationic GSH-T activity were present. In lung V a trace of 
GSH-T pl 6.1 !'as present, as well as traces of minor anionic species 
(fig. 25.7.2). 
A single specimen of ovary was studied (fig. 25.8). It is not 
known at wha·t stage of the menstrual cycle the death occurred, or 
whether menopause had occurred. Focusing of ovarian cytosol in the pH 
range 6.5 - 10.5 (fig. 25.8.1) yielded a trace of activity at pH 10. 
Focusing in the range pH 4 - 8 (fig. 25.8.2) yielded a minor rounded 
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Fig_._25 .6. IEF of normal adrenal cytosol. One ml of cytosc;l was applic_:i 1~ each case. The elution prof ile of GSH-T activity with CDNB is shown in a.ll specimeD.s. l"'!munorea ctivity is shown for adrenal v. 
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Fig. 25.7. IEF of normal lung cytosol. One Thl of cytosol was applied 
for lung IV, and 3 .5 ml for lung V. The elution profile of GSH-T 
activity with CDNB is sh'Jw-n in both specim2nB. GSH-T activity is 
mainly found in the anionic region. l m:nunoreac t:. vity is shown for lung 
V. Irnmunoreactivity was confined to the cationic region . 
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Fig. 25.8. IEF of nonnal ovarian cytosol. In the pH range 6.5 - 10.5 
1 ml of cyt0sol was applied. ·rn the pll range 4 - e 3 .5 ;nl of cytosol 
was applied. Ovarian GSH-1' activity is largely confined to the anionic 
region. I=unoreactivity is mainly confined to the cationic region, 
but there is a trail of activity in the neutral region. 
Cytosol from a single specimen of testis was focused in the pH 
range 3 - 10 (fig. 25.9). All three groups of GSH;T activity were pre-
sent, in approximately the same proportions as in the adrenal from the 
same patient.· 
lmmunoreactivity of the GSH-T's was examined in different tissues. 
In all tissues s~udied immunoreactivity with the anti-ligandin antibody 
was largely limited to the cationic group of GSH-T's. In the specimen 
of testis (fig. 25.9) there was a significant peak of immunoreactivity 
corre~ponding to pH; 5 .1, i.e not exactly symmetrical with the a:1ionic 
enzyme activity peak. In lung V (fig. 25. 7 .2) a trace of immunoreac-
tivity was detectable in the region of the anionic GSH-T's. 
In all tissues the cationic enzyme peaks focused identically with 
peaks of .immunoreactivity. The relative heights of the immuno- and en-
zyme reactive peaks were not identical. 
Contamination with red cell GSH-T activity was calculated to be 
less than 1% in any organ. 
In liver III a peak of enzyme activity was detected, focusing at 
· pH 8.5, which was not immunoreactive. This peak was not analysed 
further'. 
DISCUSSION 
Gel filtration is insufficiently powerful to resolve minor differ-
ences in molecular size. The reported size differences between the 
anionic and cationic GSH.-T's are too small to be detected when cytosol 
from whole liver, adrenal, kidney, testis and lung are chromatographed. 
However the finding that enzyme active and immunoreactive peaks are not 
symmetrical indicates that some GSH-T activity is due to proteins not 
167. 
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Fig. 25.9 • . IEF of normal testis cyto<:ol. 3.5 1111 of cytosol was app-
lied. Ovarian GSII-T actlvity is l~rgely confined to the anionic 




detected by RIA. Isoelectric focusing confirms this and demonstrates 
that contrary to the finding of Awasthi et al (30). and in agreement 
with Warholm et al (491) 0 anionic GSH-T's do not react with antibodies 
to cationic GSH-T's. The neutral GSH-T's are also immunologically 
separate from the cationic GSH-T's. Wuholm et al (491) t.,ave also re-
ported that the ' three groups of GSH-T are immunologically distinct. 
The three groups of GSH-T's are therefore likely to be different mole-
cules. probably derived from three genetic loci. 
Human red cells and pl~centa are known to contain mainly anionic 
GSH-T's. and to have very little or no cationic GSH-T activity. Human 
lung and ovary can now be added to this group. In addition the pre-
sence of the anionic GSH-T's has be~n shown to be ubiquitious, and in 
organs other than liver may contribute a significant percentage of 
total G SH-T activity. 
The anionic GSH-T's may be a heterogenous group. Awasthi et al 
(30) described one major and two minor anionic G SH-T peaks in human 
liver. Marcus et al (31) describe a single GSH-T in red cells. 
It should be pointed out that the assumption has been made that 
the neutral and anionic G SH-T's in each organ are the same proteins as 
in each other organ. Warholm et al (491) have reported that antibodies 
to the placental anionic GSH-T cross react with foetal hepatic and red 
cell anionic GSH-T's. This suggests that the anionic GSH-T's in all 
organs may be similar. 
Immunological similarity between the cationic G SH-T's in different 
organs is shown by the parallel dilution curves and similar elution 
volumes from G-100, and suggests that these are probably very similar 
molecules, perhaps differing. as in the liver. by charge only. 
168. 
Mukhtar et al (523) using enzyme activity with CDNB showed a wide 
range of GSH-T activity in organs of different individuals, and between 
organs of a single individual. This marked heterogeneity is reflected 
in the distribution of the GSH-T's, within and between organs, and in 
the variable contribution each group makes to overall GSH-T activity. 
Column IEF is not sufficiently powerful to separate the five cat-, 
ionic GSH-T's described by Kamisaka et al (16). It is likely that not 
all individuals have all five GSH-T's, since IEF yielded such different 
patterns, on occasion only a single peak. A further point of differ-
ence is that the pl of the cationic GSH-T's in this study did not cor-
respond to those described by Kamisaka et al, but were more cationic. 
GSH-T of Kamisaka has a pl of 8. 8, but the majority of the cationic 
GSH-T's in this study focused above 8.8. This may be due to differ-
ences in experimental. conditions, but may be equally well due tc;> con-
ditions of storage, or depend on vitro degradation. 
Enzyme forms of different pl may arise as a result of modificat-
ions occurring in vitro processing. Proteolytic digestion may have ac-
counted for the loss of GSH-T activity. In this work all cytosols were 
handled in like manner, yet yielded different relative concentrations 
of neutral and anionic GSH-T's. It is unlikely that proteolytic ac-
tivity had a differential effect on individual GSH-T's. 
Sources · of interindividual differences in drug metabolising en-
zymes include genetic factors, age, diet, smoking, drugs, alcohol and 
environmental pollutants. The genetics of the human GSH-T's have not 
been well studied, and have been discussed previously (see lit. rev.). 
This study and immunological evidence from other sources (also pre-






volved, one for each group of GSH-T's. Contrary to the conclusions of 
Board (329) there is no nul allele for any locus, since all three forms 
are found in any individual, although not all forms are expressed in 
all organs. 
Inter-organ variation is a manifeste.tion of gene repression/derep-
ression, and is , also affected by induction of drug metabolising en-
zymes. The mechanism for organ variation and protein expression in 
general (e.g. why do only red c:ells make haemaglobin) is unknown. 
The effect of drug metabolising en:,:yme inducers is exerted mainly 
mainly on the liver. work in rats has shown that GSH-T activity in 
organs other than the liver is difficult to induce. Indeed only the 
kidney apart from liver, responds, to any major degree to inducing 
agents. Each organ may have it own set of endogenous or exogenous in-
ducers, as yet undefined. Studies of induction of GSH-T activity to 
date have almost exclusively considered only total enzyme activity and 
not induction of individual G SH-T's. In the human there are no studies 
of GSH-T induction and therefore the role that inducing agents may play 
in human GSH-T concentrations cannot be assessed. It is not known 
whether any or all of the human G SH-T's are inducible. 
In this study tissue was obtained postmortem from victims of death 
by violence. No medical history was obtainable. No other pathology 
was found at postmortem. Since e.g. therapy with diphenylhydantoin, or 
phenobarbitone or drug or alcohol abuse could not be excluded the role 
of drug metabolising enzyme induction in accounting for the variation 











GLUTATHIONE S-TRANSFERASE IN HEPATOCELLULAR CARCINOMA 
INTRODUCTION 
Alterations in protein metabolism and secretion have been des-
cribed in many malignant tumours. both in man and in experimental 
animals. In particular hepatocellular carcinoma is well known for its 
secretion of foetal ·antigens, 
antigen. 
a-foetoprotein and carcinoembryonic 
The molecular correlation concept enunciated by Weber (492) re-
lates phenotypic variation in malignant cells to the rate of growth of 
these cells. This concept was formulated when experimental tumours of 
different growth rates became available for study, the so-called Morris 
hepatoma's (493). 
Weber and others were able to show that many enzymes of glucose 
synthesis, DNA catabolism and RNA catabolism are decreased proportion-. 
ately to the growth rate of the malignant cells, while · enzymes of the 
opposing pathways, i.e. glycolysis, DNA and RNA synthesis, are increas-
ed. Specifically. pyruvate kinase and hexokinase activity was increas-
ed while gluC'ose-6-phospliatase, fructose-1,6-diphosphatase and phospho-
enolpyruvate carboxykinase decreased (494,495). DNA polyr..erase and 
thymidine kinase are examples of DNA synthetic enzymes which increase 
in activity in malignant cells. Thymidine phosphorylase is a DNA cata-
bolic enzyme which decreases in activity (492). 
In some instances isozyme shifts were noted, the high Km isoen-
zymes becoming diminished and low Km isoenzymes becoming increased 
(492). Hexokinase and glucokinase both convert glucose to glucose-6-
171. 
phosphate but hexokinase is a low Km enzyme. while glucokinase has a 
high Km. With progressive malignancy glucokinase activity decreases 
and hexokinase activity increases. Similarly high Km liver pyruvate 
kinase becomes replaced with low Km muscle-type pyruvate kinase (494, 
495). 
Ligandin concentration and GSH-T enzyme activity have been shown 
to be decreased in experimental tumours induced in rats (99,496,497). 
In human hepatocellular carcinoma measurement of ligandin by RIA has 
shown ligandin concentration to be reduced to a variable extent in 
tumour specimens. In addition serum ligandin has been shown to be 
elevated in some patients with hepatocellular carcinoma (92). 
In this chapter the distribution of GSH-T in human hepatocellular 
carcinoma !s studied, both biochemically and histochemically. The re-
lationship between serum and tumour ligandin is also explored. 
METHODS 
Histochemistry: -
Formalin fixed paraffin embedded liver biopsies were studied. The 
sections were stained routinely with haematoxylin and eosin for morpho-
logical assessment. Sections were also stained for ligandin using a 
peroxidase-antiperoxidase (PAP) sandwich method using ar. antibody 
raised against the cationic human GSH-T's (498-500). 
The paraffin embedded sections are rinsed in absolute alcohol, 
then immersed in 0.3% hydrogen peroxide in methanol for 30 minutes. 
All subsequent reagents are made up in 0.11\t sodium phosphate buffer, 
0.15M NaCl, pH 7 .4, and between steps the sections were washed in the 











swine serum diluted 1: 20 for 10 minutes. rabbit antihuman ligandin 
antiserum 1:800 for 24 hours at 4°C. swine antirabbit serum 1:20 for 30 
minutes. rabbit peroxidase-anti peroxidase complex 1: 20 for 30 minutes • 
The colour reaction is developed by soaking in 5 mg of 3.3'-diamino-
benzidine tn 10 ml PBS with 0.1 ml hydrogen peroxide. The sections a!'e 
then counterstained with Mayer's heamatoxylin. Each batch was control-
led using non-immune rabbit serum in place of rabbit antiligandin anti-
serum. Each reagent in turn was left out of the staining procedu1·,1 to 
left out of the staining procedure to exclude any 1>lf,ining due to non-
specific reagents. Sections were also stained using rabbit anti-lig-
andin antiserum to which had been added human liver cytosl,! in the 
ratio 8: 1. The mixture was allowed to stand at 4°C for 48 hours and 
then centri:uged at 18,000xg for 30 minutes. The supernatant was used 
in the staining schedule. 
Ligandin concentration in the biopsy section was estimated semi-
quantitatively using a grading system as follows:-
Distribution of staining:-
No staining 
Few clusters of cells stained 
Many clusters of cell stained 
Diffuse staining 









Tumour morphology was graded into well differentiated or undiffer-
entiated tumours. Well differentiated tumours had either glandular 














those with anaplastic cells. and those which consisted of sheets of 
cells in which the architectural pattern was lost. 
Preparation of cytosol:-
Since young South African Black males have one of the highest in-
dicences of this 'tumour tissue was limited to that obtained from Black 
patients dying of hepatocellular carcinoma (courtesy Prof. M.C. Kew. 
University of the Witwatersran,j Johannesburg). ThE> diagnosis was made 
during life. Tissue was removed within 12 hours after death and frozen 
at -70°C till used. 100, OOOx g Supernatants were prepared from 25% 
homogenates in O. 25M sucrose if destined for isoelectric focusing. or 
in O.OlM sodium phosphate buffer, 0.15M sucrose, pH 7.4 if destined for 
g"l filtration. 
Molecular size of immunoreactive ligandin in hcpatocellular carcinoma:-
Cytosol from four tumours were chromatographed on Sephadex G-100, 
column size 90 X 1.5 cm. The column was poured and developed in 0.011\t 
sodium phosphate buffer, 0.15M NaCl, pH 7.4. Elution was by pump 
driven upward flow at a rate of 20 ml/hour. Four ml fractions were 
collected. Protein content of the eluate was measured spectrophoto-
metrically at 280 nm. Ligandin concentration was measured by RIA and 
G SH-T enzyme activity with CDNB. The column was calibrated with marker 
proteins to allow the estimation of molecular size of the immunoreac-
tive peaks as before. 
174. 
lmmunoreactivity of ligandin in hepatocellular carcinoma:-
This was assessed by comparing the slope of the dose response 
curve of serial dilutions of cytosol with the slope of the assay stan-
dard curve as before. 
Ligandin concentration in cytosol:-
Ligandin in cytosol was measured by RIA. Supernatant protein was 
measured by the method of Lowry as before. Results were expressed as 
ug/mg protein. Ligandin was .also measured in the seJ.·um of patients with 
hepatocellular carcinoma. Results were expressed as ng/ml. 
lsoelectric focusing: -
This was performed in an LKB 4101 IEF column as before. Running 
conditions were as before. 
The volume of cytosol used in each instance and the pH 1·ange are 
given in . the legend to the figures. 
At run completion the column was drained by pump at a flow rate of 
2 ml/min. Two ml fractions were collected. pH was measured immediate-
ly. The fractions were also assayed for G SH-T activity with CD NB, and 
for ligandin by RIA. 
Assessment of red cell GSH-T activity:-
The contribution of red cell contamination to anionic G SH-T acti-
vity in tissue was assessed by comparison with the haemoglobin concent-
ration of whole blood as before. 
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RESULTS 
Biopsy material from 36 patients with hepatocellular carcinoma 
were studied. In all patients hepatocellular carcinoma was confirmed 
on morphology and on clinical grounds. Twenty of these tumours were 
well differentiated and 16 were poorly differentiated. 
The PAP technique stains a brown colour when positive. In normal 
liver all hepatocytes were uniformly stained a dark brown (fig 26 .1). 
There was no difference in intensity of staining between · the three 
zones of the hepatic acinus. Backgroung staining ·vas a fo.~nt brown 
colour seen in the portal tracts. The Kupfer cells did not take up 
stain. Most hepatocyte nuclei also took up stain. Non-immune controls 
in which antiligandin antibodies were omitted, or in which one of the 
reagents were omitted stained a faint blue with no brown colour at all 
(fig. 26.2). Sections stained with antiserum adsorbed with l1gandin 
also showed no brown colour at all. 
Staining of tumours varied from absent (fig. 26. 3) to intense dif-. 
fuse staining (fig 26.4 Ii 26.5). Generally however , staining in the 
tumour was more patchy (fig. 26.6), and was limited to clusters of 
cells. Generalised patchy staining was the commonest pattern of stain-
ing seen. In some sections staining was limited to one or two clusters 
of cells in the whole section • 
. Diffuse generalised staining was seen in three tumours, two undif-
ferentiated, and one well differentiated. Completely negative staining 
was seen in two trabecular carcinomas and 5 poorly differentiated 
lesions. 
176. 
Fig. 26.1. Ligandin immunohistochemistry. Section of no!lllal liver 
stained with ant5.-ligandin antiserum with peroxidase - antiperoxidase 
method (see text for details-). Positive staining gives a bro ... "!\ colour. 
Normal hepatocytes arc positive, while the surrounding fibrous tissue 
is negative. 
Fig. 26 .2. Ligandin immunohistochemistry. Non-imn,une -:ontrol of 
normal liver. Specific anti-ligandin antiserum was ommitted from the 
staining procedure. 
~ _26.3. Hepatocellular ca::cinoma. Section stained as for fig_. 26.1. In this specimen normal liver stains positively, but tumour .LS negati"e. 
Fig. 26.4. Hepatocellular carcinoma. Section stained as for fig. 
26.1. Diffuse intense s:aining in a poorly differentiated hepato-
cellular ::arcinoma. 
Fig. 26.5. Hepatocellular carcinoma, 
. 26.1. Diffuse staining in a well 
carcincma. 
Section stained as for fig • 
differentiated hepatocellular 
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Of twenty well differentiated tumours only 2 were completely neg-
ative, 7 stained weakly (score 1), 8 moderately (score 2-3), and 3 
stained strongly (score 4-5) By contrast 6 of the 16 poorly different-
iated tumours stain did not at all, a further 4 stained weakly, three 
mode~ately, and three &trongly. 
Semiquanti~ative scores for the two groups and the frequency dis-
tribution in which the scores occur are shown in table 26.1. The fre-
quency distributions of ligandin in well and poorly differentiated 
tumours are significantly different using the x 2 goodness of fit 
test. 
Nuclear staining was present in 8 tumours, 6 well differentiated, 
and 2 poorly differentiated • 
lmmunoreactivity of tumour ligandin :-
This was tested in four tumours. In each case the slope of the 
dose response curve of dilution of cytosol from tumours was parallel to 
the slope of the assay standard curve (figs. 26.7). 
Molecular size of immunoreactive ligandin in tumours:-
Cytosol from 4 tumours were chromatographed on G-100. In each 
case immunoreactive material and enzym~ activity eluted at 1. 5 x the 
void volume, · corresponding to a molecular size of 47,500 daltons. The 
peaks were superimposable (figs. 26.8). There was no immunoreactivity 
in the void volume, indicating the absence of macromolecular forms, nor · 
was there evidence of smaller immunoreactive forms, which might have 
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Ligandin im.~unoreactivity was measured by RIA, and enzyme activity was 











































Fig. 26.8. Immunochemical displacement curves 
imens cf human human hepatocellular carcinoma. 
are as for fig. 10.1. 
of cytosol from 4 spec-
Ordi;iate and at-scissa 
GLUTATHIONE S-TRANSFERASE IN HUMAN HEPATOCELLULAR CARCINOMA 
Tumour no. Immuno- Ligandin Specific Enzyme GSH-T Specific 
reactivity Activity Activity Activity 
ng/ml ng/mg protein 'IJlllOl/min/ml umol min/mg 
I 146 22 0.11 0.02 u 8815 940 0.31 0.03 
III 144000 8150 1.80 0.10 
IV 2545 218 0.43 0.04 
VII 7979 566 1.25 0.09 
VIII 1235 176 3.75 0 .S:3 
Liver 7 79512 8737 2.20 0.24 
Uvei" 8 36567 2203 1.50 0.09 
Table 26.2. Glutathione S-transferase activity with CDNB, and ligan-







Quantitative estimation of ligandin in hepatocellular carcinoma: -
Results of assay of tumour ligandin by RIA and GSH-T activity with 
CDNB are shown in table 26.2. 
Serum ligandin in hepatocellular carcinoma:-
Serum from 24 patients whose biopsies were studied was suitable 
for assay. A further 31 samples from patients in whom biopsy was not 
suitable for immunohistochemistry, or was not done. were studied. In 
those patients in whom biopsy was not done the diagnosis of hepato-
cellular carcinoma was made by finding an elevated a-foetoprotein or by 
angiography in the appropiate clinical setting. Mean serum ligand in 
was 11.5 ng/ml, S.D • .!. 16.2ng/ml. The median was 8 ng/ml (range 0-90 
ng/ml). Elevated values were seen in 31% of patients. There was no 
correlation between serum ligandin and HBsAg, a-foetoprotein, age, sex, 
or SGOT level or tumour morphology or the amount of ligandin in the 
tumour measured by the semiquantatitive scores. 
IEF of tumour GSH-T's:-
Recovery of enzyme activity following IEF was 31-62% (mean 42%). 
This is similar to that found when normal liver cytosol was subjected 
to this procedure. 
In tumour 1 (fig. 26.9) the cationic GSH-T peak was undetectable 
with CDNB as substrate. Peak immunoreactivity in this region focused 
at pH 8.7 and was less than 80 ng/ml. An anionic (pH 4.8) and a 
neutral (pH 6.3) peak of enzyme activity were present. 
Tumour 2 (fig. 26.10) had two major cationic peaks. Immunoreac-
tivity corresponded to the cationic enzyme activity peaks. A neutral 
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Fig. 26. 9. IEF of cytosol from tumour 1. One ml of cytosol was 
applied. Ligandin immunoreactivity was determined by RIA, and enzyme 
activity was measured with CDNB as substrate. 
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Fig. 26 .IO. IEF of cytosol from tumour 2. One ml of cytosol 1o.>as 
applied. Ligandin immunoreactivity was determined by RIA~ a~d enzym~ 





peak focused at pH 6 and an anionic peak at pH 4. 7. There was a small 
peak of immunoreactivity corresponding to the neutral peak, but the an-
ionic peak had no immunoreactivity. 
Tumour ·3 (fig. 26.11) had 3 peaks of enzyme activity. The cation-
ic peak focused at pH 9.2, with a shoulder at pH 8.8 - 9.0. The neut-
ral peak was at pH 6.5. The anionic peak was relatively small, focus-' 
ing at pH 4.7. 
In tumour 4 (fig. 26.12) only a trace of enzyme activity was de-
tectable in the cationic region. Immunoreacfrrity in this region 
focused at pH 8.1. Peaks of enzyme activity were seen at pH 6.4 and at 
pH 5.3. The neutral peak of enzyme activity falls within the curve of 
immunoreactivity and in this instance it is not possible to be sure 
whether this enzyme peak is related to GST \J or to the cationic GST's. 
Tumour 5 (fig. 26 .13) has a large peak of enzyme activity at pH 10 
- 10.2, as well as traces of activity at pH 6.5, 5.6 and 4.6. Similar-
ly tumour 6 (fig. 26.14) has a large peak of activity at pH 10 - 10.2, 
and a tail in the region of pH 8. 9. In this tumour there is no enzyme 
peak in the neutral region. 
focuses at pH 4.8. 
The anionic enzyme peak is minor and 
Two further tumours and non-tumorous liver from the same patients 
were available. Tumour 7 (fig. 26.15.1) had two peaks, focu ::,ing at pH 
6 and pH 10.2. There was no anionic peak. In the liver from the same 
patient · total enzyme activity was reduced (fig. 26.15.2)(see table 
26.2). Peaks of enzyme activity were detected in the cationic and an-
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Fig. 26 .11. IEF of cytosol from tumour 3. One ml of cytosol was 
applied. Ligandin immunoreactivity was determined by RIA, and enzyme 
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Fig. 26 .12 ; IEF of cytosol from tumour 4. One ml of cytosol was 
applied. Ligandin immunoreactivity was determined by RIA, and enzyme 
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Fig. 26 .13. IEF of cytosol from tumour 5. One ml of cytosol was 
applied. Ligandin i~unoreactivity was determined by RIA, an~ enzyme 
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Fig. 26 .14. IEF of cytosol frol!l tumour 6 • One ml of cytosol w. s 
applied. Ligandin immunoreactivity was determined by RIA, and enzyme 
activity was measured with CDNB as substrate. 
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Fig. 26 .15. IEF of tumour cytosol and cytosol from the non-tumorous 
liver from the same patient. Four ml of cytosol was applied in each 
case. Ligandin immunoreactivity was determined by RIA, and enzyme 
activity was measured with CDNB as substrate. 
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Fig. 26 .16. IEF of tumour cytosol and· ·cytosol fror.i the non-tumorous 
liver from the same patie!lt. Four ml of cytosol was applied in each 
case. Ligandin immunoreactivity was determined by RIA, and enzyme 
activity was measured with CDNt as substrate. 
GLUTATHIONE S-TRANSFERASE IN HUMAN HEPATOCELLULAR CARCINOMA 
Tumour no. Cationic GSH-T Neutral GSH-T Anionic GSH-T 
estimated activity estimated activity estimated activity 
\JIIOl/min/ml vmol/min/ml v mol/min/ml 
I 0.05 (47%) 0.06 (53%) 
II Q.11 (34l) 0.12 (39%) 0.08 . (27%) 
III 1.30 (72%) 0.43 (24%) 0.07 ( 4%) 
IV o.os ' (12%) 0.08 (19%) 0.30 (69%) 
V 12.83 (86%) o.75 ( 5%) 1.34 ( 9%) 
VI 11.61 (96%) 0.48 ( 4%) 
VII 0.13 (10%) 1.13 (90%) 
VIII 0.30 ( 8%) 0.34 (17%) 3.11 (83%) 
Uver 7 1.02 (68%) 0.26 (17%) 0.23 (15%) 
Uver 8 2.09 (95%) Q.11 ( 5%) 
Table 26 .3. Estimated GSH-T activity in human hepatocellular car-
cinoma. 'l'he estimated activity for each group of GSH-T was derived as 
a percentage of the activity in cytosol before fractionation. The per-
centage of total acti~ity due to each group of GSH-T was estimated froa 
the area under the curve of that GSH-T activity on isoelectric focus-
ing, and is given in parenthesis. 
In tumour 8 (fig. 26.16.1) the cationic GSH-T'S were virtually un-
detectable. A trace of enzyme activity was present at pH 6.8, but the 
major enzyme activity was found in a peak focusing at pH 5.5. In the 
corresponding liver (fig. 26.16.2) total GSH-T activity was again re-
duced. Two peaks of activity focused above pH 9.0, with traces of ac-
tivity at pH 9.3~ pH 5.7 and in region of the neutral GST's. 
DISCUSSION 
It is widely accepted that the term malignancy implies loss of 
control of growth, and that growth rate of tumours is a measure of 
their degree of malignancy (501,502). This concept has its patho-
logical equivalent, in that highly malignant tumours, i.e. rapidly 
g?'owing, often have histological features which distinguish them from 
less malignant tumours. Features such as anaplastic cells, i.e. cells 
with no distinguishing features, suggest high grades of malignancy. It 
is also widely accepted that as a cell deviates from its original 
phenotype, i.e. as it becomes more malignant, it alters more and more 
in its phenotypic expression. This has been demonstrated for enzymes 
of glucose metabolism, (503) RNA metabolism (504), DNA metabolism 
(492), and purine metabolism (505) amongst others. 
Drug metabolising enzymes however are not well studfad in neo-
plasms. This present work demonstrates that in keeping with concepts 
of enzyme expression in tumours in general, the GSH-T's are present in 
decreased amounts in human hepatocellular carcinomas. There is a rough 








It is known that occasionally morphologically well differentiated 
tumours behave in a highly malignant fashion and vice versa. If the 
concept expounded by Weber. the molecular correlation concept (492) is 
correct. then heavy staining for ligandin in poorly differentiated 
tumours and the lack of staining in well differentiated tumours may be 
examples where the biochemical phenotype is a better guide to malig-
nancy than the morphological characteristics. 
data to prove this assumption are lacking. 
Unfortunately clinical 
Many workers have occupied themselves with the: problem of phcno-
typic variation between tumours derived from a single cell type. How-
ever less work has dealt with phenotypic variation within u single 
tumour. This present study shows that although in some tumours ligan-
din is diffJsely present. in others it occurs in scattered islands, the 
cells of which might stain quite strongly. 
Although malignant tumours are believed to be clonal in origin 
morphological variation within a single tumour is self evident. 
Several lines of evidence suggest that within a malignant tumour a 
significant proportion of cells are not malignant (506. 507). 
With respect to glutathione transferases in hepatocellular car-
cinoma it ml!y be that islands of persistent staining in an otherwise 
anaplastic sample represent normal or relatively normal cells that have 
retained many of the phenotypic features of the parent cell. · An al-
ternative but complementary hypothesis is that since it is known from 
cell culture work with rat hepatocytes. that ligandin is produced dur-
ing the early lag phase and stationary phase. and is decreased during 






resent post-mitotic, non-dividing resting phase or stable cells. Such 
cells have been described in other tumours (508). 
A final possibility is that these rests of cells represent normal 
non-neoplastic liver isolated from the rest of the liver by invading 
tumour. 
Ohmi et al (100) have shown by transplanting hepatoma cells into 
nude mice that serum ligandin rises as the tumour grows, and that the 
tumour is the source of the serum ligandin. In man however this cur-
rent work does not allow such a conclusion since although elevated 
serum ligandin levels are seen in some patients with hepatocellular 
carcinoma there is no correlation with the intensity of tumour stain-
ing. Nor is it possible to exclude ligandin release from non-tumorous 
liver. Expanding tumour may cause adjacent cells to become necrotic, 
thereby releasing ligandin. 
Immunoreactive material in human hepatocellular carcinoma is pro-
bably identical to purified ligandin, since the immunoreactive material 
elutes at the same volume from Sephadex G-100 as purified ligandin, has 
similar atfinity for the antibody. as shown by dilution studies, and 
has a similar range of isoelectric points as ligandin in normal liver 
cytosol. 
Both G SH-T activity and ligandin immunoreactivity may be markedly 
reduced in human hepatocellular carcinoma. Ohmi et al (100). have re-
ported similar data with a ligandin RIA. As with normal tissues im-
munoreactivity is restricted to the cationic G SH-T's. 
Although the relative contribution of the neutral and anionic 
GSH-T's to total GSH-T activity increases, the absolute amounts of ac-








ent loading volumes is not much different in tumours and normal liver. 
Therefore the major abnormality in tumours is the reduction in the cat-
ionic GSH-T, but this is variable. The activity of the cationic GSH-T's 
ranges from barely detectable to within normal levels. 
Non-tumorous liver from patients with hepatocellular carcinoma has 
decreased GSH-T activity. In one patient liver and tumour had the same 
. GSH-T's, albeit, in different concentrations, but in the other patient 
the 'normal' liver had no neutral GSH-T, while the tumour arising from 
that liver had no anionic GSH-T. 
It has been pointed o_ut that suitable control tissue for studies 
of the metabolic abnormalities in tumours is somewhat conh·oversial 
(492). Tumour bearing liver is probably not a good control tissue 
since it may be subject to many unknown influences secondary to the 
tumour itself (509). Regenerating liver is considered the best control 
tissue since it is growing at approximately the same as that of the 
most rapidly growing tumours (501). However regenerating human liver 
is for p_ractical purposes unobtainable. 
One may speculate that tumour bearing liver, which has been sub-
ject to the same influences as the original neoplastic cell, will show 
some phenotypic changes which may be considered as preneoplastic. It 
· is known that, in the rat, ligandin immunochemical staining patterns 
mature with progressive nodule formation during chemicul carcino-
genesis, resembling the maturation patterns seen during normal post-
natal maturation of the liver (511). The earliest nodules of induced 
carcinogenesis have reduced ligandin staining. It is feasible (if the . 




cinoma) that the non-tumorous liver represents this early stage carcin- . 
ogenesis. Alternatively decreased concentration of ligandin may be a 
non-specific result of the host of metabolic abnormalities induced by 
the tumour, and which affects a many other proteins as well as GSH-T. 
It is also of interest that in the human foetal liver the anionic 
GSH-T's constitutes a greater proportion of total activity than is ever 
seen in the adult (491). In the adult the anionic GSH-T's never 
contribute more than 5% of total activity, but in the foetus the 
anionic GSH-T's contribute approximately 30 - 40% of total activity. 
The increased contribution of anionic activity in tumours may thus be 
an example of retrodifferentiation which is said to be the mechanism of 















SUMMARY AND CONCLUSIONS 
This thesis describes both clinical and biochemical studies on the 
glutathione S-transferases. In the first part of the thesis the puri-
fication of ligandin is described, together with the development of a 
RIA for ligandin which has allowed its measurement in human subjects. 
Although the human cationic GSH-T's have been previously purified and 
characterised, the purification procedure used in this work has not 
been described before. Using a modified scheme. similar to that used 
to purify rat ligandin, a h~man ligandin has been purified to apparent 
homogeneity. Only gel isoclectric focusing shows inhomogeneity. which 
is probably due to minor differences in net charge, since all other 
criteria of purity are met. The p,rotein purified here resembles that 
purified by others, in structure, and to a lesser extent in en.zyme 
specific activity and · kinetic parameters. The purification scheme 
makes use of anion exchange and gel filtration, in five relatively 
simple steps. TEAE-cellulose used in the first chromatographic step is 
somewhat tedious to prepare, but an anion exchange resin which is 
easier to use, eg DEAE-cellulose or DEAE-Sephadex may yield similar 
results. It may well be that the newer technique of chromatofocusing 
may considerably simplify purification of ligandin. 
Using the previous!y purified ligandin n monospecific antiserum 
was raised in rabbits. The antiserum gave a single precipitin line 
when run in immunodiffusion against pure ligandin, further proof of 
purity of the antigen. Indeed when the pure ligandin was run against a 
heterogenous antiserum raised against soluble hepatic proteins, 















The requirements for a successful radioimmunoassay are:-
1. A pure antigen. 
2. A monospecific antibody of suitably high affinity and titre. 
3. A pure labelled protein of high specific activity which retains im-
munoreactivity. 
To provide the labelled protein the chloramine-T method of iodin-
ation was used. ' The intact labelled protein was separated from damaged 
products of iodination and from free labelled iodine by a combination 
of gel filtration and anion exchange in a single column. This tech-
nique achieved good separation as was shown by TCA precipitation and 
chromatelectrophoresis of the peaks eluted from the purification 
column. 
The RIA developed utilised the, double antibody method to separate 
antibody bound from free labelled antigen. The assay protocol allowed 
rapid initial processing of a large number of samples. Runs of 300 
samples were not uncommon. Although the two incubation times meant 
that a single assay took 4 days to complete (including counting time) 
this was not a major obstacle since ligandin in tissues, serum and 
urine could be stored. The assay compared favourably to other RIA's in 
that it was sensitive in the low nanogram range; the least detectabl~ 
concentration was less than 1 . ng/tube; it was reproducible with a low 
coefficient of variation and was free from non-specific interference as 
far as was tested. Although there was some degree of cross reactivity 
with rat ligandin, the assay could not be used to measure rat ligandin 
as the dilution curve of rat ligandin was not parallel to the assay 
standard curve. 
186. 
The RIA was used to study the release of ligandin in human hepatic 
diseases. These studies suggested that serum ligandin levels were not 
a useful diagnostic aid, since the high levels seen in initial speci-
mens often returned to normal within the first few days. This was pro-
bably due to the fact _ that the half-life of ligandin in blood is very 
short. However the fact that normalisation of ligandin was associated 
with clinical recovery suggests that ligandinaemia may be particularly 
suitable as an index of recovery. which may thus be determined at an 
early . stage. Although ligandinaemia persisted in the few patients 
whose illness ran a prolonged course no patients in this series de-
veloped chronic hepatitis following acute hepatitis. The hypothesis 
that persistent ligandinaemia preceded chronic hepatitis could there-
fore not be tested. 
In a separate study in patients with established chronic active 
hepatitis the degree of ligandinaemia was significantly correlated with 
histological severity of disease activity while there was no corre-
lation between histological severity and SGOT levels. Although the 
• series is small, the results are encouraging. and suggest that a larger 
study is warranted. 
Studies of ligandinuria in situations in which acute tubular nec-
rosis might be expected to develop, i.e. post renal transplantation, 
following hypotension, and in the setting of acute infection, revealed 
that ligandin release does indeed occur in these patients, but that the 
release is not predictive of ensuing renal failure. The highest levels 
of ligandin in the urine were seen post renal transplantation and fol-
lowing severe prolonged hypotension. When ligandin release did occur 




has limited clinical application for these reasons. 
Part 2 of this thesis deals with the distribution of the gluta-
thione S-transferases in tissues. The occurrence of GSH-T activity in 
humans is not as simple as first thought. It is now known that there 
are t~ree groups of GSH-T activity in human liver, and that at least 
two of these groups may consist of multiple isoenzymes. Prior to this 
work no information has been available on interindividual variation of 
the GSH-T's in organs other than the liver. or in various organs of the 
samr, individual. This thesis has shown that, like red cells and 
placenta, the lung and ovary have predominantly anionic GSH-T's. 
Furthermore in the kidney the anionic GSH-T's comprise a significant 
proportion of total GSH-T activity. The neutral GSH-T 's , which had 
previous!y been described only in the liver. have now been shown in 
testis and adrenal tissue as well, The small number of individuals 
surveyed precludes any firm conclusions on the pattern of distribution. 
However the findings are sufficient to challenge the previously held 
concept, that the neutral GSH-T is coded for at a locus which has a nul 
• and two functional alleles, since the neutral GSH-T was detected in 
organs . in individuals in whose liver it was absent. 
It is obvious that · there is wide variation in the distribution and 
the concentration of the GSH-T's both between organs and between in-
dividuals. The factors governing this variation are at present conjec-
tural. To what extent genetic factors and environmental factors are 
important is unknown. Presumably the human GSH-T's. as in other 
animals, are subject to induction by ingested chemicals. To what ex-
188. 
tent this occurs in man, and what chemicals may be responsible, are 
also unknown. 
In hepatocellular carcinoma there is also a wide variation in U1e 
pattern of GSH-T activity. Similar variation is seen in the dist-
ribution of ligandin immunoreactivity within these tumoui.'n. Immuno-
histochemical studies reveal a rough correlation between the degree of 
differention of the tumour, and the ' amount of stainable ligandin pre-
sent. These findings may be i.."l accord with the current concept, that 
the activity of an enzyme varies with tile degree of Iralignancy of the 
cell, but in a heterogenous tissue such as a tumour such a conclusion 
is difficult to prove. 
This work may have clinical importance, in that a tumour which is 
known to be deficient in a drug metabolising enzyme should theoretical-
ly be more sensitive to the effects of chemotherapeutic agents which 
are metabolised by that enzyme. If on the other hand, a chemothera-
peutic agent requires activation by the enzyme in question, then a 
tumour deficient in that enzyme will be resistant to the chemothera-
peutic agent. 
The role of the GSH-T's in drug metabolism is not clear. Although 
many drugs are conjugated to GSH in vitro, the extent of in vivo reac-
tion is unknown. Until further information is available the activity 
of drug . metabolising enzymes in tumours will remain a subject of aca-
demic interest only. 
This thesis is the culmination of four years of pleasant labour in 
the laboratories of the Liver Research Group Of the University of Cape 
Town and the Medical Research Council of South Africa. It is my hope 
that these bodies are suitably rewarded for their support, by the 
189. 
fruits of my labours. and that this work will stimulate those who come 
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